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ABSTRACT
Changes in health care and increasing provision of community services have resulted in
an increased number of community dwelling older adults with intellectual disabilities
(ID), leading to questions about future planning for service delivery. Although selected
aspects of functioning have been explored in various research studies, less longitudinal
information pertaining to broad aspects of health is available to planners.  This
longitudinal project was designed over 10 years ago with the primary purpose of
exploring individual and systemic issues in the health needs of this challenging
population, leading to improved service planning.
Cross-sectional and longitudinal health data were collected from 360 adults with
intellectual disabilities (ID) recruited from social services agencies from across the
province of Saskatchewan.  Data collection included caregiver information, chart
information and directly administered tests of selected aspects of cognitive functioning. 
Formal data-collection occurred every second year for a maximum of four test times,
and was supplemented by follow-up phone calls.
Analysis of study results showed that young, rather than older people without DS had a
greater severity of health needs related to their underlying conditions, and more
problematic behavioral and mental health issues.  The reason for this was likely the
increased survival of multiply handicapped young people, and the increasing trend for
these people to be maintained in the community rather than in large institutions.  This
population was more likely to receive psychotropic medications, both for underlying
problems such as seizure disorders, but also for difficult behaviors such as aggression.
On the other hand, adults with DS had relatively fewer problems in their younger adult
years, but had increasing problems as they aged.  Most aspects of functioning were
decreased in the older compared to the younger cohorts, which was consistent with the
iv
longitudinal, individual level data showing yearly declines in most measured skills. 
These declines were greater than those found in adults without DS.  Although yearly
declines were noted in most age cohorts, the largest declines were noted in the oldest age
groups, 50 years and over, suggesting that, while aging related decline was present from
an early age, declines severe enough to suggest a dementing process probably do not
start until after middle age.  Declines in visual memory appear to precede those in
praxis.
Mortality was increased with age, lower baseline functioning, DS, male gender, and
baseline depressive symptoms.
The use of aging programs did not change much during the course of the study, but
interesting differences in service use between people with and without DS were noted. 
Adults with DS were more likely than those without DS to participate in generic aging
services, which was thought to be due to people with DS presenting with more typical,
Alzheimer type behaviors, rather than severe behaviors such as aggression.
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11.  INTRODUCTION
1.1  Initiation of the study
This study was prompted by community caregiver awareness and concern about the
increasing numbers of adults with intellectual disabilities (ID) and dementia (especially
those with Down Syndrome (DS)).  Caregivers from Elmwood Lodge in Saskatoon
expressed to this author that they wished to learn more about the assessment of dementia
in adults with intellectual disabilities, and that they were experiencing some difficulties
already in meeting care needs of their clients already suffering with dementia.  They
wanted to know how much the cognitively impaired population with intellectual
disabilities was expected to increase in the future, as this would affect the services they
would need to provide.  Particular questions were raised about where services for adults
with intellectual disabilities and dementia would best be provided.  Choices available at
the time of initiation of this study included continuing care in a facility designed for
adults with intellectual disabilities, which might require modification of physical
environments, or discharge to a nursing home with specialized facilities for dementia
care. Prior to beginning the study, specialized day programs for older adults  with
intellectual disabilities were not yet available in the Saskatoon region.
The study that forms the basis for this thesis was therefore initially conceived to collect
information to help with future service planning for aging adults with intellectual
disabilities, particularly those with progressive, age related cognitive impairment.
21.2  Background Information and problem statement
Although the likelihood that people with childhood onset intellectual disabilities will
reach old age is still reduced compared to the general population, over the last few years
their life expectancy has increased throughout the western world (Janicki, Dalton,
Henderson & Davidson, 1999).  This has led to an increased number of people with ID
and aging-related health problems such as dementia, which has resulted in changes in
social and service delivery needs.  Service needs for this population are further increased
because of continuing deinstitutionalization of people with ID, resulting in increased
community presence of people with high physical and mental morbidities.
Certain subgroups of people with ID have specific increased age-related risks, such as
those with DS, who have a genetically based increased risk for dementia (Janicki &
Dalton, 2000). Others, such as those with cerebral palsy (CP) have been noted to have a
high risk of physical aging related deterioration, particularly relating to mobility (Strauss,
Ojdana, Shavelle & Rosenbloom, 2004), sometimes starting in young adulthood
(Jahnsen, Villien, Egeland, Stanghelle & Holm, 2004). 
The demonstrated demographic pattern of increased longevity in people with ID points
to a continued future increase in the proportion of older adults with ID, but does not
adequately address the more significant changes in the prevalence of associated physical,
mental and behavioural problems, as well as functional deficits in these cohorts, which
will have an impact on their need for support.  Even in currently older adults with ID
there is a dearth of broad, linked data that would be helpful to planners, but more
problematically, these cohorts may not be good models for the future extrapolation. 
Current older adults have lived vastly different lives than cohorts who will be the older
adults of tomorrow, and these differences will very likely have a profound effect on all
aspects of intellectual, emotional, medical and functional outcomes in late life. 
Extrapolating care requirements for older adults with ID from older adults without  ID is
3not appropriate, as those with ID have had more restricted life experiences, with reduced
functional independence and coping skills, and generally  have no adult children to assist
in late life functioning. 
1.3  Purpose of study   
The purpose of this study was to explore biological, psychological, and functional
aspects of the health of adults with ID, exploring cross-sectional predictive factors
relating to birth cohort (age and diagnostic category), as well as predictive factors for
individual longitudinal changes. The study also sought to study issues related to care
provision and the use of  psychotropic medications.
Measured health outcomes to be included were to be mortality patterns, physical and
mental health symptoms, functional abilities and selected dementia related abilities
(memory, dyspraxia).  Potential determinants of these health outcomes were to include 
age, sex, cause of intellectual disability, medication use (anti-inflammatories, hormonal
therapies, psychotropic medications, vitamins), baseline mental health and premorbid
intellectual functioning.  Aspects of care provision to be studied were the perceived
adequacy of services for physical, emotional, behavioural or psychiatric problems, the
frequency of psychiatric contact, and the use of generic and aging-ID specialized aging
services.
The study and its hypotheses were built on the basic tenets of the biopsychosocial model,
which assumes that health, disease and functional abilities are a complex interplay of
basic biological processes (such as genetics), psychological factors (such as behavior,
learning and cognition) and social factors (such as culture, values, support and political
organization), as well as environmental factors such as life events.  For example,
functional abilities in adults with DS are assumed to be affected to some extent by
structural and neuropathological brain factors related to trisomy 21, but also by learned
4behaviours and skills, as well as social opportunities and expectations present during the
past and present years for individual cohorts.
1.4  Study questions
Many questions pertaining to aging and health in adults with ID were of interest, but not
all questions were feasible to answer in a small, relatively short study such as this. 
Specific questions of clinical interest that had a reasonably expectation of being
answered were therefore elucidated, and are shown below.
Epidemiology/Mortality
• What are  the determinants of mortality in adults with ID?
Physical morbidity
• What is the pattern and frequency of physical morbidity in adults with ID?
Emotional, behavioural and psychiatric morbidity
• What is the pattern and frequency of emotional, behavioural and psychiatric
morbidity in adults with ID?
Functional-cognitive decline
• How do functional abilities vary across diagnostic and age groups in adults with
ID?
• What are  the determinants of individual level change of functional abilities in
adults with ID?
• How do specific neuropsychological functions associated with dementia, such as
memory and praxis vary across diagnostic and age groups in adults with ID ?
• What are the determinants of individual level change in  specific
neuropsychological functions associated with dementia in adults with ID ?
Service provision
• How does provision of psychiatric care vary across diagnostic and age groups in
adults with ID ? 
5• How do perceived deficits in service provision for physical, emotional,
behavioural and psychiatric needs vary across diagnostic and age groups in adults
with ID ?
• How do perceived deficits in service provision for physical, emotional,
behavioural and psychiatric needs impact on participant re-institutionalization
(for example, to a nursing home) in adults with ID .
• How does the use of specialized and generic aging programs vary across
diagnostic and age groups in adults with ID ?
• Is there a change over time (individual longitudinal change or cross-sectional
comparison) in the use of aging services for adults with ID?
Psychotropic medication 
• How does the use of psychotropic medication vary across diagnostic and age
groups in adults with ID ?
• Is there a change over time (individual longitudinal change or cross-sectional
comparison) in the use of psychotropic medication in adults with ID ?
1.5  Hypotheses
The author’s clinical experience working with adults who have ID was augmented by the
known literature exploring aging issues in ID (summarized in the next chapter) to
develop the following hypotheses relating to the study questions:
Epidemiology/Mortality
• Male gender, older age, more severe baseline impairments in physical and mental
functioning, and a diagnosis of DS will be associated with increased mortality.  
Physical morbidity
• Cross-sectional data on the general health of adults with ID will reveal more
typical, aging related medical problems in older compared to younger cohorts
with ID, but fewer severe health conditions related to genetic, chromosomal or
6birth conditions. 
Emotional, behavioural and psychiatric morbidity
• Emotional, behavioural and psychiatric problems will be more common in those
without DS, particularly in the youngest cohorts.   
Functional-cognitive decline
• Cross-sectional data  from adults with ID without DS on behavioural and
functional measures will reveal better functioning in mid-age compared to
younger cohorts (related to continued learning and differential community
placement), but poorer scores in the functions typically affected by aging in the
oldest cohorts.  
• Cross-sectional data from adults with ID and DS on behavioural and functional
measures will reveal a pattern of poorer scores with older age starting with the
youngest age cohorts.
• Longitudinal data from adults with ID on behavioural and functional measures
(using a standardized caregiver instrument) will reveal yearly decline in most
functions, most noticeably in the oldest cohorts, and more in those with DS
compared to those without DS.  Specific functions will exhibit different rates of
decline.       
• Cross-sectional data from adults with ID on specific neuropsychological
measures (using standardized instruments to measure dyspraxia and visual
memory) will not reflect continued learning (as in the case of functional data),
but will show slightly lower functioning in older age cohorts, except in the oldest
cohorts with DS, where scores will be more noticeably decreased. 
• Longitudinal data from adults with ID on specific neuropsychological measures
(using standardized instruments to measure dyspraxia and visual memory) will
reveal a small yearly decline in most functions, most noticeably in the oldest
cohorts, and more in those with DS compared to those without DS.  Specific
functions will exhibit different rates of decline.
Service provision
7• Participants will be less likely than the underlying population to have seen a
psychiatrist recently, but psychiatric contact will be more likely in younger
people without DS and older people with DS compared to the total study group.
• Perceived deficits in service provision for emotional, behavioural or psychiatric
problems will be greater than perceived deficits in service provision for physical
problems.  Younger participants without DS will have greater perceived deficits
in service provision for physical, emotional, behavioural and psychiatric
problems than older participants without DS, but older participants with DS will
have  perceived deficits in service provision for physical, emotional, behavioural
and psychiatric problems than younger participants with DS.
• Perceived deficits in service provision for physical, emotional, behavioural and
psychiatric needs will increase the likelihood of institutionalization (for example,
to a nursing home), and this will be more pronounced for younger people with
behavioural unmet service needs and older people with physical unmet service
needs.
• Older participants will be more likely than younger participants to use aging
programs. Older participants with DS will be more likely than older participants
without DS to participate in a generic (rather than a specialized ID) aging
program (because their behaviours will be more typical of a generic Alzheimer
service population).  
• The overall use of aging programs will increase over the time of the study. 
Psychotropic medications
• Overall, people without DS will be more likely to use psychotropic medications
than those with DS.  
• Older people without DS will be more likely than younger people without DS to
use sedative-hypnotic medication but less likely to use medications such as
antipsychotics to treat behavior disorders.  
• Older people with DS will be more likely than younger ones with DS to use
antipsychotic, sedative hypnotic, and anxiolytic medications because of the
8increased prevalence of dementia.  
• Antidepressant use will be most common in middle-aged females. 
• There will not be much change in the individual, longitudinal use of particular
psychotropic medications.   
 • There will be a systemic increase in the use of all psychotropic medications
throughout the time of the study, consistent with underlying population trends.
There will be an increase in the use of the newer, atypical antipsychotics
throughout the time of this study, but this will be less noticeable than that seen in
the underlying population.  People with ID will be more likely to use
antipsychotic medications, but less likely to use antidepressant medications than
adults in the underlying population.     
1.6  Anticipated significance
It was anticipated that this study would give valuable information about the longitudinal
aging-related changes in adults with ID, separating cohort from individual aging effects,
which would help provide planning information for changes in service needs with the
aging of the ID population.  It would also give helpful information about health practices
and their change with time in ID, such as the use of psychotropic medications, which
have been overused in the past in this population, and which are known to have
significant potential adverse effects, especially in older people.  Identification of subtle
changes occurring prior to the development of frank dementia will help more clearly
identify the course and recognition of dementia in its pre-clinical stages, which may also
be relevant to dementia of the Alzheimer type in adults without ID.
92.   LITERATURE REVIEW
In this chapter the published literature pertaining to the core study questions about health
and health care in adults with ID is reviewed: epidemiology/mortality data in people with
ID, physical morbidity data, emotional, behavioural and psychiatric morbidity,
functional-cognitive decline, service provision, and the use of psychotropic medications. 
2.1  Epidemiology of intellectual disabilities
The DSM-IV (American Psychiatric Association, 1994) states that mental retardation
(MR) is characterized by significantly subaverage intellectual functioning (an IQ of
approximately 70 or below) with an onset before 18 years, and that there are concurrent
deficits or impairments in adaptive functioning.  The deficits and functioning should be
in at least two of the following areas: communication, self-care, home living,
social/interpersonal skills, use of community resources, self-direction, functional
academic skills, work, leisure, health and safety. Mental retardation is divided into four
levels of severity: mild (IQ ranging from 50-55, to approximately 70), moderate (IQ
ranging from 35-40 to 50-55), severe (IQ ranging from 20-25 to 35-40) and profound (
IQ below 20 or 25). According to this definition, about 85% of people with mental
retardation are in the mild category, 10% are in the moderate category, 3 to 4% are in the
severe category, and only 1 to 2% of people are in the profound category.
The prevalence of ID varies by the age of samples studied. Children tend to be diagnosed
with ID once they enter the school system, resulting in the apparent increased prevalence
around this age.  After school completion, prevalence figures tend to decrease again,
probably reflecting decreased testing and monitoring, and possibly decreased intellectual
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demand, which results in the functional requirements of the diagnostic criteria no longer
being met.
There is also some variation in the published prevalence figures from around the world. 
Although there is some variability across the United States (Centers for Disease Control
and Prevention, 1996), the mean prevalence of ID is generally assumed to be about 1%
(American Psychiatric Association, 1994), whereas Canadian, Australian and
Scandinavian figures are somewhat lower. For example, Bradley, Thompson and Bryson
(2002) surveyed adolescents aged 14 to 20 years living in the Niagara region of Ontario,
finding an overall prevalence for ID (MR) of 7.18/1000.  They found a prevalence of
mild mental retardation of 3.54/1000 and for severe mental retardation of 3.64/1000. 
Leonard, Petterson, Bower and Sanders (2003) found an Australian prevalence rate of
14.3 per 1000, 10.6 per 1000 for children with mild or moderate and 1.4 per 1000 for
those with a severe level of intellectual disability. They also found a greater prevalence
rate in males (with a prevalence ratio of 1.6) and in children of Aboriginal mothers (with
prevalence ratio of 2.3). 
2.1.1 Causes of intellectual disabilities
Intellectual disabilities can be caused by various biological or psychosocial factors,
acting either alone or in combination. In a significant minority of people with ID, no
clear cause for the ID can be determined.  The major causes of ID (Medline Plus, 2006)
are listed below.
 
• Trauma: Intracranial hemorrhage before or after birth, lack of oxygen to the
brain,  severe head injury 
• Toxic: Intrauterine exposure to alcohol and other drugs, methylmercury
poisoning, lead poisoning 
• Infectious (congenital and postnatal): Congenital rubella, meningitis, congenital
11
cytomegalovirus, encephalitis, congenital toxoplasmosis, listeriosis, HIV
infection
• Chromosomal Abnormalities: Errors of chromosome numbers (DS), defects in
the chromosome or chromosomal inheritance (Fragile X syndrome, Angelman
syndrome, Prader-Willi syndrome), chromosomal translocations and deletions
(cri du chat syndrome 
• Genetic and other inherited metabolic disorders: Galactosemia, Tay-Sachs
disease, phenylketonuria, Hunter Syndrome, Hurler syndrome, Sanfilippo
syndrome,  metachromatic leukodystrophy, adrenoleukodystrophy, Lesch-Nyhan
syndrome, Rett syndrome, tuberous sclerosis 
• Metabolic: Reye's syndrome, congenital hypothyroidism, hyperbilirubinemia,
hypoglycemia    
• Environmental: Poverty, low socioeconomic status, deprivation syndrome 
• Nutritional: Malnutrition 
2.1.2  Changes in the age composition of people with ID
The age distribution of people with ID in most developed countries has changed
throughout the last century.  This can largely be attributed to changes in the life
expectancy of people with childhood onset intellectual disabilities (ID).   Although the
likelihood that they will reach old age is still reduced compared to the general
population, life expectancy has increased (Janicki, Dalton, Henderson & Davidson,
1999), leading to an increased number of older people with ID in the population.  This is
particularly noticeable in the community because of deinstitutionalization, as discussed
later on in this chapter.  
The aging of the ID population has brought with it an increased prevalence of age-related
health problems, which are superimposed on early onset health problems associated with
the cause of the ID (discussed in more detail later).  These aging problems are very
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similar to those seen in the general population, such as cardiovascular and respiratory
problems and sensory impairment, although people with ID have been reported to have a
reduced rate (compared to the general population) of hypertension, hyperlipidemia and
adult-onset diabetes (Janicki et al., 2002).  Social and service delivery systems have
needed to adapt to these changes, as is discussed later in the section on service provision.
2.1.2  Mortality and life expectancy
People with intellectual disabilities are known to have higher mortality rates than the
underlying population, although this has improved over the course of the last century. 
Increased mortality in people with ID has been related to a variety of factors, as reviewed
by Sutherland, Couch and Iacono (2002).  Most important is the etiology of the
intellectual disability, such as DS for example, which has associated health issues such
as congenital heart disease, reduced immunologic function, and an earlier aging pattern. 
Epilepsy in people with ID is associated with significant morbidity and mortality. It is
well-known that there is a small rate of sudden unexplained death in people with
epilepsy (Lhatoo, Langan & Sander, 1999).  The cause of this death may be related to
falls and injuries (including drowning) from an unpredicted seizures, but sometimes no
reason can be found, and cardiac arrhythmias are implicated (Sperling, 2001). Seizures
can also be a secondary cause of increased mortality, as a late presentation is known to
be  associated with serious underlying illness, such as strokes and malignancy (Velez &
Selwa, 2003), which increase mortality.  
Mortality appears also to be increased among those in the general population who had a
lower childhood IQ.  For example, in the recent 35 year cohort study published by Patja,
Iivanainen, Vesala, Oksanen and  Ruoppila (2000), those with ID who had the most
severe impairment were found to have significantly lower life expectancy, whereas those
with mild ID had similar life expectancy to the general population.  There have been
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various speculations about causal mechanisms to account for lower life expectancy in
people with greater disabilities (Batty & Deary, 2004), and these include associated birth
complications, childhood illnesses, increased smoking, childhood socioeconomic
disadvantage, poorer adult social position with increased occupational risk, and even
associated lower reaction time (Deary & Der, 2005). 
Residential placement has been a controversial issue, as there have been contradictory
suggestions that either institutional placement or community placement might increase
mortality.  These contradictory findings might be explained by differing rates of
underlying medical complexity in study samples.  For example, those with multiple
complex medical conditions may receive inadequate care in the community unless
intensive supports are available, whereas those with mild disabilities may improve in the
community because of decreases in institutional mediated infections and improved
biopsychosocial well-being.
The role of depressive symptoms in predicting mortality has not been formally studied in
people with ID, but may also be of significance based on general population data.  In the
general population, there is a suggestion of a relationship between depression and
mortality, with a poorer outcome associated with a variety of medical illnesses if
depressive symptoms and/or depressive illness are also present (see review by Wulsin et
al., 1999).  Causality is not always well understood in this relationship, as severe medical
illness may result in depressive symptoms, but depressive disorders have also been
described to have adverse effects, possibly mediated through stress mechanisms. 
Other factors that have been described in the literature to increase mortality in this group
are poor mobility, poor feeding skills, poor functional abilities in general, male gender
and increased age.  One large Australian database study has also shown decreased
survival by people with ID who are of indigenous background (Bittles et al., 2002).
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2.1.3  Down Syndrome (DS)
DS is believed to be the most common cause of moderate to severe mental retardation,
and is of most interest to aging studies because of its association with early dementia,
and possibly other early aging features.  The majority of young people with clinical DS
have complete trisomy of chromosome 21, but a small proportion (approximately 5%)
has only partial trisomy 21 (from translocations), and about 2% has mosaicism (some
cells with trisomy 21 and some without) (Nora & Fraser, 1993). Interestingly, the extra
chromosome 21 may be lost with aging (Jenkins et al., 1997) in some cells, which might
result in higher rates of mosaic DS (i.e. not all cells have trisomy 21) in older
individuals.
The likelihood of giving birth to a DS child increases with the age of the mother, and in
children of mothers with an unbalanced translocation of chromosome 21.  Health Canada
(2002 ) reports that the total birth prevalence rate of DS in Canada has remained constant
over the period from 1991 to 1999, with a 9-year average at 13.2 per 10,000 total births.
Most (95.2%) of infants born with DS now survive the first year of life.
The percentage of people with DS in the population decreases with age because of
increased mortality rates, as discussed later.  Exact prevalence figures for DS in later
adulthood are not known because there is no complete Canadian register of people with
intellectual disabilities. There is a current initiative to develop a register of those with
DS, but this is expected to be voluntary and therefore will also not be complete.
2.2  Physical morbidity
2.2.1  Epilepsy/seizures
Epilepsy is more common in people with ID compared to the general population.  Recent
analysis of data from the Canadian National Population Health Survey has shown that
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the self-reported epilepsy rates in the general population tend to increase with age,
ranging from a low of 2.5 per 1000 in those aged 0-11 to a high of 6.9 per 1000 in those
over 65, with an overall rate of 5.2 per 1000 (Tellez-Zenteno, Pondal-Sordo, Matijevic
&, Wiebe, 2004).
However, epilepsy rates are higher in those with ID, and range from 18.3% to 44%
(Bowley & Kerr, 2000), with rates highest in the most disabled people and in those
living in institutions.  People with DS have slightly lower reported rates than this (8.1 to
13.6%), and appear to have a bimodal age of onset, with the majority presenting either
very early or in later decades (McDermott et al., 2005;  Pueschel, Louis & McKnight,
1991).  
As mentioned earlier, epilepsy is associated with increased mortality for a variety of
reasons.  It is also associated with increased morbidity, which may be caused by the
medications used to treat epilepsy, or interactions between seizure medications and other
medications.  Epilepsy may also cause a restriction in the potential for independent
living, because of the unpredictability of seizures and the risks associated with this.  For
example, people with poorly controlled epilepsy may be at risk riding a bicycle, or even
bathing alone.
There is also a known link between dementia and seizures.  Hesdorffer, Hauser,
Annegers, Kokmen and Rocca (1996) conducted a general (non-ID) population-based
case-control study in the United States and showed that in the absence of other prior
neurologic injuries, dementia resulted in a sixfold increased risk of seizures when
controlling for age, sex, and length of medical follow-up. The association between
dementia and seizures is particularly strong in people with ID and DS (Evenhuis,1990;
Lai & Williams,1989; Puri, Ho & Singh, 2001).  For example, Lai and Williams (1989)
have found that up to 84% of people with DS and dementia developed seizures, and
conversely, late onset seizures in people with DS is associated with the development of
16
Alzheimer Disease (Menendez, 2005). 
Mortality is known to increase in people with epilepsy and ID, and is particularly
increased if seizures are frequent (Forsgren, Edvinsson, Nystrom & Blomquist,1996). 
For example, Forsgren et al. (1996) found a standardized mortality ratio (compared to
the general population) of 1.6 for people with ID only, 5.0 for people with ID and
epilepsy and 5.8 for people with ID, epilepsy and cerebral palsy.
2.2.2  Cardiac problems
Congenital cardiac problems are more common among people who have DS or Fragile X
Syndrome (Sutherland et al., 2002), and in the past have caused high mortality rates in
childhood.  With improvements in surgical interventions for these disorders, and an
increase in life expectancy for people with ID, a pattern of cardiac morbidity and
hypertension more similar to the underlying population is emerging (Janicki, Dalton,
Henderson & Davidson, 1999). Patterns of increased risk factors such as obesity and
decreased physical activity in people with ID are anticipated to further increase
cardiovascular disease in middle to old age, although some risk factors such as cigarette
smoking, are notably less frequent in the ID population.
2.2.3  Respiratory problems
Transmissible respiratory infections tend to be increased in large congregate
environments such as institutions, but are also more common in people whose
disabilities decrease their ability to maintain personal hygiene.  The prevalence of
specific respiratory problems also varies depending on the cause of the ID.  For example,
people with DS are particularly likely to have respiratory infections and sleep apnea
(Pueschel, 1990). On the other hand, people with ID secondary to cerebral palsy are
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more likely to have aspiration related infections secondary to swallowing difficulties
(Del Giudice et al., 1999).  If the cerebral palsy is associated with significant
kyphoscoliosis there may be also restriction of lung capacity.
2.2.4  Gastrointestinal problems
Constipation is very common in people with ID, especially in those residing in
institutions. Bohmer, Taminiau, Klinkenberg-Knol and Meuwissen (2001) found that
69.3% of this population suffered from constipation, and 15% suffered from fecal
soiling.  They also found that the constipation was significantly correlated with being
non-ambulatory, having cerebral palsy, using particular medications, having food refusal,
or an IQ < 35.  High rates of laxative use are common in this population.
The rate of gastrointestinal problems varies with the cause of the disability. Cerebral
palsy is known to be associated with feeding difficulties and other functional
gastrointestinal abnormalities that can lead to bowel obstruction, vomiting, and
constipation (Krigger, 2006). DS is associated with hypothyroidism, which is well
known to cause constipation.
2.2.5  Dental problems
Recent studies on oral health in people with ID has shown some interesting differences
from the general population.  For example, Scott, March and Stokes (1998) found that
people with ID living in the community were more likely than the general population to
see a dentist (65% versus 50% in the last 12 months), more likely to have oral mucosal
pathology requiring treatment (15 per cent vs 2 per cent), more likely to have severe
periodontal disease (16 per cent vs 3 per cent), and more likely to have moderate to
severe malocclusion (26 per cent vs 11 per cent).  People with ID who reside in less
restrictive living situations, those who have milder intellectual disability and those with
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DS seem to have higher rates of caries (Gabre, 2000), possibly because of greater access
to sweet food, and reduced compliance with oral hygiene. 
Lifshitz and Merrick (2004) interviewed families and caregivers of 108 community
dwelling adults over 40 with ID, and found that 30% overall were considered to have
ongoing dental problems, with even higher rates for those who lived with their families.
2.2.6  Diabetes
Diabetes is an increasing problem in the general population because of the rising
prevalence of obesity, which is largely a function of excessive caloric intake for
individual requirements based on physical activity levels.  The Canadian Community
Health Survey found that 23.1% of adult Canadians were obese, with roughly equal
male-female rates, but higher rates in middle-aged (45-64 year old) adults compared to
younger and older adults (Tjepkema, 2005).  Specific age cohort rates were reported to
be: 11% at ages 18-24, 21% at ages 25-34, 20% at ages 35-44, 30% at ages 45-54, 30%
at ages 55-64, 25% at ages 65-74 and 24% for those 75 years and older.
Obesity rates are also high in adults with ID, although more restricted environments
which control access to food appear to result in lower rates.  As a result of this, the
overall rates of obesity in adults with ID have been found to be lower than those in the
general population (Moran, et al., 2005), although selected groups, for example females
with DS (Melville, Cooper, McGrother, Thorp & Collacott, 2005), have been found to
have greater odds of being obese (OR=2.17)  compared to their matched, non-ID
counterparts.  
Probably because of lower overall obesity rates, diabetes rates in adults with ID have
been found to be reduced compared to those in the general population (Janicki et al.,
2002), with only 2% of those aged 40-49, 5% of those aged 50-59, 7% of those aged 60-
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69 and 8% of those aged 70-89 years reported as having diabetes, compared to 4%, 8%,
12 %, and 14% in the equivalent age groups in the general population. 
 
2.2.7  Thyroid problems
Thyroid problems are common in the general population, and can mostly be divided into
disorders of excessive thyroid hormone (hyperthyroidism) and inadequate thyroid
hormone (hypothyroidism).  Spontaneous hypothyroidism occurs in 1 to 2% of the
general population, increases with age, and is about 10 times as common in women as in
men (Vanderpump & Tunbridge, 2002).  Overt hyperthyroidism has a prevalence rate of
1.9%, which does not seem to change with age (Tunbridge et al., 1977).
Thyroid disorders are more common in people with ID, especially those with DS.  Kapell
et al. (1998) collected data from a random sample of adults with DS and a matched
group of adults with ID not due to DS. These data were compared to population data
from the National Health Interview Survey, which was conducted in 1993 in the United
States. The prevalence of thyroid disorder among those aged 45 to 64 was 2.7% in the
general population, 33.6 % in those with DS and 5.7% in those with ID and not DS.  In
those aged 65 to 74, the prevalence was 3.7% in the general population, 45.5% in those
with DS, and 9.1% in those with ID, but not DS.  The Standardized Morbidity Ratio was
12.5 for people with DS aged 65 to 74, and 2.2 for people with ID but not DS aged 65 to
74.
Although the data on thyroid disorders in people with ID shows an increased prevalence
with age, even samples of children who have DS already show a significant prevalence
of thyroid dysfunction, usually hypothyroidism (Pueschel, Jackson, Giesswein, Dean &
Pezzullo, 1991).
Thyroid disorders can cause significant changes in behavior, function and cognition, and
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therefore need to be carefully considered when any unexplained clinical changes occur.
2.2.8  Vision problems
Vision problems are also more common in people with ID. A very recent cross-sectional
survey from the Netherlands notes that the prevalence of visual impairment ranges from
2.2% in young adults with mild ID and no DS to 66.7% in older adults with profound ID
and DS, as compared to 1.4% in the general Dutch population 55 years and older (van
Splunder, Stilma, Bernsen & Evenhuis, 2005). Most concerning was the authors’ finding
that visual impairment or blindness had remained undiagnosed in 40.6% of these.
Undiagnosed vision problems have been shown to be common in a number of studies,
largely because of difficulties of assessment in the most handicapped subgroup, but also
possibly because of poorer general health care.  This is a particular concern, as impaired
vision can further decrease the functional abilities of this already compromised
population, and may even give the erroneous impression of dementia.
People with DS are particularly likely to have vision problems, even as young children.
Da Cunha and Moreira, (1996) have shown very high rates of the following conditions in
their pediatric DS survey: astigmatism (60%), strabismus (38%), lacrimal system
obstruction (30%), blepharitis (30%), retinal abnormalities (28%), hyperopia (26%),
amblyopia (26%), nystagmus (18%), cataract (13%), and myopia (13%).  
Surveys of older people with DS generally show a high prevalence of childhood onset
visual problems with superimposed aging onset visual problems.  For example, van
Allen, Fung and Jurenka (1999) in their survey of 38 adults with ID living in a British
Columbia residential center found acquired sensory deficits including loss of vision due
to early onset of adult cataracts in 50%, recurrent keratitis in 21%, and keratoconus in
15.8%.
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Other risk factors for vision problems in ID include premature birth and cerebral palsy.
2.2.9  Hearing problems
Hearing problems are also more common in people with ID. Evenhuis, Theunissen,
Denkers, Verschuure and Kemme (2001) surveyed 672 people with mild to profound ID.
They found that the prevalence of hearing disabilities varied by the severity of
intellectual disability, by age and by diagnosis.  For example, people under 50 years with
mild or moderate ID who did not have DS had a 21% prevalence of hearing impairment
compared to the general prevalence of 2-7% in the general Dutch population under 50. 
This prevalence increased sharply in people who had DS and in those over 50.  Similar
to the findings with vision loss, a large percentage of people with ID and hearing loss
had not previously been identified.
2.2.10 Adequacy of health care in adults with ID
The adequacy of care provision for health problems in adults with ID is not well
understood in Canada, although data from the United States suggests a high prevalence
of poor health maintenance practices, communication difficulties with care providers,
and difficulty in accessing care, especially by individuals living independently
(Edgerton, Gaston, Kelly & Ward, 1994).  Statistics Canada (2002A) reports that even
12.5% of the general Saskatchewan population identified themselves as having unmet
healthcare needs, so based on the greater prevalence of health problems in adults with ID
as well as challenges of service provision,  it is likely that the prevalence of unmet needs
in this population is even higher. 
2.3  Emotional, behavioural and psychiatric morbidity
Behavioral problems in people with ID are known to be much more common than in the
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general population.  For example, a recent community survey in Massachusetts by
Freedman and Chassler (2004) found that almost half of the 629 participants in their
survey had self-injurious, disruptive or uncooperative behaviour problems.  This
increased prevalence has multifactorial roots, with etiologic factors including the
underlying cause of the ID (which may have caused problems with understanding,
attention, impulse control and irritability), impairments in the learning of socially
appropriate behaviors, and various environmental factors such as institutionalization. 
The frequency of behavioral problems varies widely between different surveys,
depending on the instruments used and the population studied. (Deb, Thomas & Bright,
2001) found that over 60% of people with ID had at least one behaviour disorder (18%
had severe behavioural problems), and that those with more severe ID generally had
more behavioral problems than those with less severe ID.  Researchers exploring the
association of residential placement with behaviour, such as Sigafoos, Elkins, Kerr and
Attwood (1994) have found that those in institutions have more severe behavioral
problems such as aggression (35%) than those in group homes (17%) or in other
community settings (3%).  Younger people with ID are also generally thought to have
more behavioral problems than older ones, although developing dementia has also been
found to be also associated with the resurgence of behavioral problems (Prasher & Filer,
1995).  Different etiologies may have different patterns of behavioral pathology.  For
example, adults with Fragile X Syndrome appear to have higher rates of inattention,
hyperactivity and explosive and aggressive behaviour to others or self (Tsiouris &
Brown, 2004) , whereas people with DS may have higher rates of obsessional traits
(Charlot, Fox & Friedlander, 2002), but fewer behavioural problems overall (Blacher &
McIntyre, 2006).
Published prevalence estimates of mental health disorders vary widely depending on the
survey (Kerker, Owens, Zigler & Horwitz, 2004).  A variety of diagnostic strategies have
been used to make the diagnoses, and study populations have also varied in terms of
diagnostic and core age and gender distribution.  Kerker’s group summarizes the
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following information about reported prevalences of mental disorders. The prevalence of
anxiety disorder may be significantly higher in those with ID than in the underlying
population (31.4% compared to 13.1-18.7 %).  The prevalence of schizophrenia in ID is
particularly contentious, with very high rates being reported for people with severe ID
(46.7%) compared to mild to moderate ID (16.7%), or to the general population (1%).  It
is not clear whether this high prevalence is an accurate representation of increased
prevalence of schizophrenia, or a reflection of increased abnormal behaviors related to
the ID, which have diagnostic similarities to core psychotic symptoms.  Depression in
institutionalized adults with ID has been reported to have a similar prevalence (8.9%) to
that in the general population (7%).  However, published prevalences of depression in
people with mild to moderate ID has been reported as high as 20%, whereas similar
prevalence studies in people with severe ID have found no cases of depression.  Because
of the difficulties with communication in people with severe ID it is likely that
depression is underdiagnosed in this population.
The prevalence of rigorously diagnosed mental disorders in individuals with DS may
differ from the underlying ID population.  Prasher (1995) carefully assessed 215 people
with DS (mean age 40.9 for males and 43.6 for females), finding that 28.9% had a
current mental disorder using DCR-10 criteria (World Health Organization, 1993).  The
prevalence of mental disorders was as follows: 13.4% had dementia of Alzheimer’s
disease, 5% had a depressive episode, 4.5% had obsessive-compulsive disorder, 4% had
conduct disorder, 1.5% had general anxiety disorder, and 0.5% had phobic anxiety
disorder.
2.3.1 Adequacy of care provision for emotional, behavioural and psychiatric problems
The adequacy of care provision for emotional, behavioural and psychiatric problems in
adults with ID is not known.  In Saskatchewan, the best general data on unmet mental
health needs comes from the Canadian Community Health Survey, which found that 
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4.4% of the general population identified themselves as having unmet healthcare needs
associated with mental health problems (Statistics Canada, 2002B).  Based on the greater
prevalence of mental health problems in adults with ID as well as challenges of service
provision,  it is likely that the prevalence of unmet needs in this group is even higher.  
 
2.4  Functional and cognitive decline
2.4.1  Dementia in the general population
Dementia is defined in the DSM-IV (American Psychiatric Association, 1994) as
progressive cognitive (including memory) decline that has reached the point of
significant impairment in social or occupational functioning.  It must represent a
significant decline from a previous level of functioning, which differentiates it from
early life cognitive disabilities such as ID.  Although the key deficit in dementia is
memory, the DSM-IV also requires one or more of the following cognitive disturbances:
aphasia (language disturbance), apraxia (impaired ability to perform skilled motor
activities despite intact motor functioning), agnosia (failure to recognize or identify
objects despite intact sensory function) and disturbance in executive functioning (i.e.
planning, organizing, sequencing, abstracting).
The most common type of dementia is Alzheimer’s Disease (AD), which is
characterized by gradual, usually insidious decline of memory and other associated
cognitive functions, eventually resulting in profound disability and death.  AD is
associated with characteristic neuropathological changes in the brain, including cerebral
atrophy, plaques and neurofibrillary  tangles. The precise, causal correlation between
these pathological changes and clinical changes of AD is less understood, as is the role
of amyloid protein (Bishop & Robinson, 2002; Obrenovich, Joseph, Atwood, Perry &
Smith, 2002). 
All dementias have a profound impact on the affected individual and their family, and in
addition, place a huge burden on health care resources, increasing as the severity of the
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dementia increases.
In the developed world, dementia is one of the most prevalent, disabling, and expensive
health conditions.  The Canadian Study of Health and Aging (CSHA, 1994) found that
8.0% of all Canadian adults 65 and over had dementia.  However, these rates varied by
age group:  2.4% aged 65 to 74 years, 11.1% of those aged 75-84 years, and 34.5% of
those aged 85 and over had dementia. AD was the most common type of dementia (5.1%
overall), followed by vascular dementia (1.5%). 
Multiple risk factors have been identified epidemiologically for the development of
dementia in the general population, with most of the work being conducted specifically
for AD.  Potential pathways of causation have been summarized by Ritchie and
Lovestone (2002).  In brief, although increased age is clearly the most prominent risk
factor, it is thought that genetic factors may increase this risk, as may female sex,
infections, abnormal lipid concentrations, head injury, and even exposure to anesthetic
gases.  Recent work has linked untreated hypertension (Peila, White, Masaki,
Petrovitch,& Launer, 2006), a history of mood disorder (Jorm, 2001; Kessing & Nilsson,
2003) and elevated plasma homocysteine (Seshadri et al., 2002) to later increased rates
of AD. Potential protective factors as summarized by Ritchie and  Lovestone (2002)
include hormone replacement therapy, use of non-steroidal anti-inflammatory
medications, moderate alcohol consumption, and high education.  Other authors have
added leisure activities (Verghese et al., 2003), ongoing cognitive stimulation (Wilson et
al., 2002) and exercise (Laurin, Verreault, Lindsay, MacPherson & Rockwood, 2001) as
potentially protective factors.
Although most patients with AD have no known familial inheritance pattern, some early
onset forms of AD have been associated with genes on chromosomes 21 (genes coding
for amyloid precursor protein, APP), chromosome 14 (presenilin 1), and chromosome 1
(presenilin 2).  A late onset form of AD is coded for on chromosome 19 (Apo E4). 
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Recent gene linkage work has suggested other significant genes for AD (Schott, Fox &
Rossor, 2002). 
Canadian epidemiological studies of  risk factors for incident cases of AD were explored
recently by the Canadian Study of Health and Aging (Lindsay et al., 2002).  Unlike most
previous risk factor studies, which based their analyses on retrospective data, this study
looked at risk factors identified prospectively in adults not initially found to be suffering
with dementia.  The CSHA found that the only significant risk factors for AD were 
increasing age, fewer years of education, and the apolipoprotein E epsilon4 allele (Apo
E4).  Protective factors found included the use of nonsteroidal anti-inflammatory drugs
(NSAIDS), wine consumption, coffee consumption, and regular physical activity. 
Interestingly, this study, unlike others, did not find a statistically significant association
for family history of dementia, sex, history of depression, estrogen replacement therapy,
head trauma, antiperspirant or antacid use, smoking, high blood pressure, heart disease,
or stroke.
2.4.2  Pattern of cognitive decline, reserve, symptom progression
The pattern of cognitive decline and the progression of characteristic symptoms of
dementia is more predictable in Alzheimer disease than it is in other types of dementia,
such as vascular dementia. The Global Deterioration Scale (GDS) by Reisberg, Ferris, de
Leon and.Crook (1982), describes characteristic deterioration in people with
Alzheimer’s disease, dividing the progression into seven stages.  In the first stage there
are no subjective complaints of memory problems, and no abnormalities are found on
clinical interview.  In the second stage there are some subjective complaints of memory
deficits, but these are not apparent on clinical interview.  In stage three there are mild
changes in a number of areas, including orientation, vocational performance, word
finding, memory, and possibly concentration.  In stage four there are a clear-cut deficits
in knowledge about current and recent events, memory of recent personal events,
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concentration (as measured by serial subtraction), orientation (as seen in the decreased
ability to travel), or the ability to handle finances.  In stage five, people with Alzheimer
disease can no longer survive without some assistance.  They may have trouble recalling
their address or telephone number, names of family members, or names of the schools
which they have attended.  In stage six, they may forget the name of their spouse, and
generally will be unaware of all recent events and experiences.  They will often require
help with basic activities of daily living, may become incontinent, and require assistance
to undergo travel.  There are frequently personality and behavioral changes such as
delusions, repetitive actions, anxiety, agitation, aggression, and apathy.  By stage seven,
all verbal abilities are lost, and 24-hour care will be required for all activities of daily
living, including feeding and toileting. Deficits in motor functioning and extrapyramidal
symptoms also occur in severe Alzheimer disease (Clark et al., 1997).
Subtle changes in frontal/executive functions may occur very early in the disease (Reid
et al., 1996), but are frequently not evident on commonly used tests of cognition such as
the Mini-Mental state examination.
The age of initial presentation and the rate of progression through these stages is not
uniform, which is probably related to the heterogeneous etiology of this disease.  For
example, Alzheimer disease associated with presenilin 1 and presenilin 2 genetic
variants presents at earlier age than Alzheimer disease associated with ApoE-4, which is
associated with later onset forms of dementia.  More severe deficits in various
psychological functions, such as in attention span, working memory and praxis have also
been found to be more prevalent in early onset disease (Reid et al., 1996). 
The rate of progression of Alzheimer’s disease has been found to be faster in people who
have an early onset of their Alzheimer disease (Jacobs et al., 1994).  The severity of
functional decline in people with AD has also been found to be greater in those who
have psychotic symptoms, or who are treated with antipsychotic medications (Lopez,
28
Wisniewski, Becker, Boller &  DeKosky, 1999).  Increased cognitive reserve may defer
the onset of AD, but then result in faster decline once compensatory abilities are lost.
This is supported by research published by Andel, Vigen, Mack, Clark and Gatz (2006),
who found that patients with AD who had a life of higher occupational complexity
declined faster when controlling for age, gender, native language, and dementia severity.
2.4.3  Cognitive decline and dementia in people with ID
Although most knowledge about dementia has come from the general rather than the ID
population, over the last 20 years the growing number of older adults with ID has
precipitated an increasing interest in cognitive decline with age in this group.  Within
this population, the increased prevalence of dementia in people with DS has been clearly
established, with evidence coming from neuropathological studies, neuroimaging, cross-
sectional clinical studies and longitudinal clinical studies. Most studies have found no
change or a decreased prevalence in people with ID who do not have DS (Zigman et al.,
2004), although at least one large study has made contradictory claims (Cooper, 1997).
Of potential significance to health outcomes in ID, including late life intellectual decline
is the Intelligence Quotient (IQ). In a number of clinical populations, measures of early
adulthood pre-morbid functioning, such as lower IQ,  have been linked to later aging
related progressive decline, although there have also been some contradictory findings
(Bush & Beail, 2004).
2.4.4  Neuropathological studies of adults with DS
Morphological, postmortem studies have shown that the frontal lobes of people with DS
appear to be underdeveloped prior to the development of dementia (de la Monte &
Hedley-Whyte, 1990).  However, age-related changes in older people with DS, which are
similar to those shown in people with Alzheimer disease in the general population, are
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even more striking. There is a large literature, most clearly beginning with
groundbreaking research by Wisniewski, Wisniewski and Wen (1985) that has clearly
established that typical neuropathological changes of AD are found by midlife in almost
all of the brains of adults with DS, and recently Bush and Beail (2004) have reviewed
this topic in more detail.  These changes include neuritic plaques formed by extracellular
beta-amyloid protein, and intracellular neurofibrillary tangles.  Pathological studies show
that the deposition of â amyloid occurs in children with DS as early as eight years of age
(Leverenz & Raskind, 1998). 
2.4.5  Neuroimaging studies of adults with DS
The advent of sophisticated neuroimaging has allowed for detailed investigations of
brain morphology and functioning without the availability of postmortem tissue. For
example, computerized tomography was used by Lawlor, McCarron, Wilson and
McLoughlin (2001), to analyze the CT scans of 10 adults with DS and functional
decline, using temporal lobe-oriented views.  All of those with dementia showed
significant medial temporal lobe atrophy, which is a known pathological finding in AD. 
Magnetic resonance imaging has been a more recent development, but has demonstrated
the ability to give more detailed data about the brain.  MRI studies of older adults with
DS also confirms changes in areas of the brain that are typically involved in AD. For
example, Aylward et al. (1999) used MRI imaging in 25 adults with DS (eight of whom
had dementia) and 25 cognitively normal adults who were individually matched on age,
sex, and race to show that the hippocampus was disproportionately small in individuals
with DS, and significantly decreased in those with DS over the age of 50. However, MRI
data suggest that, not only the allocortex, in which deficits are typically associated with
Alzheimer disease, but also the neocortex is impaired in people with DS prior to the
diagnosis of dementia.  For example, Teipel et al. (2004) recently published magnetic
resonance imaging data on 27 Down’s syndrome adults without dementia (average age
30
41.1 years) that showed grey matter volume decreases over time in cortical areas
including the parietal cortex bilaterally, the frontal cortex bilaterally with left-sided
predominance and the left occipital cortex, among others. Supporting evidence about the
early involvement of the neocortex has also been published by others such as Kesslak,
Nagata, Lott and  Nalcioglu (1994). Early cortical impairment in people with DS is
consistent with clinical data, presented later, suggesting early frontal behavioral changes
in older people with DS.
Positron emission tomography provides the most sophisticated information about
functioning of the brain, but is also less available and more expensive, so there are fewer
studies in this area. One available study using this technology is by Schapiro, Haxby and
Grady (1992), who used positron emission tomography in older DS adults with
dementia, and found identical patterns of abnormal glucose metabolism as those known
to occur in AD.
2.4.6  Genetic studies in adults with DS (APOE4)
Apolipoprotein E 4(APOE4) previously been mentioned as a risk factor or Alzheimer
disease in the general population.  APOE4 has also been studied in a DS population,
where it has been linked t to an increased risk for dementia (Schupf et. al., 1996) as well
as early life language deficits, which are thought to modulate later life dementia
(Alexander et al., 1997).  Consistent with this, the epsilon2 allele has been found to
confer a protective effect (Lai et al., 1999) in the development of dementia. 
  
2.4.7  Neurological findings in aging adults with DS
Core neurological symptoms known to be associated with dementia in the general
population, have also been studied in DS.    Many clinical studies have noticed an
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increased prevalence of seizures in older people with DS, particularly in those noted to
have functional deterioration with age (Wisniewski, Dalton, McLachlan, Wen &
Wisniewski, 1985;  Lai & Williams, 1989;  Evenhuis, 1990; Collacott, 1993; Brodtkorb,
1994; Van Buggenhout et al., 1999;  Puri, Ho & Singh, 2001).  Olfactory dysfunction is
also more common in Alzheimer disease in the general population because of the
geographic proximity between the olfactory and the limbic systems.   Consistent with the
increased  rate of dementia in DS, olfactory impairment has been found to increase in
older, but not younger people with DS (Nijjar & Murphy, 2002; Zucco & Negrin, 1994;
McKeown et al., 1996).  Poorer odour identification has also been associated with adults
who have DS and an APOE4 allele (Sliger, Lander & Murphy, 2004).
An increased prevalence of primitive reflexes, known to be associated with advanced
Alzheimer disease in the general population, has been found in clinical studies with
older adults who have DS (Wisniewski, Howe, Williams & Wisniewski,1978; Lott &
Lai, 1982; Sand, Mellgren & Hestnes, 1983;  Thase, Tigner, Smeltzer & Liss,1984;
Vieregge, 1991;  Haw, Barnes, Clark, Crichton, & Kohen,1996; Nelson, Orme, Osann &
Lott, 2001).  
2.4.8  Neuropsychological studies in aging adults with DS
A variety of studies with older adults who have DS have addressed increased
deterioration (compared to younger adults with DS or similarly aged adults with ID but
not DS) in core symptoms of dementia, such as memory, aphasia, apraxia, agnosia and
executive functioning.  Deficits related to memory functioning are of particular interest
in Alzheimer’s disease, and these declines may occur long before the identification of
functional decline (Devenny, Zimmerli, Kittler & Krinsky-McHale, 2002), especially in
individuals who have low environmental demands placed upon them.  Unfortunately,
complicating the evaluation of memory deficits as a symptom of dementia in people with
DS are pre-existing problems with verbal memory, which are found even in children and
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young people with DS (Carlesimo, Marotta & Vicari, 1997; Jarrold, Baddeley & Hewes,
2000; Lanfranchi, Cornoldi & Vianello,2004), making the interpretation of later
disabilities more complex. For example, differences found in cross-sectional
comparisons of older persons with DS with age matched controls without DS (Thase,
Liss, Smeltzer &  Maloon,1982;  Zigman, Schupf, Lubin & Silverman, 1987) might not
indicate aging related pathology as much as pre-existing deficits.  However, various
studies have reported increased deficits in memory functioning in older compared to
younger persons with DS (Wisniewski, Howe, Williams & Wisniewski,1978; Haxby,
1989; Das, Divis, Alexander, Parrila & Naglieri, 1995; Alexander et al., 1997; Brugge et
al., 1994), which may, more accurately, represent deterioration of memory (and related
functions) with age in DS, although there are still potential problems with cohort effects. 
Longitudinal studies of memory deterioration are best designed to assess true aging
changes. Some published studies using this methodology, especially those without
significant numbers of older participants, or those excluding participants with existing
decline have not found significant age related differences in the rate of individual
memory decline in adults with DS (Burt et al., 1995; Devenny et al., 1996; Burt et al.,
2005).  This negative finding may be explained by an true lack of difference in age
related decline in people with DS, but it may also be explained by instruments relatively
insensitive to early decline, a population too young to have started to decline
significantly, or a population already over-selected against those who have early decline.  
Other longitudinal studies have found greater decline in older compared to younger
people with DS: but not in the area of memory, rather in frontal lobe pathology such as
apathy and behavioural change (Holland, Hon, Huppert &. Stevens, 2000).  This study is
supported by the work of Nelson, Orme, Osann and  Lott (2001), who also found that the
earliest longitudinal declines in people with DS and suspected Alzheimer’s Disease were
in emotional domains and in apathy.  They noted that their findings were consistent with
neuropathological findings of increased amyloid deposition in the frontal cortex of adults
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with DS. 
Most consistent with available neuropathological evidence are larger scale longitudinal
studies with adults who have DS, which show individual declines in memory, most
prominently in the oldest cohorts (Dalton, Mehta, Fedor & Patti, 1999), with other
neuropsychological functions, such as praxis affected later.   Some authors such as
Devenny, Krinsky-McHale, Sersen, and Silverman, 2000 also found this decline in
memory, but noted that clinical dementia in DS should not be universally expected, and
that when it does occur, the age of onset may be later than previously expected. 
Longitudinal declines in memory  in older people with DS were also found by Hawkins,
Eklund, James and Foose (2003), in their complex, multilevel modeling study, and in
this ten year study, short term memory declined throughout the lifespan, whereas long-
term memory did not show noticeable declines until after age 45.  
Age-related declines in language are also a key part of the dementing process.  Language
plays a very interesting role in people with DS and dementing disorders, as pre-existing
language/linguistic impairment has been well described in healthy children with DS
(Chapman & Hesketh, 2000), appears to be increased in people with DS and APOE4 
(described earlier), and has also been found to be one of the earliest (early adulthood)
predictors of later onset of dementia in the general population, as described by Snowdon,
Greiner and Markesbery (2000).  In this, now famous “Nun Study”, linguistic ability in
early life was associated with the severity of Alzheimer’s disease pathology in the brain
many years later, after the sample had aged.  This has been a fascinating finding to
researchers in the area of DS and aging, has many raised many interesting questions
about the role of language in the production of intellectual decline.    
Possibly because of this association between early language ability and risk for
Alzheimer’s disease, language functions such as aphasia in adults with DS have not
always been associated with age cohort differences once initial levels of disability were
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adjusted for.  However, in a well-designed longitudinal study, individual changes are
more likely to be apparent.  Oliver, Crayton, Holland, Hall and Bradbury (1998), in their
four-year prospective study of age-related cognitive change and adults with DS, assessed
aphasia and agnosia by asking participants to name 14 pictures of everyday objects and
identified pictures following a verbal instruction.  The authors found that aphasia (as
well as other symptoms of severe cognitive deterioration) was more common in older
subjects with DS, and that the rate of deterioration increased with age and the degree of
pre-existing cognitive impairment.  They also found that the deterioration of memory
related functioning occurred before deficits in  aphasia , agnosia and apraxia.    
  
Another core symptom of dementia is apraxia.  This was defined by Yesavage, Brooks,
Taylor and Tinklenberg (1993) as the  “inability to carry out purposive or skilled acts due
to brain damage but not due to other reasons such as failure to comprehend, weakness,
paralysis or sensory losses which may result in imperfectly executed movements”. These
researchers studied 127 adults with Alzheimer’s Disease (not ID), and found that
Alzheimer’s Disease patients with apraxia had a more rapid decline, based on scores on
the Mini Mental State Examination (MMSE).  
Complicating any cross-sectional comparison of praxis in adults with DS compared to
adults without DS is the fact that even children with DS have been noted to have
dysfunctions in  praxis (Fidler, Hepburn, Mankin & Rogers, 2005).   This limits studies
such as that by Thase, Liss, Smeltzer and Maloon (1982), who explored praxis (no
definition given) in their cross-sectional comparison study of institutional adults with
and without DS, matched for age and IQ .  The authors found that people with DS were
more frequently apraxic (40% compared to 10% of controls), but because of cross-
sectional methodology it was not possible to separate pre-existing changes from aging
changes.  
Oliver, Crayton, Holland, Hall and Bradbury (1998) also assessed apraxia (by asking
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participants to carry out simple action such as clap their hands) in their four-year
prospective study with adults who had DS.   As in the section on aphasia, the authors
found that apraxia was more common in older subjects with DS, and that the rate of
deterioration increased with age and the degree of pre-existing cognitive impairment.    
Soininen et al (1993) studied praxis in their cross-sectional comparison group of  adults
with DS, adults with probable Alzheimer’s disease and age matched controls.  They
explored simple movements, kinesthetic basis of movement, optic-spatial organization,
dynamic organization of motor activity, oral praxis and ideomotor praxia.  Although DS
patients were overall less impaired than Alzheimer patients in praxis, in people with DS,
age was significantly related to decline in praxis.   
Burt et al (2005) found weak evidence of  increased decline in fine motor tasks in adults
with DS compared to those without DS.  
Changes in executive functioning over time are also a key part of the diagnosis of
dementia..  Many instruments designed to measure aspects of core cognition in dementia,
such as the MMSE, do not adequately measure deterioration of executive dysfunction
(Stokholm, Vogel, Gade & Waldemar, 2005), although these symptoms are frequently a
key source of distress to caregivers and families.   
2.4.9 Clinical diagnosis and prevalence of dementia in aging adults with DS
Whereas some findings, such as neuropathological evidence of plaques and tangles, are
relatively reproducible and “objective”, the ascertainment of specific symptoms such as
memory or apraxia (described above) necessarily involves more subjectivity, with
resulting variability of results, as it depends more on assessment approaches as well as
vissicitudes of the testing process.  The diagnosis of dementia in people with DS is even
more fraught with rater subjectivity, as it is dependent on individual rater factors, current
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patterns of clinical beliefs about dementia in this population, and understanding of the
typical biological, psychological and sociocultural issues in the DS population.
It is also inherently a very difficult clinical task, as its symptoms progress gradually, with
no one, obvious cut-point at which the gradual decline can be suddenly called
“dementia”.  By the DSMIV (American Psychiatric Association, 1994), there must be
significant decline from previous functioning, and this is in the final analysis a value
judgement based upon clinical observation of meaningful change in people.  The choice
of “cut-point” therefore involves a fair amount of arbitrariness, which can significantly
affect prevalence rates.  
The practical assessment of dementia in people with ID is further limited by baseline
deficits in functioning,  including poor language skills, physical and mental comorbidity,
impoverished social opportunities for learning, floor effects of on instruments designed
to measure cognition in the general population, and a lack of universally applicable
instruments to make this diagnosis (Aylward, Burt, Thorpe, Lai & Dalton, 1997). 
In spite of the uncertainties listed above, there is some general agreement on the issue of
DS and dementia.  Firstly, the well-established Alzheimer type pathology (by the age of
35) in the brains of people with DS is not accompanied by the expected, equally early
clinical development of dementia, but by a more delayed clinical process, whose details
are still under debate.  Secondly, it is generally agreed upon that the overall prevalence of
clinically diagnosed dementia in people with DS is increased compared to those without
DS.  Still under debate is whether all people with DS will eventually get Alzheimer’s
disease, and what protective factors help some individuals age so well into very old ages.  
Some clinical awareness of the increased risk of dementia in people with DS was already
apparent in the literature from over a hundred years ago, when Fraser and Mitchell (1876)
published their article on “precipitated senility” in people with DS. It was not until 1948,
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however, when Jervis published his seminal article in the American Journal of Psychiatry
(Jervis, 1948), that the formal association between DS and dementia was more widely
recognized.
A variety of methods (cross-sectional versus longitudinal, prospective versus
retrospective, descriptive versus clinical trial, direct assessment versus caregiver
information) and diagnostic criteria were used in early studies of cognitive decline in
people with DS, accounting for a wide variation in prevalence figures.  Not all of these
were able to publish age-based prevalence figures, many had no appropriate controls and
many of these had small numbers of study participants. Most early studies also did not
assess sensory impairment, and many were based on primarily institutional samples,
which may not be representative of the general population of people with DS.  Even
more problematic is the fact that many of the studies were based on nonrandom
populations, often clinical samples, giving rise to large sources of potential bias.  
Increased complexity of the study population and differences in study methodology have
resulted in widely varying results for the prevalence of dementia, as was summarized by
Zigman, Schupf, Haveman and Silverman (1997).  Cross-sectional record reviews of the
prevalence of dementia, as published by Haveman, Maaskant and Sturmans (1989) are
particularly problematic in assessing true outcomes because of the lack of ability to
assess comorbidities that may be contributing to decline.  Some of the key studies
addressing the prevalence of dementia are summarized below, but full details are
available in the references publications.
Lai and Williams (1989) studied a  group consisting of 73 institutionalized and 23
community-based adults with DS.  Neurological assessments were performed and 
treatable causes of dementia were explored.  Electroencephalograms and CT scans were
performed in almost all patients who had dementia.  Some longitudinal data were
available, and autopsies were available on 12 participants. Dementia was defined as a
38
decline in one or more of the assessed skills.  The authors reported that about half of
their population of 96 DS individuals over the age of 35 had dementia, with an average
age of onset being 54.2 ± 6.1 years.  They found that dementia occurred in 2 of 25
subjects between ages 35-49 years, 11 of 20 between 50-59 years, and 6 of 8 over 60.  
Evenhuis (1990) studied all 17 patients with DS who died after the age 40 and older
from an institution for mentally retarded persons, attempting to obtain both clinical and
neuropathological data.  She found that 15 of 17 of these had a clinical diagnosis of
dementia, largely based on diagnostic criteria of the DSM-III-R (American Psychiatric
Association, 1987), and that their symptomatic decline was similar to that seen in AD of
people without DS. 
Franceschi, Comola, Piattoni, Gualandri and Canal (1990) examined 50 community
dwelling adults with trisomy 21 (verified by chromosomal examination).  Neurological
examinations were performed on all of the sample, and further imaging studies were
performed on a subgroup.  Functional and behavioral information was obtained from
caregivers, and the diagnosis of dementia was made according to an adaptation of
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's
Disease and Related Disorders Association (NINCDS/ADRDA) criteria (McKhann et
al., 1984).  Dementia was found in18% of patients aged 20-52 years, with an age-related
increase in prevalence apparent in this sample: the prevalence was 0 in the 20-29-year-
old group, 33% in the 30-39 year-old group, and 55% in the 40-52-year-old group. 
Neuroimaging findings were consistent with clinical findings.
Roeden and Zitman (1995) assessed 71 adults with chromosomally verified DS (45 from
an institution and 26 from group homes) using a variety of direct and caregiver based
measures over a period of up to 4 ½ years.  Experimental measures included tests of
adaptive functioning, assessment of intelligence, assessment of functioning as measured
by the Dementia Questionnaire for Person with Mental Retardation (DMR) by Evenhuis
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(1992), assessment of motor function, and medical examination, including assessment of
sensory abilities.  The diagnosis of dementia was made using modified DSM-III
(American Psychiatric Association, 1987) criteria, and depression was carefully ruled
out.  Ten individuals met the criteria for dementia (aged based prevalence could not be
assessed from the sample), and all of these came from the institutional subgroup.
Devenny et al. (1996) studied 91 adults with DS and 64 adults with ID, but not DS, who
worked in a community workshop, were older than 30, had an IQ greater than or equal to
35, had no uncontrolled seizures or recent development of seizures, no significant,
uncorrected sensor impairments, and no pre-existing suspicion of decline in their
functioning at the time of entry to the study.  IQ scores were obtained from the most
recent standardized assessments in their records.  Diagnoses of DS was made on the
basis of phenotypic characteristics, although many of these also had chromosomal testing
available.  There was no mention of specific medical assessment to rule out concurrent
medical illnesses in the group as a whole, although participants who developed dementia
were assessed by specialists in more detail later.  Participants were followed for up to
five years, and given an annual test battery consisting of the IBR Evaluation of Mental
Status (Wisniewski & Hill, 1985), as well as modified forms of the Selective Reminding
Test (Buschke, 1973) and the Visual Memory Test (Devenny, Hill, Patxot, Silverman &
Wisniewski, 1992).  The Block Design, Digit Span and Coding subtests of the Wechsler
Intelligence Scale for Children- Revised (Wechsler, 1974) were also administered.  The
diagnosis of dementia was made on the basis of declines in functioning in everyday
memory and current disorientation. Statistical analysis used hierarchical linear modeling. 
Results showed that scores on the mental status examination were stable over repeated
evaluations, with no effect of age or diagnosis.  However, participants without DS
improved more over repeated testing than did those with DS.  Among participants with
DS, older participants showed a small decline in performance over test times, whereas
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younger participants tended to improve.  However, tests for the slopes were not
significant on the longitudinal measures.  Only four out of 91 people with DS were
thought to have a diagnosis of AD. The authors concluded that adults with DS and mild
to moderate ID had a lower risk for dementia in their fourth and fifth decades than
previous studies had suggested.
One of the most cited population dementia prevalence studies among adults with DS was
performed by Holland, Hon, Huppert, Stevens and Watson (1998).  Seventy-five  people
from the Cambridge Health District in the UK were included in the study group. 
Authors used the informant interview of the Cambridge Examination for Mental
Disorders of the Elderly (CAMDEX: Roth, Huppert, Tym & Mountjoy, 1988), but also
compared it with other diagnostic criteria including the DSM-IV(American Psychiatric
Association, 1994) and the ICD-10 (World Health Organization, 1992). Whenever
possible, laboratory investigations were also conducted. Final diagnoses were
determined by consensus between the research psychiatrist and the research
psychologist.  Using the CAMDEX criteria, this study found the following prevalence
rates of dementia: 3.4% in the 30-39 year-old age group, 10.3% in the 40-49 year-old age
group, and 40% in the 50-59 year-old age group.  Researchers did not find that there was
a relationship between the level of intellectual disability and dementia, although the most
severely impaired individuals were more likely to be given a diagnosis of frontal lobe
dementia.
Prasher, Chung and  Haque (1998) studied age-related changes in adaptive behavior in
128 adults with DS (mean age 43.44 years) using annual assessments over a 3-year
period. Detailed physical examination as well as laboratory examination was performed,
medication use reviewed, caregiver information obtained using the standard instrument,
the DMR (Evenhuis, 1992), and data on adaptive behavior collected using the Adaptive
Behaviour Scale (Nihira et al., 1974).  Diagnoses were made using the Diagnostic
Criteria for Research (WHO, 1993) , and dementia was only diagnosed when there was
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deterioration of adaptive behavior in cognitive and behavioral features for a minimum of
two years.  There was a significant decline in the overall group, as measured on part I of
the ABS, and a DCR-10 diagnosis of dementia was made in 26 out of 128 (20%) adults. 
Authors did not find an association for decline with gender, sensory loss, severity of
mental retardation, or place of residence. Their study did suggest caution in interpreting
individual decline to dementia because of a high rate of physical and mental
comorbidity.
Schupf et al. (1998) studied a community-based sample of 111 adults with
cytogenetically confirmed DS, making a diagnosis of dementia (based on a caregiver
interview and review of medical records), and carrying out APOE genotyping.  23% of
males and 14% of females were found to have dementia, but 43.5% of those with APOE
3/4 and 4/4 genotypes had dementia. The authors also found that males and those with an
APOE epsilon4 allele had an earlier onset of AD, and speculated that this might be due
to different gender variation in hormonal function in adults with DS compared to those
in the general population.  
Tyrrell et al. (2001) studied 285 people with DS, making a diagnosis of dementia using
modified DSMIV criteria, and administering the Down's Syndrome Mental Status
Examination (Gedye, 1995), the Test for Severe Impairment (Albert & Cohen, 1992) and
the Daily Living Skills Questionnaire (National Institute on Aging, 1989).  The overall
prevalence of dementia was found to be 13.3%, and occurred at a mean age of 54.7
years.
2.5  Service provision for people with ID
2.5.1  Review of Saskatchewan service changes over the last century
Lorne Elkin (1976) published a review of care issues for people with intellectual
disabilities in Saskatchewan, illustrating changes over the last century, particularly the
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transition from institutional to community care.  This section of the thesis draws
extensively on this publication, as very little information on care issues in Saskatchewan
is otherwise available.
Around the turn of the last century and for many years afterwards, documented attitudes
to people with intellectual disabilities appear astonishingly devaluing and dehumanizing. 
Elkin excerpted parts of a document issued by the Bureau of Social Research
Governments of Manitoba, Saskatchewan and Alberta in 1916.  This document
addressed the problem of the “mental defective”, whose “childish mind in his adult years
inevitably brings him into conflict with laws, customs and rules of conduct...”. 
Regarding education, the document stated that “the mentally defective, not only are
retarded, but they retard the whole class and, not infrequently, cause endless trouble in
the school.”  Furthermore, the government document warned, “mental defectives are
here in hundreds: they are multiplying rapidly: more are coming in every shipload of
immigrants.” After setting the stage for increased fear and resentment for those with
intellectual disabilities, the document then recommended stricter immigration laws,
amended marriage laws, and special protection, including supervision, sterilization or
segregation.  Of course, as has been well publicized by court actions in recent years,
eugenic policies such as involuntary sterilization did then become publically acceptable
and very common. According to Elkin, it continued to be advocated by the government
in Saskatchewan until the 1940s.
What little organized care was provided for those with intellectual disabilities was
provided by the Department of Health in the same settings as care for people with mental
illnesses: (i.e., preferentially large institutions).  In Saskatchewan, these were originally
located in North Battleford and in Weyburn.  It was not until 1947 that 700 people with
intellectual disabilities were moved from the mental hospital in Weyburn to temporary,
but specialized facilities at the Weyburn airport.  Once the new, permanent facility (the
Saskatchewan Training School) for people with intellectual disabilities was opened in
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Moose Jaw in 1955, the Weyburn residents were moved there, joining residents from
other parts of the province. 
The training school was initially seen as a major improvement in care for people with
intellectual disabilities.  Its design involved the construction of 18 separate cottages for
residents with underground tunnels connecting them. Along with the recreation and
therapy facilities, laundry, hospital, worship facilities, school, workshop and
administrative areas, the centre became a self-contained community, proving jobs and
economic prosperity to a large percentage of Moose Jaw citizens. At its highest
occupancy, 1,150 people resided in this training facility.  Unfortunately, as Elkin
documents, the new building was filled to capacity rapidly, and because of crowding and
staff shortages, individualized care was generally not possible.  Education and vocational
training was only provided to the highest functioning residents, and lower functioning
residents had minimal custodial care only.  
Pressure was taken off the Moose Jaw facility by the opening in 1961 of the new satellite
centre in Prince Albert: the Prince Albert Training School. However, soon after its
opening, the drive for community care gained strength, with much of this emphasis
driven by advocacy organizations representing parents of intellectually disabled children. 
Up until this point, care for people with intellectual disabilities was provided under the
auspices of the Department of Health.  However, there was much popular demand for a
new government agency that would be responsible for those with intellectual disabilities,
so in 1972, Core Services, under the Department of Social Services, was established, and
took over this mandate from health.
Core Services took the position that the community should take a large role in
developing and providing services, and thus instigated and supported the development of
community boards, which administrate independently run services.  These services
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include small to large group living facilities, workshops and other supportive programs,
and have now sprung up in small, medium and large centers throughout the province.
There has been much improvement in the provision of education to people with
intellectual disabilities.  In the earlier part of the century, the education act allowed
schools to exclude children with intellectual disabilities.  Fortunately, in 1971, after
much effort by advocates, Bill 122 made the provision of education mandatory for all
children.  Initially, the emphasis was on the provision of special schools, or special
classrooms within general schools for children with intellectual disabilities.  One of the
last such schools built was the John Dolan school in Saskatoon.  However, the
predominant force was now for mainstreaming children into the regular school system,
and this has gradually become the generally accepted policy over the last 40 years, with
most children with ID now participating in regular school programming. 
Unfortunately, there are still difficulties with children who have severe or multiple
handicaps.  Assessment and intervention programs for these children had to be
developed.  The best-known of these is the Alvin Buckwold Center, part of the Royal
University Hospital in Saskatoon, which opened in 1975, led by a trained child
psychiatrist, Dr. Witold Zaleski. The Alvin Buckwold Center provided, and still does
provide various assessment and treatment services for children throughout the province,
using a multidisciplinary model and outreach services as well as office based care.  Staff
are actively involved in teaching and research as well. 
In contrast to these services for children, services for adults with intellectual disabilities
and severe multiple handicaps are less well developed.  In particular, although originally
at the Saskatchewan Training School, a psychiatrist provided clinic leadership, and there
are some behavioral therapists in the province hired by the Community Living Division
of social services (now called the Department of Community Resources and
Employment), there are currently no formal, specialized psychological or psychiatric
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services for adults with intellectual disabilities in Saskatchewan.  Generic mental health
services only incompletely meet the needs of this challenging population.  
Valleyview Center, previously called the Saskatchewan Training School, has over time
decreased the number of people living there to 362, as noted in its last updated web site,
as reviewed on August 31, 2005 (Saskatchewan Department of Community and
Employment, 2005).  A major goal of administrators is to discharge the remaining
residents, and almost no new admissions take place now.  Adults with intellectual
disabilities and highly challenging physical and mental health issues have been dispersed
throughout the province, for the most part with apparent success.  However, some have
continued to have challenging needs, such as significant behavioral problems, which
have not been well met in a community setting.  As a result of this, and because of the
aging of this population, some have eventually  moved into another institution, such as a
nursing home (see later section on transinstitutionalization), which may pose even
greater concern to quality of life issues such as autonomy and participation in
meaningful activity.  
Increases in the community dwelling, aging population with intellectual disabilities have
also prompted the gradual development in Saskatchewan of modified community work
situations, day programs for older adults, and even the potential for retirement. Although
many smaller localities do not yet have access to these services, there has been
significant growth in this area, which is continuing at this point in time.
2.5.2  Institutionalization
Although the development of institutions specialized for people with intellectual
disabilities was an improvement over institutionalization in facilities designated for
people with mental illness, increased attention to the adverse impact of
institutionalization itself has resulted in service changes throughout the Western world,
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similar to those discussed above for Saskatchewan.
Much has been written about the adversities of institutionalization, but a recent review
from the American Association on Mental Retardation (AAMR, 2004) summarizes the
issues well.  Abuse and neglect are thought to be more likely and more difficult to detect
in institutions because of the common experiences of crowding and depersonalization. 
There may be a “wall of silence” protecting abusers among institutional staff, and
frequently there is also inadequate staffing and a lack of other resources that could
contribute to improvements in the quality of life.  Provision of care to large numbers of
people in one site may also contribute to dehumanization, or the regarding of
institutionalized people without human dignity and respect. Segregation and isolation
from the surrounding community decreases involvement of the person with their family
of origin, friends, and other normalizing organizations. Institutionalization, including
restriction to a facility without adequate access to challenge or appeal also constitutes a
loss of human and civil rights.  Residents have little individualization in their services,
and are often deprived of privacy, choice and control in their lives. They also often have
less access to education and the opportunity to increase their own skills, leading to
excessive dependency. 
Aside from these psychosocial issues, large, congregate living situations contribute
towards higher prevalence of certain infections, such as hepatitis and Helicobacter pylori
(Wallace, 2004).  There may also be increased mortality of those in institutional settings
compared to community settings, although there is some disagreement on this, and
differences may depend on the medical complexity of the pre-existing developmental
disability. For example, Shavelle, Strauss, and Day  (2005) analyzed data from over
2000 people transferred from institutional to community care in California, finding a
47% increased mortality in those who were deinstitutionalized.
2.5.3  Deinstitutionalization
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The recent trend to deinstitutionalization of people with intellectual disabilities in
Saskatchewan was described earlier.  This trend is consistent with trends across Canada
and the Western world, particularly in the USA, where there has been a striking
depopulation of institutions, as reviewed by Anderson, Lakin, Mangan and Prouty (1998)
and Coucouvanis,  Polister, Prouty and Lakin (2003).
Many published studies have shown positive outcomes in people with intellectual
disabilities who are moved from the institution into the community. These studies have
recently been reviewed in depth by Kim, Larson and Lakin (2001), who concluded that
there is good evidence that deinstitutionalization usually results in improvements in daily
living skills, community participation, contact with community family members and
others in the community, greater choice, and satisfaction. This of course, depends on the
degree of community resources available, and selected changes may therefore not always
be apparent.  For example, the use of psychotropic medications for behavioral problems
may not necessarily decrease (Nottestad & Linaker, 2003), especially not in the short
term, as the learning of new, more adaptive behaviors, requires skilled staff supports and
time.
There may be cost benefits also, in moving people from institutions to the community,
and this has been described in a number of scholarly publications such as that by Spreat,
Conroy and Fullerton (2005).  Unfortunately, without considerable advocacy, cost
savings may be realized by the provision of cheaper and less appropriate community
resources, possibly resulting in poor care and quality of life, particularly for those with
high needs. 
The greatest challenge lies in meeting the needs of those people who have the most
severe, comorbid medical and mental disabilities, and Canadian data does suggest that
there is considerable physical and mental morbidity after deinstitutionalization
(Fotheringham, Abdo, Ouellette-Kuntz, & Wolfgarth, 1993).  Quick mobilization of
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additional staff from a larger environment in responding to severe aggressive behaviors
may be able to achieve and maintain safety for the person and others without the
administration of regular, higher dose, tranquilizing  medications. However, the same
severe behavior in a small group home with only one staff on at night, may necessitate
much higher doses of ongoing sedation, and possibly transfer to an inpatient psychiatric
facility, where restraining medications will very likely also be increased.  The needs of
people with serious medical problems such as refractory seizure disorders may also
outstrip the resources of caregivers and medical staff in the community.  This is
exacerbated by the deficits in training opportunities in ID in Canada, which are discussed
elsewhere. 
Other concerns that have been raised about deinstitutionalization (especially that
occurring rapidly without adequate provision of community resources) include fears for
community safety by the public, suspicion that deinstitutionalization is a vessel for
decreasing public expenditures rather than increasing the quality of life of people with
ID (Holden, 1992), lack of community resources with potentially inappropriate and
revolving door psychiatric admissions and trends to transinstitutionalization to facilities
for the aging and correctional institutions.  There is also data suggesting that increased
contact with non-developmentally delayed persons in the community may be less likely
than had been hoped (Fotheringham et al., 1993).
2.5.4  Transinstitutionalization.
Transinstitutionalization is a term reflecting the move from one institution, only to
ultimately end up in another one.  Some adults with intellectual disabilities who are
discharged from an institution for people with ID, accompanied by others whose mental
and physical needs outstrip community resources, are eventually placed in nursing
homes.  The full magnitude of this pattern in Saskatchewan is not well understood, as
there is no roster of adults with intellectual disabilities, and statistics on their treatment
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in the long-term care system are not uniformly available. Some nursing homes, such as
Parkridge Center in Saskatoon, have responded to this clinical need by designating
specific areas of the nursing home for those with intellectual disabilities, aiming to
enrich the daily environment in a developmentally appropriate way, but also to enable
staff to streamline and improve the care provided.  
The general provision of care to  people with intellectual disabilities in nursing homes is
not a new phenomenon, and has been described from around the world.  For example,
Lakin, Hill and Anderson (1991) found significant numbers of older people with
intellectual disabilities in nursing homes in the United States, with some variation
between States.  Hand (1994) and Hand and Reid (1996) found that 13% of older people
with intellectual disabilities in New Zealand lived in rest homes, presumably designed
for the generic older adult population.  Major legislative changes were made in the USA
regarding nursing facilities in 1987, resulting in decreases in the proportion of those with
ID who lived in this type of environment.   Prouty, Smith and Lakin (2005) published a
major review of residential trends for persons with developmental disabilities in the
USA and found that  about 5.9% of people with ID or developmental disabilities (DD)
receiving services were in nursing home facilities in the USA, which had decreased by
13.4% since 1970.
For the most part, nursing home institutional care has allowed for closer proximity to
families of origin, and blending with generic, not intellectually disabled populations. 
However, nursing homes are still institutions, and suffer from a variety of issues
common to this care setting such as rigid institutional routines, nosocomial infections
and lack of resident autonomy.  Furthermore, unlike the situation in institutions such as
Valleyview Center, where staff developed considerable expertise with intellectual
disabilities, most staff in nursing homes are not familiar with the mental and physical
needs of this group.  There is also frequently a lack of developmentally appropriate
programming, and those with intellectual disabilities are often not well accepted by the
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generic, aged population.  Lastly, prescribing of psychotropic medications may not be
improved in nursing homes.  For example, Spreat and Conroy (1998) found that over
30% of people with mental retardation admitted to a nursing home were given
antipsychotics, and raised concern over this type of placement. 
Transinstitutionalization is not always to a nursing home.  Among people with
borderline to mild intellectual disabilities, another possibility is transinstitutionalization
to the correctional system.  This form of transinstitutionalization has been well described
for people with mental illness (Morrissey & Goldman, 1986), particularly after closure of
large psychiatric institutions.  It is also known that the correctional system houses many
people with intellectual and learning disabilities, and that these probably do not receive
appropriate services (Barron, Hassiotis & Banes, 2002) and have high recidivism rates. 
People with FAS and Fetal Alcohol Effects (FAE) are particularly at risk for entering the
correctional system (Streissguth et al., 2004) because of impulse control problems which
are difficult to manage in open settings without sufficient structure.  Unfortunately, FAS
and FAE are still not optimally identified in correctional systems (Burd, Selfridge, Klug
&  Bakko, 2004).
Transinstitutionalization can result in an apparent decrease in the institutionalization of
adults with intellectual disabilities, yet actually represent another form of institutional
care that may be even less appropriate. 
2.5.5  Psychiatric care
Psychiatric services to adults with ID are  generally supplied by general  adult 
psychiatrists with no special training in ID, and no special mandate (or financial
incentive) to supply services to people with ID.  There is no formal mandatory training in
ID within Canadian psychiatric training programs, nor a subspeciality training stream,
unlike in other countries, such as the UK.  The clinical training that is available in
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Canada is fragmented, variable and thought to be suboptimal (Lunsky & Bradley, 2001;
Leichner, 1977; Leichner,1987).  Although some interest has been expressed recently in
establishing additional training in this area, the process to achieve this at the level of the
Royal College is anticipated to be lengthy, and will be limited by the shortage of
academic psychiatrists trained in ID.  Issues related to reimbursement are also
problematic, as adults with ID generally have complex presentations of psychiatric
illness resulting in diagnostic challenges, increased time requirements for a full
assessment, and increased need for on-site evaluation (as environmental and staff factors
are frequently instrumental to the clinical presentation).  Fee-for-service models, which
reimburse consultations irrespective of complexity and penalize outreach and intensive
team involvement, serve to deter full, multifactorial assessment of the adult with ID and
complex emotional, behavioral or psychiatric needs.
In Saskatchewan, 2.5 % of the general population receives some formal mental health
care (defined as a visit with a psychiatrist or a psychologist) each year (Vasiliadis,
Lesage, Adair & Boyer, 2005).  The extent, intensity and adequacy of psychiatric care of
adults with ID is not known.  Although the increased prevalence of behavioural
problems would suggest increased psychiatric contact compared to the general
population, Canadian research findings that less privileged people have reduced
frequency of psychiatric contact (Steele, Glazier & Lin, 2006) would suggest decreased
psychiatric contact.  It is likely that people with ID are more likely to see a psychiatrist in
consultation occasionally for significant mental health problems, but that they also
receive less frequent, continuing services such as psychotherapy. 
2.5.6  Aging related care issues: day programs, retirement, long-term care
Special service development for older people with intellectual disabilities is fairly recent,
in response to the increased community prevalence of older adults within this
population, as discussed earlier.  However, as early as in 1987, published reports indicate
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that many generic aging services were supplying services to older adults with intellectual
disabilities, and that in some of these services at least 10% of the clientele had
intellectual disabilities (Seltzer, Krauss, Litchfield & Modlish, 1989).  Seltzer (1988)
performed a telephone survey of staff in Massachusetts exploring service use by older
people with ID.  He found that there was an increased number of older people with ID in
the population, that these required  an increased number of services, and that they were
frail.  Problems with integrated ID services that provided care for older adults were lack
of provision of appropriate age related activities.  The practical provisions made for
older people with ID to retire was another problem noted. On the other hand, Seltzer also
noted difficulties with providing services to people with ID within generic aging
systems, because of a lack of appropriate available programming geared to this group.  
Janicki and Dalton (1997) performed a very large scale mail survey of 4028 individual
residence and the service settings in the state of New York.  As well as ascertaining rates
of suspected dementia, they also surveyed the use of various programming, finding that 
19.26% of people with ID resided  in nursing facilities (7.09% with DS and 25.62%
without DS).  This survey ascertained that only 1.63% of study participants were
involved in retirement activities (0.37% with DS and 2.29% without DS), and only 7.3%
attended senior centers (4.85% with DS and 8.22% without DS). 
Cooper (1997) found that older adults with ID in Leicestershire, England, received less
day care and less respite care than younger people with ID, which is likely similar in
Saskatchewan.  
Because of concerns that generic aging facilities for people with ID may not always be
developmentally appropriate for or desired by the intellectually disabled population, a
second alternative, therefore, is to enrich existing programming for people with
intellectual disabilities so that older people can “age in place” ( i.e., maintain familiar
environments and the friendships while they age, rather than disrupt their lives by
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making major changes when they need more care). There are also challenges to this
approach because age related problems may increase the complexity of care required. 
Modifications to day programming are needed to adapt to increasingly frail clients, and
staffing adjustments may be needed to allow for the possibility of total retirement from
day work programs.  In the case of dementia clients, secure wandering areas are required,
and increased training for staff to manage dementia specific behaviourial changes. 
A third alternative is to develop separate and specialized programming for older people
with intellectual disabilities. This could involve a separate residential facility, or just
attendance at a special day program specialized for older adults with intellectual
disability, for example.  These specialized facilities will likely only be feasible in larger
urban centers.
2.6  Use of psychotropic medications
A long-standing issue of concern has been a high, and not necessarily appropriate use of
psychotropic medications among people with intellectual disabilities (Kiernan, Reeves &
Alborz, 1995;  Singh, Ellis & Wechsler, 1997;  Spreat, Conroy & Jones, 1997;  Holden
& Gitlesen, 2004;  Sachdev, 1991;  Stone, Alvarez, Ellman & White, 1989).  A high
prevalence of the use of antipsychotics in particular, has been reported from most of
these studies.  This is of concern for two main reasons.  Firstly, these medications were
initially developed and approved for psychotic disorders, yet are more frequently used in
people with intellectual disabilities to suppress undesirable behaviors (Matson et al.,
2000), for which behavioral interventions are thought to be more appropriate.  Secondly,
there are well-established, significant adverse short and long-term effects of
antipsychotics, including adverse effects on motor domains, cognition and learning and
even life expectancy.  
Although some surveys have suggested that the use of antipsychotics in adults with
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intellectual disabilities is decreasing with time (Hancock, Weber, Kaza & Her, 1991), the
prevalence is still higher in adults with ID than in the general population.  Hopes had
been high that deinstitutionalization would result in individual reductions in the use of
antipsychotics, but unfortunately, longitudinal studies have generally not shown an
individual pattern of change (Thinn, Clarke & Corbett, 1990, Nottestad & Linaker,
2003), unless special medication reduction strategies are put in place (Radouco-Thomas
et al., 2004).  In fact, some surveys have suggested that community dwelling people with
intellectual disabilities might even have an increased rate of use of antipsychotics (Pary,
1993).
Whereas there has been a historical pattern of overuse of antipsychotics in people with
intellectual disabilities, it is thought that there has been a correspondingly low use of
antidepressants, in spite of a substantial prevalence of depression in this population
(White, Chant, Edwards, Townsend & Waghorn, 2005) when it is carefully screened for.
This is probably the result of difficulties in diagnosing depressive disorders in people
with significant cognitive impairment, especially if there is a severe communication
disorder.   Recent pharmacological reviews have suggested that the rate of antidepressant
use is increasing (Spreat, Conroy & Fullerton, 2004), although it is clear that the
knowledge base pertaining to the prevalence and treatment of mood disorders in this
population is still not optimal (Davis, Judd & Herrman, 1997).
2.7 Summary
A number of broad conclusions can be drawn from the published literature, as
summarized in this chapter.   The proportion of people with ID surviving into old age is
increasing, with a number of disparate factors affecting mortality.  Physical morbidity is
higher in those with ID than those in the general population, with specific morbidities in
younger ages most closely tied to the underlying cause of the ID, whereas age related
changes are fairly similar to those seen in the general aging population.  Sensory deficits
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may be particularly common, especially in DS, contribute to functional impairment and
are not always well identified.   Emotional, behavioural and psychiatric morbidity is very
common in people with ID, especially in younger ones and in those with specific
diagnoses (such as Fragile X), although there appears to be a resurgence of problems in
older ages, which is associated with cognitive decline.  Functional and cognitive decline
with age is accelerated in those with DS (compared to those with ID but without DS) ,
although the actual diagnosis of dementia is less frequent than suggested by
neuropathological data.  Service provision for people with ID has undergone major
changes in the forty years, particularly in the shift from institutional to community focus,
and the impact on health and quality of life has mostly been positive, although large
challenges remain.   The use of psychotropic medications in people with ID remains a
concern, with a high frequency of use of sedative or tranquilizing medications to treat
behaviours, but a sub-optimal (but improving) treatment of mood disorders.
The methodology described in the next chapter was designed to obtain information on
the above aspects of health and health care in community dwelling Saskatchewan adults
with ID, with the understanding that this information may differ from the published
literature, mostly because of differences in service patterns and health care delivery, and
may therefore impact future needs.
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3.  METHODOLOGY
This chapter presents information on methodology (data collection and  specific
instruments used), and statistical analysis (how data were analyzed and why particular
methods of analysis were chosen).
3.1  Data collection and instruments
3.1.1  General challenges of data collection 
As cognitive decline in adults with DS had been the predominant concern voiced by
caregivers of adults with ID in the health region, this was the initial defined goal of the
study.  A full literature search had been performed to explore assessment instruments
and protocols for age related intellectual decline in adults with ID, particularly those
with DS.  Details of this are reported more fully in the literature review chapter. 
One outcome of this search was that there was a lack of universally acceptable
instruments for use in this population. The biggest reason for this was that this
population is highly heterogeneous in multiple domains, including baseline intellectual
functioning (IQ), medical comorbidity, and various psychosocial factors.
In particular, baseline IQ ranges from extremely low scores in those who are profoundly
impaired (no independent functioning, no language, no other form of reliable
communication) to almost normal scores (community dwelling, engaged in gainful
employment and fully verbal).  This means that instruments designed to discriminate
between abilities at the higher IQ ranges can not be administered to those at the lowest
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ranges, and that the more basic instruments designed to measure core functioning at the
lowest ranges would have severe “ceiling effects” for those with higher IQ scores.
Also found to be important was significant medical heterogeneity of adults with ID. 
Some have few medical problems, but others have ID secondary to major chromosomal
syndromes or neonatal injuries.  These often have related other serious and pervasive
medical challenges, including sensory deficits and refractory epilepsy requiring high
doses of anticonvulsant medications.  Some of the most severe medical problems might
impair the ability of assessors to accurately measure cognition.
Cognitive and behavioural functioning may also be affected by lifetime experiences and
learning.  Adults with ID have had widely varying exposures to these experiences, some
due to geographic availability of resources, some due to societal belief systems about
those with ID, and some due to their own families’ wishes. Those who have resided
much of their life in institutions have had particularly different experiences, but may also
have been highly selected for having more profound intellectual disabilities, or more
severe challenging behaviour, such as aggression.  There is a also a potential cohort
effect present in this regard, as those born with ID in the last twenty to thirty years or so
in Saskatchewan have had greatly increased early medical, social and educational
interventions.  They have also been gradually more integrated into the mainstream
society, with continuing decrease in institutionalization and increase in community
living, even among those with very severe and profound disabilities.  This may have had
positive effects on individual adult cognitive functioning, yet, may have paradoxically
decreased the mean intellectual functioning of this community dwelling younger adult ID
cohort. 
3.1.2  Protocol development
Instruments that were considered for the study were to be readily and freely available,
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easy and efficient to administer, and ideally have acceptable published psychometric
data. Participants should also consider the tests acceptable and not too stressful to
perform.  To help in planning the protocol for the study, the lead investigator attended a
variety of international meetings about aging in adults with ID, and participated in a
panel to develop guidelines for the assessment of cognitive decline in those with ID. 
Potential participants, as well as clinical and administrative staff involved in the care of
people with ID were also consulted about the development of protocol for the larger
study.  These included administrative staff from the Department of Social Services, and
a number of direct service workers. Consultation meetings were then held with the
provincial advocacy organization, the Saskatchewan Association of Community Living,
so that community and family concerns could be included, and ethical issues related
particularly to incomplete competency to consent to research could be addressed. 
To deal with the concern about heterogeneity of baseline intellectual functioning,
medical comorbidity, and various psychosocial factors, it was decided that only
community dwelling adults would be enrolled.  To minimize bias and maximize
generalizability it was also decided that the study population would not be selected from
a clinical population, which would be expected to have higher rates of pathology. Ideally
the sample would be selected randomly from all community dwelling adults with ID in
Saskatchewan.  Unfortunately, there was no register of all people with ID in
Saskatchewan.  As a result, the decision was made to recruit from those using
community services designated for adults with ID, and the Division of  Social Services
responsible for those with ID (Community Living Division) agreed to supply the
addresses and main contact names for these. It was likely that this population would not
include those with the lowest IQ or those with the most challenging medical
comorbidities (who might still reside in institutions for those with ID), and might also
miss those with the most severe aging related deterioration, such as dementia, who might
have moved into nursing homes and thus left the Social Services register. Conversely,
this recruitment strategy might also miss those with the highest functioning, who might
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not require any services from social services.
It was also decided that an appropriate comparison group for the adults with DS would
be required.  The group most likely to have similar psychosocial experiences was
thought to be a group of adults with ID but who did not have DS, so the decision was
made to recruit a sample of adults with ID who had a variety of diagnoses, including DS. 
This would allow for later comparison (cross-sectional and longitudinal) of functioning
in various domains.
Instruments to be used in the study to assess the health outcomes of interest were chosen
using the criteria described in section 3.1.2, and involved a combination of direct and
indirect sources, including direct cognitive tests, caregiver reports and chart review. The
outcomes of interest as defined in the introduction were dementia related abilities
(including memory, orientation, aphasia, apraxia and executive functioning), functional
abilities, physical and mental health and mortality.  Instruments designed to best measure
these outcomes reliably are described in more detail later. 
This study also set out to assess care issues in this population, choosing to focus
specifically on the use of psychotropic medications and the use of aging services. This
information was to be obtained from caregiver reports and chart review.  
The consensus among the various agencies involved in preliminary discussions
regarding consent was that those people with ID who clearly understood the process of
the study would provide their own consent. If a person was not able to comprehend the
study process, the person who normally consented to health care interventions would be
asked to provide consent for the person’s participation.  If there was partial or unclear
competence to consent, both the person and their usual medical decision maker would be
asked for their consent.  In all cases, it was attempted to obtain the participant’s assent.
No participants would be included whose family or immediate caregivers were not
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supportive of the study.  
Appropriate authorization for the whole study was then obtained as required from the
University of Saskatchewan Ethics Committee (see appendix A for ethics approvals).
Procedures followed were in accordance with the ethical standards of the Helsinki
Declaration of 1975, as revised in 2000 (World Medical Association, 2000). 
3.1.3  Participant  inclusion criteria
Participants were to be community dwelling adults, who were considered by service ID
care providers as having childhood onset ID, and who could provide appropriate assent
and consent. People without DS as well as those with DS would be recruited. 
3.1.4  Recruitment and follow-up
Participants were recruited from a list (supplied by the Community Living Division of
the Department of Social Services) of all residential homes and workshops for adults
with ID in Saskatchewan.  Letters were sent out to the administrator of each home and
workshop, informing them of the study, explaining the consent procedure, and the
inclusion criteria.  Consent forms were included in the mailed package, and were
returned by the administrator after appropriate consent had been obtained for each
participant.  Phone follow-ups were made by research personnel to further explain the
study, and in some cases additional information about aging and ID was sent.  
Study assessments were planned for two year intervals, for a maximum of four
assessments.  Enrollment commenced in summer 1995 and continued until summer
1997.  Last clinical assessments occurred in summer of 2001, but phone contact was
made with all caregivers of remaining participants in Spring of  2003 and in summer
2005.   Only data on whether the participant had deceased, along with dates of death
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were coded at the last two phone contacts. Appropriate consents were obtained at all
stages of entry into the program.  Information on all participants’ health and functioning
was collected from caregivers. For those who were able and willing to be interviewed by
research personnel, cognitive and functional tests were administered for a maximum of
three times, and an interview addressing quality of life issues was administered.
No financial reimbursement was given to participants, but at each wave of data
collection a printed certificate of participation was presented.  
3.1.5  Data collection and study instruments
3.1.5.1  Demographics and general health 
Basic demographic and health information was collected at each wave from caregivers
on a standard form. It was expected that caregivers would not be able to give detailed
information about the presence and severity of most health problems. However, of
almost equal interest was the degree of caregiver awareness about various problems,
such as sensory loss, which could then be compared to known rates established by others
directly.  Problems were described in the lay terms most likely to be understood by
caregivers, as these were known to come from varied, and sometimes impoverished
educational backgrounds.  For example, mental health problems were described as
emotional, nervous, behavioural or psychiatric problems, as these terms are all more
widely understood than the formal diagnostic categories in the DSMIV.
Caregivers were asked to rate other health problems as follows:
0. Never a problem as far as you know
1. Previously a problem, but not any more
2. Still a problem, but generally well controlled, and minimal effect on life
3. Intermittently a significant problem, but not at this time
4. Currently a significant problem
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3.1.5.2  Seizure disorders and epilepsy
The primary data on participant seizure history were based on caregiver answers to the
following question:  Does he/she have a history of seizures?
0. No 3. Yes, one to four per month
1. Yes, but none for over a year 4. Yes, two to six per week
2. Yes, less than one per month 5. Usually daily or more
As detailed neurological assessments of epilepsy status were not available, participants
were considered to have epilepsy at baseline if their caregiver stated that they had
experienced a seizure in the past, and medication records indicated that they were taking
an anticonvulsant at the time.  “New seizure” was coded positive if the participant was
assessed by the caregiver as never having had a seizure at the first assessment, but
subsequently had at least one seizure documented.
3.1.5.3  Intelligence Quotient (IQ) and level of intellectual functioning
Historical IQ data were sought from all study participants, prioritizing the earliest IQs
performed after age 18. It was expected that IQs performed later in life might be a less
accurate measure of early functioning as they might potentially also reflect superimposed
decline, such as that caused by dementia. 
Because it was anticipated that measured IQs would not be available for all participants,
care staff were asked to estimate the level of the premorbid intellectual disability based
on their information of the participant’s best functioning in early adulthood. A functional
definition of this level of disability was used based on the supplementary description in
the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (APA, 1994): 
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Premorbid impairment: Caregiver rating of best functioning in early adulthood
1. Borderline normal (a slow learner but fully functional in all areas) 
2. Mildly disabled    (social/vocational abilities sufficient for self-support, but
requires guidance in complex situations)
3. Moderately disabled (only basic communication skills, requires help for self
care, may perform unskilled work) 
4. Severe - profoundly impaired  (Minimal communication, major impairments in
all areas, full care required)
This information was expected to be dependent on how well and how long the caregiver
knew the participant, and less an accurate estimation of formally established IQ than an
estimate of known functional abilities.  Plans were to compare this caregiver assessment
with known IQ data in the subset of participants with available IQ testing.
3.1.5.4  Dementia Questionnaire for Persons with Mental Retardation
Standardized caregiver rated instruments sent out included Evenhuis’ Dementia
Questionnaire for Persons with Mental Retardation (Evenhuis, 1992).  These were filled
out by the direct caregiver who declared him/herself most knowledgeable about the
participant’s health and functioning.
The DMR is one of the most widely known and translated, as well as the most easily
used caregiver rated instrument designed for the evaluation of cognitive and functional
decline in those with ID.  This standardized 50 item instrument is based on the dementia
criteria in the DSMIII-R (American Psychiatric Association, 1987), but was adapted to
allow for easier scoring in those with baseline intellectual disabilities. Higher scores on
the DMR (based on behaviour over the last three months) indicate more impairment.
Subscales of the DMR include short-term memory (STM), long-term memory (LTM),
spatial and temporal orientation (SPA), speech (SPE), practical skills (PRA), mood
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(MOOD), activity and interest (ACT) and behavioural disturbance (BEH). These
subscales are of interest as they may illustrate different patterns of functional and
cognitive change over time. Individual subscale scores at baseline may also differentially
predict outcomes such as mortality. 
Specific items included in each sub-scale can be viewed in the original publications of
the DMR, and selected questions appear in Appendix B.  The subscales themselves have
been summed to derive two major sub-scales: the Sum of Cognitive Scores (SCS), which
have a score range of  0 to 44, and the Sum of Social Scores (SOS), which has a range of
0 to 60.
Sum of Cognitive Scores Number of items  Score range
1. short-term memory (STM) (7 items) 0 -14
2. long-term memory (LTM) (8 items) 0 -16
3. spatial and temporal orientation (SPA) (7 items) 0 -14
Sum of Social Scores Number of items  Score range
4. speech (SPE) (4 items) 0 - 8
5. practical skills (PRA) (8 items) 0 -16
6. mood (MOOD) (6 items) 0- 12
7. activity and interest (ACT) (6 items) 0 -12
8. behavioural disturbance (BEH) (6 items) 0 -12
The preferred use of the DMR in the screening for dementia is by analyzing longitudinal
score changes, as the baseline IQ affects most of the items in the DMR.   However,
Evenhuis’ manual (Evenhuis, Kengen & Eurlings, 1991) published criteria for single
completion as well, which have cutoffs for the screening of dementia that take into
account the baseline intellectual functioning of the person. These are shown below, with
SOS cutoffs for severe ID not listed, as they have not yet been developed.
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Level of ID IQ SCS cut-off SOS cut-off
Mild 55-70 7  10
Moderate (high range) 45-55 15  15
Moderate (lower range) 35-55  25  15
Severe 25-35  34
Evenhuis’ published criterion for a positive dementia screen on the basis of longitudinal
score changes is either an increase of the SCS of 7 points or more and/or an increase of
the SOS of 5 points or more.  
The inter-rater reliability of the DMR ranges from 0.44 to 0.94, with only the subscale
“behavioral disturbance” showing a low correlation between two different raters (0.44).  
Individual items within subscales have good internal consistency.  Sensitivity and
specificity for the detection of dementia based on longitudinal score changes (see later)
have been shown by Evenhuis, Kengen and Eurlings (1991) to vary with the cohort
studied. For older  people with intellectual disability but without DS aged 70 years and
over, the sensitivity is 100% and the specificity is 73%.   For people with DS the
sensitivity is 100% in the specificity is 75%.  The DMR is not sufficiently sensitive in
people with the most severe intellectual disability, or in those with significant other
disabilities such as hearing loss.  
Sensitivity and specificity for the detection of dementia based on single completion of
the DMR  is significantly lower, with particularly low specificity in older adults without
DS, who have  probable early vascular dementia.  
The practical utility and validity of using the DMR in  tracking cognitive and functional
changes is widely accepted, and is supported by literature published by authors other
than Evenhuis. For example, Thompson (2003), showed measurable aging changes over
short periods of time (six months) in subscores such as Sum of Social Scores.
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3.1.5.5  Dyspraxia Scale
Along with memory impairment, one of the symptoms of Alzheimer’s Disease in the
general population is apraxia, as discussed earlier in the literature review.  Despite its
presence in the diagnostic criteria for Alzheimer’s Disease in the DSMIV, apraxia is not
formally assessed as often as is core memory loss, although work linking apraxia to more
rapid decline (Yesavage, Brooks, Taylor & Tinklenberg, 1993) makes its measurement
in the early cognitive impairment of DS particularly important.
The Dyspraxia Scale (Dalton & Fedor, 1998) is a directly administered, standardized test
with good psychometric properties, designed to assess dyspraxia in adults with DS.  
Test-retest reliability of this scale was excellent, with a correlation coefficient of r= 0.96. 
 The split half reliability analysis of this scale  was found to have a reliability coefficient
of r=0.98.  Cronbach’s Alpha values ranged from 0.94 to 0.97.  Developers of this
instrument found significant longitudinal deterioration of praxis in older adults with DS, 
most noticeable in the oldest subgroup.  This clinical pattern was consistent with the
pattern of decline published in a variety of other studies of older people with the DS,
suggesting a high degree of face validity.  
The Dyspraxia Scale has three subscales: 
• Part 1- Psychomotor skills (20 items, maximum score 80)
• Part 2- Apraxia (20 items, maximum score 80)
• Part 3- Body parts/coin task. (22 items, maximum score 88)
Each item (listed in Appendix B) has a detailed scoring guide, and the total maximum
score is 248. The Dyspraxia Scale was administered (starting in the second wave when it
became available to the investigator) to all participants in this study who consented to
direct testing and who were capable of following the testing protocol. Testing was
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performed by trained researchers either in the participant’s own home or the sheltered
workshop.  
Research assistants performing the testing were asked to code problems that they
believed had limited the test administration process as:
No problem Problem
Hearing 0 1
Language development 0 1
Second language 0 1
Attentional problems 0 1
Compliance problems 0 1
Other problems 0 1 (details written in)
3.1.5.6  Dalton/McMurray Visual Memory Test (DMTS) 
The Dalton/McMurray Visual Memory Test (Dalton, 1992), also called the Delayed
Matching to Sample (DMTS) Test, is also a directly administered, standardized test with
good psychometric properties, designed to assess various aspects of memory in adults
with ID. This instrument is useful for adults with ID who may not be verbal enough to be
tested with other, more language based instruments.  It requires the use of a computer
with a colour monitor. A variety of shapes and coloured pictures are presented, followed
by variable length pauses, and then the participant is prompted to point at the image just
seen, choosing it out of a few selections that include the original. Results are
automatically entered into the computers that are equipped with a touch-screen, or
manually entered by an assistant with a keyboard if no touch-screen is available.  
Scoring includes separate results for coloured pictures and shapes. The process is simple
to administer, and participants generally enjoy the testing.
This test was administered  (starting in the second wave when it became available to the
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investigator) to all participants who consented to direct testing and who were capable of
following the testing protocol.  As with the Dyspraxia test, testing was performed by
trained researchers either in the participant’s own home or the sheltered workshop, and
test administration problems were coded as noted earlier.  
3.1.5.7  Chart and medical records review
Full trisomy 21 is fairly easily recognized clinically, but translocations and mosaicism
may result in heterogeneous clinical presentations, and may not be identified correctly
without cytogenetic testing.  Therefore, confirmatory medical information about IQ
testing, chromosomal testing for DS and other significant health history was sought from
medical records at the Royal University Hospital. It was anticipated that a sizable
percentage of study participants would have had at least one assessment there, either
through medical genetics or through the Alvin Buckwold Centre (for children with ID).  
The preferred time of chromosomal testing was felt to be childhood, so that increased
mosaicism occurring in later adulthood would not obscure the earlier developmental
impact of trisomy 21.  However, it was known that the results of chromosomal testing in
childhood would not be universally available for participants, so testing at the time of the
study was considered.  This testing was eventually not included in the study because of
concerns about the invasiveness of this component, which was of particular concern
because of the participants’ perceived vulnerability to abuse, and also because some of
the potential participants were known to “hate needles”.  
Plans were therefore made to explore the validity of using caregiver assessment instead
of formal chromosomal tests to establish a diagnosis of DS.  Available chart data on
chromosomal testing were to be compared with the diagnosis recorded by caregivers.  If
there was strong agreement between the caregiver information about DS diagnosis and
the available chromosomal reports, caregiver reports would be used as a valid surrogate
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for chromosomal testing. 
3.1.5.8  Baseline data on Community Living Division program participants.
To establish the representativeness of the initial sample, baseline 1995 service provision
data were obtained (total numbers as well as severity and age distribution) from the
division of the Department of Social Services responsible for people with ID, the
Community Living Division (CLD).  
3.1.5.9 Service issues
Caregivers were asked whether the participant had seen a psychiatrist within five years
of the study visit, and whether he/she had any physical, mental or emotional  problems
that were difficult to deal with using existing resources.  They were also asked about the
use of aging related services (such as seniors’ day programs), and if used, whether the
programs were geared to intellectually disabled people or whether they were designed for
the general older population.  Finally, they were asked whether in their opinion the aging
process was causing increased difficulty with care.
3.1.5.10  Medication use
A complete listing of medications taken by each participant was collected at each
assessment, with a plan to explore the use of psychotropics in particular detail. 
Medication use was to be explored both as an independent variable that might predict
cognitive, behavioural and functional deficits, but also as a dependent variable that might
vary depending on other factors such as diagnosis, age and sex. 
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3.1.6  Data verification, cleaning and storing
All data were initially recorded on paper except the DMTS, which was directly coded
into the computer at the time of testing. Hard copies were later printed out and stored
with the primary file.  All primary data were stored in a locked hospital filing cabinet
with access only to the designated research assistants. Data entry into a database program
was performed by hired assistants.  Prior to data analysis, ten percent of electronic data
were compared to the original source data by a separate researcher to establish accuracy
of data entry. Data entry errors of over 5% in some participant files resulted in the
decision to review every electronic data point with the source data in all files. The final,
corrected data set had less than 0.1% data entry errors in randomly chosen files (10% of
the total). 
3.2  Statistical data analysis
3.2.1  General data management and approaches to model building
Full data were available from four formal data-assessment waves, and limited data were
available from two telephone follow-up surveys.  Descriptive results of the data were
organized into tabular and graphic forms, and then predictive models were built for
various outcomes of interest using appropriate statistical techniques. The independent
variables to be included in the models were:
• Demographic variables (DS diagnosis, age and sex)
• Standardized measures of functional abilities at baseline (continuous DMR
subscale scores at entry to the study)
• Core health problems that were thought to have face validity for potential
contributions to increased mortality (and for which accurate information could be
obtained)
• Use of psychoactive medications and nonsteroidal anti-inflammatory medications. 
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The initial baseline model for all outcomes was to include DS diagnosis, sex, age at entry
to the study, and the age-DS interaction term.  The age-DS term would be entered into all
models initially, as early data exploration and graphing had strongly suggested that aging
patterns for many of the dependent outcomes were different in those with or without DS.  
Many biological functions are also known to have a non-linear relationship with age. 
Incorrectly assuming a linear relationship with age can obscure clinical findings, as, for
example,  the age relationship with an outcome may be U-shaped in real life, but appear
non-significantly related if approximated as a straight line.  Data transformation,
whenever necessary, of the available age variables is therefore useful to increase the
validity and usefulness of the analysis.  In analyses presented in subsequent chapters, 
data exploration includes the assessment of a variety of possible relationships between
each dependant variable and age by the means of curve analyses, available through SPSS. 
Curve analysis then suggests the form of the age variable to be included, such as, for
example, age  for quadratic relationships, rather than the linear age variable alone.  2
In model building, independent variables were initially to be explored as univariate
(unadjusted) contributors to each outcome, and results tabulated.  The initial plan was to
add these variables one at a time to the baseline model if their initial bivariate
significance level was p 0.25. However, some of these additional independent variables
showed positive interactions with baseline variables, even when the univariate
association was highly insignificant.  Therefore, variables were added individually, one at
a time, and then with the interaction term with each baseline variable, regardless of
univariate significance.  The model was to be re-run after each addition, and the
significance of the contribution of each variable to the overall model was to be tested
with the likelihood ratio test.  Variables left in the final model would include all those
with statistical significance at the p<0.05 level, as well as those almost significant at this
level (with 0.05  p<0.1) but which had potential significance based on existing
information.  
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Three main methods were used to analyze the data:
1. Cross-sectional analysis of outcome variables at entry to the study, with the main
focus being differences between age and diagnostic cohorts.
2. Longitudinal analysis of changes in the outcome variables.
3. Survival analysis to explore risk factors for the occurrence of particular discrete
outcomes, such as death, over the course of the study.
3.2.2  Cross-sectional analysis
The cross-sectional approach was expected to provide descriptive clinical information,
which could be useful to providers of services to community dwelling adults with ID. 
Differences in cross-sectional results at different times of data collection may also
suggest changes in patterns of service delivery and care.  For example, an increased
percentage of participants taking an antidepressant in more recent  years and a decreased
percentage of participants taking an antipsychotic would be a positive finding in this
population. The statistical analysis of this type of cross-sectional data was simpler than
for the longitudinal data analysis, and was conducted using SPSS version 11.5 (SPSS,
2002) for descriptive statistics and graphical representation of the raw data, as well as
logistic and linear regression.  Models were built using SPSS to predict various outcomes
for a specific cohorts.
3.2.3  Longitudinal analysis
The longitudinal assessment of the individual pattern of change is more useful for the
assessment of  aging because of large variations in baseline functioning in this very
heterogeneous population. However, greater practical challenges are to be expected in
this approach, not only in data management (because of the length of followup,
inconsistences in data gathering  and anticipated data loss), but also in the methods of
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statistical analysis.
One possible way to analyze the longitudinal data is to utilize the Generalized Estimating
Equations (GEE) methodology by Zeger and Liang (1986).  This method is based on the
multivariate quasi-likelihood theory, which can handle the complexities of longitudinal
studies, e.g. repeated observations for each subjects and data missing completely at
random. In interim data analyses, marginal models to predict various outcomes using the
GEE approach were fitted using SAS version 8.2 (SAS Institute, 2000) procedure PROC
GENMOD. The average annual yearly decline for each participant was then calculated
using these predicted scores.  However, examination and discussion of these predicted
scores with subsequently calculated annual yearly declines suggested that even this
method of calculating decline  was highly contingent on baseline raw scores, which were
known to be subject to significant cohort effects.  It was decided that, whenever possible, 
a preferred approach to data analysis would be to use individually observed yearly
changes rather than raw scores, in any model building process.
As an alternate approach that focuses on analyzing change over time rather than
predicting raw scores and then calculating predicted change, it was therefore decided to
use the two-stage model introduced by Wishart (1938), which is based on the well-known
least squares method (Colton, 1974).  The two stage model is a particular case of random
effects models.  In the first stage, this method can be used to calculate a separate slope for
each individual representing change over time in a particular test.  Slope is calculated for
each participant by the following formula:
ijIn this equation, for n participants who had 3 tests each,  y  represents the outcome for
ijthe ith participant at the jth time, and x  is the independent variable for the ith participant
i iat the jth time. y  represents the mean outcome for the ith particpant, and  x  represents the
mean value of the independent variable for the ith participant.
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In the second stage, this slope can then be used as an outcome variable in the model
building process to predict yearly change at various levels of individual independent
variables. 
However, for measures that were directly obtained from participant testing, an additional
challenge was the research assistant finding of improved participant cooperation on the
second and third tests compared to the first one, at which many participants appeared
hesitant to answer questions, less confident and less comfortable with the test process.
Possibly as a result of this, participant scores at the second testing were generally
improved, and research assistants felt that this was not necessarily related to
improvement in the person’s abilities.  Of course, an additional learning effect, defined as
the improvement of a score on a test, not related to an overall change in the abilities of
the participant, but related to a specific practice effect, may also have been present,
although the two year interval between tests made this less likely.
Methods of statistical analysis that pool data from all repeated tests of an individual
participant (such as the least squares method) and do not take into account this poorer
performance on the first test, may miss significant aging changes.  For example, if there
are only three tests available, and the apparent improvement (related to improved
compliance) from test 1 to test 2 in a particular participant is equivalent to the aging
deterioration from test 2 to test 3, the slope calculated from this formula will be zero, and
indicate that there has been no aging related deterioration, whereas the actual
deterioration between time 1 to time 3 might have been quite important.
Because of this problem, it was decided that for directly measured longitudinal data, 
aging effects would be assumed to be the change in individual scores from the second test
onwards, and that the first testing would be considered the “run in phase” similar to the
process in experimental drug studies.
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3.2.4  Survival analysis.
Survival analysis was used to assess differential mortality during the course of the study. 
Participants were followed for varying lengths of time, with some (very few) leaving the
study prematurely, and some dying prior to the last scheduled assessment. For most
participants the last contact was a scheduled phone contact after the formal data
collection of the study was completed.  Cox’s proportional hazards modeling technique
(Kleinbaum,1996) was used to assess differential mortality, as it allows for the analysis
of  mortality rates based on different lengths of followup, adjusting for various
independent variables in the regression model. Variables were added to the Cox
regression model in the same manner as variables were added to the linear regression
models.
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4.   DATA SET AND GENERALIZABILITY
This chapter presents baseline participant data including regional participation,
demographics, genetic testing, and intelligence quotient (IQ). The experimental data are
compared with 1995 service data, which were obtained from the division of the
Saskatchewan Department of Social Services that has responsibility for people with ID.
4.1  Participation data 
360 participants entered the study, and 215 (60%) of these had four complete waves of
caregiver data available. Followup time (including phone follow-ups after the completion
of the four main waves of data collection) ranged from 0 to 8.49 years, with a mean time
of 6.41 years.  276 (77%) people participated in individual interviewing and testing. 
Table 4-1 shows the number of participants completing each test.  
Table 4-1.  Number of participants (percentage of total sample) completing test





Demographics 360(100) 348(97) 309(86) 222(62)
Health problems 360 (100) 348(97) 309(86) 222(62)
Medications 360 (100) 348(97) 314(87) 215(60)




Dyspraxia Scale 276(77) 250(69) 191(53) *
DMTS test Shapes 264(73) 236(66) 166(46) *
Colours 266(74) 243(68) 179(50) *
* Test only available in three waves as described in methods
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Participants came from all areas of the province except for the area north of Prince
Albert, with the largest number originating from the areas around Saskatoon and the 
Battlefords.  The geographic distribution is tabulated in Table 4-2.   
Participant living situations included Community Living Division group homes, private
care homes, mental health approved homes, assisted living facilities, independent
dwellings,  family homes, and one large congregate living site (Elmwood Lodge in
Saskatoon).  No participants were solicited or entered from Valleyview Centre, which is
the one remaining institution designated for people with ID in Saskatchewan. 
Table 4-2.  Place of residence at the first assessment (Number and percentage of total)
Nearest town Number(%) Nearest town Number(%)
Admiral 1(0.3%) Moose Jaw 25(6.9%)
Battlefords 20(5.6%) Moosomin 1(0.3%)
Biggar 1(0.3%) Naicam 1(0.3%)
Carrot River 1(0.3%) Outlook 3(0.8%)
Delisle 2(0.6%) Porcupine Plain 8(2.2%)
Gravelbourg 4(1.1%) Prince Albert 3(0.8%)
Gull Lake 1(0.3%) Redvers 23(6.4%)
Hague 6(1.7%) Regina 15(4.2%)
Hepburn 3(0.8%) Rosetown 15(4.2%)
Herbert 2(0.6%) Saskatoon 99(27.5%)
Hudson Bay 1(0.3%  Shaunavon 10(2.8%)
Humboldt 1(0.3%) Swift Current 9(2.5%)
Kindersley 7(1.9%) Theodore 1(0.3%)
Kinistino 6(1.7%) Wadena 14(3.9%)
Lloydminster 3(0.8%) Waldheim 25(6.9%)
Macklin 1(0.3%) Weyburn 20(5.6%)
Meadow Lake 1(0.3%) Wilkie 6(1.7%)
Melfort 9( 2.5%) Yorkton 11(3.1%)
Melville 1(0.3%) Total 360( hundred percent) 
4.2  Demographics and comparison with CLD service population 
Basic demographics of study participants are shown in Table 4-3. 
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Table 4-3. Demographics of participants
Non-DS DS All Diagnoses
Age Male Female Total Male Female Total Male Female Total
<30 24 16 40 13 7 20 37 23 60
30-39 42 32 74 22 19 41 64 51 115
40-49 39 26 65 19 17 36 58 43 101
50-59 21 16 37 8 7 15 29 23 52
60-69 7 10 17 2 2 4 9 12 21
70-79 8 2 10 0 0 0 8 2 10
80-89 1 0 1 0 0 0 1 0 1





















Range 17-83 20-71 17-83 20-61 20-61 20-61 17-83 20-71 17-83
More males than females entered the study (female to male ratio: 1:1.34), and the DS
group was about three years younger on average than the non-DS group (p<0.05 using
independent samples t-test). Males and females were not significantly different in age.
Age distribution of the study population is presented graphically in Figure 4-1.
Figure 4-1. Age distribution of study participants at entry to the study  
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As all of the study participants were recruited through Community Living Division
(CLD) service agencies, participant data were compared to the overall service population
data recorded by the Community Living Division of the Department of Social Services in
1995 (B. West,  personal communication, February 26, 2005). The age distribution of this
service group (compared to the study population at baseline) is shown in Figure 4-2, and
details of service needs are shown in tabular form in Table 4-4. The levels of clinical-
service need (profiles) are defined in Appendix C.  It should be noted that these care
profiles are based on both the level of intellectual disability as well as on the difficulties
of care due to various comorbidities. 
Figure 4-2.  Age distribution of CLD clients in 1995 and baseline study population
Table 4-4. Service and demographic profile of CLD Clients, March 1995
Community living division profiles, March 31, 1995
Age Level Level 1 Level 2 Level 3 Level 4 Level Unknown Total 
0-5 72 2 18 32 73 7 204
6-20 72 83 85 123 298 14 675
21-35 55 217 265 268 272 11 1088
36-54 26 141 217 296 156 5 841
55-64 10 42 47 79 39 1 218
65+ 6 38 42 75 26 1 188
Total 241 523 674 873 864 39 3214
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3214 people with ID (879 of these 20 years and younger) received services from CLD in
1995.  Their care needs varied considerably, using the definition of care profiles
described in Appendix C, with the smallest proportion coming from the lowest needs
groups. The age distribution was very similar to that of the study population, other than in
the youngest groups, which were not included in the study. 
Making the assumption that almost all of the study participants were also on the CLD
caseload at entry to the study, an estimation was made of the percentage of the service
population that was captured in various age groups of the study.  Figure 4-3  illustrates
this, suggesting that a sizable percentage of the general adult population was captured. 
For example, in the age range of 36-54, about a fifth of the active service population may
have been captured . 
Figure 4-3.  Percentage of CLD caseload captured by study participants at baseline.  
The definitions of care needs that CLD used were not equivalent to the best levels of
intellectual functioning that caregivers provided, yet the second highest impaired groups
in both populations had the greatest representation within the overall group. 
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4.3  Genetic testing
Of 116 participants with caregiver identified  DS, 18 had available chromosomal reports
(all dating back to either childhood or young adulthood). All 18 of these had full trisomy
21.  No participant identified by their caregiver as not having DS was found to have
genetic tests indicating that they did have DS.  It was therefore decided to accept
caregiver reports of the diagnosis of DS as a reasonable alternative to repeated testing.
4.4  Intelligence Quotient (IQ)
After comprehensive searching of records, only a small proportion of participants
(75/360 or 21%) had available IQs, and even fewer (61/360) had an IQ available that had
been obtained prior to age 30.  Mean IQ for those 61 adults was 42.95 (SD: 2.18).  DS
females in this group had a particularly low IQ, as can be seen in Table 4-5, below.
Table 4-5.  Descriptive data for subgroup with available IQs (performed prior to age 30)
Diagnostic Group         Number        Mean age (SE)       Mean IQ (SE)
Non-DS males 30 35.56 (1.17) 42.73 (3.42)
Non-DS females 15 37.38 (2.53) 48.27 (4.60)
DS males 10 30.24 (2.37) 40.80 (3.02)
DS females 6 39.95 (4.25) 32.67 (3.63)
The subgroup with available IQ scores prior to age 30 was used to explore potential
independent contributors to the IQ score.  These included age, sex and diagnosis.  The
final multivariate regression suggested that none of the variables were significant
predictors of IQ, although the interaction between DS diagnosis and age was almost
significant at p=0.07.
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Table 4-6.  Results of linear regression analysis for IQ in subgroup (N=61)
Parameter  (SE)â^ P value â^95 % CI for 
DS 28.48 (19.89) ns -11.35 - 68.32
Sex 3.42 (4.65) ns -5.91 - 12.74
Age (baseline) 0.28 (0.33) ns -0.38 - 0.94
DS* Age -1.03 (0.56) <0.1 -2.14 - 0.09
The reference category for DS is Non-DS and the reference category for sex is male.
4.5  Discussion
The study population represented a broad subgroup of adults with intellectual disabilities
from across the province, with the greatest numbers coming from areas close to
Saskatoon and the Battlefords.  Research assistants felt that the main factor determining
participant involvement was the support of the administrator of the group home or work-
shop, and if this person was supportive, many individual families and/or competent
participants tended to complete consent forms.  Of those administrators who were not
supportive and would speak to the research assistants, some cited excessive workload
involved in form completion, and others appeared concerned about information gathered
about them, as the government body instrumental in their funding was one of the original
advisors to the research, and was listed as such on the information forms.  
Anecdotally, informal community contacts of those homes who had refused all contact
with the study occasionally stated concerns about the adequacy of these homes.  It is
possible that these homes had a higher than usual use of psychotropic medications, or
less adherence to mandated restraint policies,  which might have decreased their comfort
with research participation.  If this was indeed the case, it is possible that study
conclusions about the use of psychotropic medications underestimated their true use, and
other measurements might also have been non-randomly impacted.
Group homes or organizations whose staff was familiar with the primary investigator
were particularly likely to support the research project, and this resulted in not only the
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most challenging clients (who had received services) obtaining consents, but also the
other, less challenging clients receiving consents.  This was fortunate, as the intent of the
study was to approximate as much as possible a population study, minimizing possible
sources of non-random error, which would have occurred if only those with the greatest
difficulties had entered the study.
The geographic distribution of the study sample was probably related to greater ease of
interaction between group home/workshop and researchers in the sites closer to
Saskatoon, as well as to relationships of trust between staff and the primary investigator
which were discussed above.  However, the second largest centre in the province, Regina,
was particularly difficult to recruit from, in spite of numerous attempts, and in spite of
being considerably closer than some of the smallest, rural workshops.  Research
assistants were unable to ascertain the reason for this, but wondered whether the
proximity to a university had already resulted in some “research burnout”.   
As the participants had been selected from the CLD service population, it was not
surprising that their age distribution was similar.   Their needs distribution also appeared
similar, in spite of the fact that the definitions that were used in the two populations were
slightly different.  The gender distribution of the sample reflected known gender
distribution of adults with intellectual disabilities, with more males represented than
females.  It is therefore likely that the study population was a reasonable representative
population of adults with intellectual disabilities in the community, especially in the mid
range of the age spectrum.  
Missing from the study population were two major groups of adults with ID.  The first
group included those who were initially in institutions of any kind (Valleyview Centre,
nursing homes, correctional facilities), and these would be expected to have more
advanced physical and mental health challenges, resulting in the failure of community
placement.  Balancing out this tendency to exclude participants with greater difficulties,
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was a second group that was largely missed from the study, consisting of mildly disabled
people with ID who did not required any formal services.  As this group with ID who
receives no formal services has been described by others as being a very significant group
(Morris, 2003), the current study likely under represented this group far more than it did
those with greater challenges.  Conclusions about decline might then have also been
over-estimated.
The lack of laboratory confirmation of DS diagnosis in most participants was
unfortunate, but as the caregiver assessment of DS diagnosis conformed closely to
independent laboratory testing in the subgroup analyzed, the use of caregiver diagnoses
was probably  reasonable.  However, this method of assessment of DS might have mis-
classified some people with small translocations as well as those with mosaicism to the
non-DS group, decreasing potential differences between the DS and the non-DS group. 
IQ testing was not available on the majority of the participants.  This meant that IQ was
not able to be included in the multivariate analysis of other age-related declines later. 
This was unfortunate, because of known information (summarized in the literature
review), showing an association between early life deficits and later life cognitive
impairment.  It would have been interesting to study whether lower IQ scores in early life
actually increased individual level decline in later years, or whether it merely decreased
the baseline measures in cross-sectional analyses. 
Because IQ was not significantly predicted in multivariate analyses that adjusted for
levels of other key factors such as sex, age, and diagnosis (which are significant to a
variety of age related declines), it was less likely that the validity of later analyses would
be compromised.  However, the numbers of available IQ scores were low, and the non-
significance of the multivariate analysis, especially for females with DS (whose trend
was to lower scores) might well have been due to power issues.  If there had been a true
association between lower functioning and females with DS, this might have further
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This chapter explores crude and adjusted mortality rates in the study population,
including all data gathered from caregiver mail-in forms, direct assessments, and follow-
up phone calls.
5.1  Deaths among study participants
As of the spring of 2005, forty three people died during the course of the followup, 33
males (16.1% of all male participants) and 10 females (6.5% of all female participants). 
Stratified into diagnostic groups, 27 participants without DS (11.1% of the non-DS
group) died, and 16 participants with DS (13.8% of the DS group) died.  Table 5-1
illustrates this information in more detail, showing also that deceased participants with
DS were about three years younger at baseline than those without DS (p<0.05 on the
independent samples t-test). 
Table 5-1.  Number (%) of the baseline cohort that was deceased at last contact. 
Diagnosis Male Female Both sexes Mean baseline age (SE)
Non-DS 20(14.1) 7(7.0) 27(11.1) 43.1(0.9)
DS 13(20.4) 3(5.8) 16(13.8) 40.1(0.9)
All 33(16.1) 10(6.5) 43(12.0) 42.1(0.7)
5.2  Age at death
In spite of the higher percentage of males who died during the study, the mean age at
death was lower in females (54.9 years) than in males (58.0 years).  There was a greater
gender disparity in the age at death of participants with DS (males 55.4 years, females
87
48.8 years) compared to the age at death of participants without DS (males 59.7, females
57.6).  Table 5-2 lists mean scores and standard errors in diagnostic and gender
categories, while Figure 5-1 illustrates this graphically.  
Table 5-2.  Mean age at death (SE) in cohorts, stratified by diagnosis and sex.
Diagnosis Male Female Both sexes
Non-DS 59.7(3.3) 57.6(4.6) 59.1(2.7)
DS 55.4(2.2) 48.8(1.9) 54.2(1.9)
All 58.0(2.2) 54.9(3.5) 57.3(1.9)
Figure 5-1. Mean age at death of participants who died during the study 
Linear regression on the dependent variable, age at death, including core independent
variables DS diagnosis, sex and age at baseline, disclosed a small and almost significant
(p=0.0819) three-way interaction term between DS diagnosis, baseline age and sex. This
interaction resulted in the mean age at death among the youngest participants being very
similar in the four diagnostic-age cohorts (DS males, DS females, non-DS males and
non-DS females), but the mean age of death in the oldest cohort being highest in non-DS
males, but progressively lower in non-DS females, DS males and then DS females. The
interaction term was left in the final model because of potential clinical significance. 
This model is shown in Table 5-3, and graphic representation of the predicted values are
shown in Figure 5-2.
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Table 5-3.  Linear regression analysis of the dependent variable, age at death. 
Parameter  (SE)â^    P value â^95% CI for 
DS 3.2186 (2.0720) ns -0.9759 - 7.4132 
Sex -0.3280 (0.8635) ns -2.0760 - 1.4200 
Age at baseline 1.0058 (0.0271) <0.0001 0.9510 - 1.0606 
DS*Age*Sex -0.0583 (0.0326) <0.1 -0.1243 - 0.0077 
The reference category for DS is Non-DS, and the reference category for sex is male
Figure 5-2.  Mean predicted age at death in participants
5.3  Mortality
Multivariate assessment of mortality is best done using Cox proportional hazards models,
which allow for the separate investigation of the potential contribution to mortality by
numerous independent variables. The calculation incorporates the length of time
followed for each participant, and a coding for whether the end of follow-up was due to
death or withdrawal (i.e. censoring) of the participant for other reasons.  
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5.3.1  Univariate approach to mortality calculation
Univariate Cox regression using independent variables with potential biological
significance to mortality was planned to give an initial indication of variables that should
be included in the model building process.  These variables included diagnosis of DS,
baseline age (in units of 10 years to simplify understanding of odds ratios),  sex,  baseline
history of epilepsy, new development of seizures, baseline functional abilities from the
DMR and the use of psychotropic medications.  It was not possible to include an early
adult IQ  (not available for most participants), or baseline medical health, as
unfortunately the caregiver data did not provide adequate accuracy in this area. 
Results of the initial univariate (unadjusted) analyses using Cox proportional hazards
models to examine the odds of mortality for each independent risk factor are available in
Appendix C.  This analysis suggested that increased age, male sex, and deficits on all
DMR subscales (except speech deficits) each separately increased mortality when the
other factors were not adjusted for. The development of a new seizure during the study
was almost significant at p=0.085, and appeared to double mortality. 
5.3.2  Multivariate approach to mortality calculation.
The final model was developed using the methodology for model building described in
chapter three, and is shown in Table 5-4.  Significant predictors for increased mortality in
this model are DS diagnosis (HR 2.53, 95% CI 1.30-4.93), male sex (HR 2.41, 95% CI
1.17-4.99), age at study entry in units of ten years (HR 1.93, 95% CI 1.57-2.38), DMR-
Baseline practical skills deficits (HR 1.13, 95% CI 1.04-1.22), and  DMR baseline mood
deficit score (HR 1.19, 95% CI 1.05-1.36).  Approximately  parallel graphs of the Log-
Minus-Log functions for DS, Sex, age (divided into four categorical groups), DMR-mood
(divided into three categorical groups), and DMR-practical skills (divided into two
categorical groups) suggested that the proportionality assumptions were met for all these
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independent variables.  There were no interactions between any of the final independent
variables.  
Table 5-4. Multivariate Cox regression analysis of mortality.
 Parameter P value HR        (95% CI)
DS diagnosis <0.01 2.532(1.300-4.931)
Sex (reference: females) <0.05 2.411(1.165-4.992)
Age (units of ten years at baseline) <0.001 1.931(1.567-2.379)
DMR Practical skills deficits-baseline <0.005 1.126(1.043-1.216)
DMR Mood symptoms-baseline <0.01 1.192(1.047-1.357)
In summary, the adjusted odds of participants dying during the followup period were 2.53
times higher (p=0.006) for those with DS compared to those without DS, 2.41 times as
high (p=0.018) for males compared to females, and almost doubled (p<0.001) for each 10
years increase in age. There were also small but significant increases in mortality for
increased baseline deficits in practical skills (p=0.002) and baseline presence of
depressive symptoms (p=0.008).  Graphic representations of mortality based on the above
Cox regression model are shown in Figures 5-3A to 5-3C.
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Figure 5-3A. Survival curves for 360 participants (Age and DS)
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Figure 5-3B.  Survival curves for 360 participants (Sex and Mood). (Mood 0-2 
represents the least mood problems and Mood 5-7 the greatest problems.)
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Figure 5-3C.  Survival curves for 360 participants (Practical Skills). Practical 0-6 
represents the least practical skills deficits and Practical 7-16 the greatest deficits.
5.4  Discussion
The adjusted mortality model developed by Cox’s proportional hazards regression
showed that older people were more likely to die than younger ones (mortality almost
doubled every 10 years), which is not surprising. A little more surprising was that, even
when adjusted for baseline functional deficits,  men had more than twice the odds of
dying than women, and that those with DS were more than twice as likely to die as those
without DS. One of the limitations of the study is that there was no access to death
certificates.  Consequently, the causes of death are unknown, and would have been
interesting to ascertain in this group.   
There was a significant (p<0.005) association between the degree of baseline deficits in
practical skills and increased mortality. Practical skills had been defined by the DMR
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questionnaire as: the ability to dress and/or undress, daytime and/or night-time
continence, ability to wash him/herself, ability to get into and out of his/her bed, ability to
use familiar objects correctly (eg comb, scissors, toothbrush), and to toilet him or herself. 
Deficits in these areas might have been due to premorbid, childhood onset developmental
handicaps, or to later developing health changes.  Both early-onset conditions causing
functional losses and age related conditions that have caused decline might account for
increased mortality.  For example,  chromosomal abnormalities which caused severe,
childhood onset functional deficits are also more likely to have caused structural
abnormalities in organ systems, such as cardiac malformations, which increase the
likelihood of death.  Cerebral palsy, also present from birth, is often associated with
swallowing difficulties, causing aspiration and pneumonia, and epilepsy, which
independently increases mortality by more complex mechanisms.  On the other hand,
functional decline that occurred later in life is commonly associated with conditions such
as dementia, strokes and Parkinson’s Disease, each of which independently increases
mortality. 
Items from the DMR that contributed to the mood subscale were weepiness, lack of being
spontaneously helpful, sleep disturbance, gloomy or sad mood, tendency to be easily
upset, and excessive physical complaints.  The DMR manual makes no claim about these
symptoms predicting depressive disorder, and in this data set it was also not possible to
determine whether there was a true depressive disorder, or whether the symptoms might
have been associated with other problems such as physical disorder or psychosocial
stressors. 
These depressive symptoms  had not been expected to be significant to mortality, and had
been left in the initial model as a matter of routine to adjust for baseline behavioural
functioning in a variety of areas.  It was therefore most interesting to find this significant
(p<0.01) association (when adjusted for age, baseline deficits in practical skills, sex and
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diagnosis of DS) with later mortality, as this finding has not been found in published
literature conducted on people with ID. 
There is, however, now a literature on the association between depression and increased
mortality in general (Schulz, Drayer & Rollman 2002; Penninx et al.,1999)  and older 
(Blazer & Hybels, 2004) populations, even when adjusted for underlying medical illness.
Mechanisms for this association are not well understood, but probably involve
biopsychosocial mechanisms that exert their effects in various interacting ways.  For
example, depression may cause direct biological, stress-mediated changes at a
microscopic level resulting in increased cell death and decreased immunity, as well as
result in grosser changes such as weight loss (which may reduce reserve) and decreased
sleep which might decrease alertness and the general ability to deal with the environment,
such as driving safely.  Depression may also decrease healthy behaviours such as
exercising and eating well, resulting in obesity, hyperlipidemia and immobility, all of
which may themselves increase mortality. Health care seeking and compliance may also
decrease in depressed people, whereas unhealthy behaviours such as smoking and other
substance use disorders tend to increase.  
On the other hand, depressive symptoms may be caused by an underlying medical
disorder that itself increases mortality.  An example of this is pancreatic cancer, which is
a fairly lethal disorder which frequently presents with depressive symptoms before it is
diagnosed (Carney, Jones, Woolson, Noyes & Doebbeling, 2003), especially if the cancer
originates in a “silent” area not resulting in early physical symptoms.  Another example is
atherosclerosis and arteriolar sclerosis, a common cause of increased mortality, which
may also cause vascular cognitive impairment from either larger strokes or from
widespread microvascular damage to the brain, with secondary mood lability (such as
easy crying) and apathy, both of which may be misdiagnosed as depression. Finally,
dementia has been well-established to increase mortality, and the symptoms of dementia 
typically overlap with those of depression in domains such as sleep loss, weight loss and
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decreased interest.
In this study it was not possible to fully adjust for medical comorbidity due to lack of
precision in the caregiver data.  However, somewhat similar to Blazer’s study with older
adults referred to above, who adjusted for functional status using the Rosow-Breslau
functional health scale (Rosow, 1966), the practical skills subscale of the DMR was used
to adjust for functional status, which may be a reasonable marker of general health.  Even
with this adjustment, the mood subscale association with later mortality was significant. 
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6.  PHYSICAL, EMOTIONAL, BEHAVIOURAL AND PSYCHIATRIC MORBIDITY
This chapter provides descriptive data on general health and care issues in the study
population,  and presents more detailed analysis on the use of psychotropic medications. 
Statistical analyses were not performed on general health and care issues because of
imprecision of the caregiver ratings, but medication data were assessed to be more
accurate and were thus analyzed using standard statistical methods.  Medication analyses
were performed in three ways: 
1. Cross-sectionally at the time of entry to the study (participants entered over the
years 1995-1999)
2. Comparatively between the four discrete waves of data collection
3. Longitudinally as the individual participant progressed through the study.
6.1  Physical morbidity
Detailed data on all the health problems which caregivers identified are tabulated in
Appendix C, and graphic presentation appears in Figures 6-1A,6-1B and 6-1C. 
Demographics of participants with available baseline health data were tabulated in Table
4-3.
6.1.1 Epilepsy/seizures
Epilepsy (defined as a history of seizures and ongoing treatment with anticonvulsant
medications) was much more common in participants without (rather than with) DS, and
within this group was commonest in the youngest cohort.  There was no noticeable age
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cohort pattern in participants with DS.  The age and diagnostic association with active
seizures (rather than epilepsy) at baseline was very similar to this.  Figures 6-1 and 6-2
illustrate the patterns graphically.
Figure 6-1.  Percentage of participants with baseline epilepsy
Figure 6-2.  Percentage of participants with baseline seizures
6.1.2  Heart or blood pressure problems at baseline
Current heart or blood pressure problems tended to be more frequent in older than
younger non-DS cohorts cohort, as would be expected in the general population. 
However, consistent with the known rate of congenital cardiac problems in DS,
participants with DS appear to have an early onset of problems, with expected additional
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aging changes across the older cohorts.  
Figure 6-3.  Percentage of participants with baseline heart or blood pressure problems  
6.1.3  Breathing problems at baseline
Current breathing problems at baseline were more common in people with DS in all age
cohorts except for the oldest one. There was no clear age association with breathing
problems.
Figure 6-4.  Percentage of participants with baseline breathing problems 
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6.1.4  Stomach, bowel or liver problems at baseline.
Participants with and without DS appear to have an overall similar rate of baseline
stomach, bowel or liver problems, although in the oldest cohort those with DS may be
more frequently affected than other diagnostic and age cohorts. 
Figure 6-5.  Percentage of participants with baseline gastrointestinal problems
6.1.5  Dental problems at baseline.
Baseline current dental problems were identified frequently by caregivers in all cohorts,
but most frequently in older people with DS. 
Figure 6-6. Percentage of participants with  baseline dental problems  
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6.1.6  Diabetes at baseline.
Current diabetes was uncommon overall, but was more  frequent in older compared to
younger cohorts without DS.  Only one participant with DS had diabetes, and this person
was in the 40-49 year age cohort.  
Figure 6-7. Percentage of participants with baseline diabetes
6.1.7  Thyroid problems at baseline.
Current baseline thyroid problems were identified much more frequently in participants
with than without DS.
Figure 6-8.  Percentage of participants with baseline thyroid  problems   
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6.1.8  Visual problems at baseline.
Current baseline visual problems were identified very frequently by caregivers in all
cohorts, but slightly more frequently in those with DS. 
Figure 6-9.  Percentage of participants with baseline vision  problems 
6.1.9  Hearing problems at baseline.
Baseline hearing problems were identified more frequently in participants with DS, and
particularly frequently in the oldest DS cohort. 
Figure 6-10.  Percentage of participants with baseline hearing  problems 
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6.1.10  Other medical problems at baseline.
Baseline “other” medical problems were identified frequently by caregivers in all cohorts,
but generally more frequently in those with DS.
Figure 6-11.  Percentage of participants with baseline medical “other” problems
6.2  Emotional, behavioural and psychiatric morbidity
Figure 6-12.  Percentage of participants with baseline nervous or psychiatric problems
Baseline nervous or psychiatric problems were identified more frequently overall by
caregivers of those without DS.  Participants with DS had a higher rate of baseline




Caregivers described patterns of health problems in the study population that were fairly
consistent with previously published research. For example, they described heart
problems as being more common in younger people with DS compared to younger
people without DS, but described typically increasing rates of health problems with age
in people without DS.  This is consistent with the known prevalence of congenital heart
disease in DS, and the known increase of hypertension and ischemic heart disease with
age in the general population.  
Baseline breathing problems were more frequently described in participants with DS than
in participants without DS, which might have been a reflection of higher rates of
obstructive sleep apnea.  
The prevalence of diabetes increased with age in participants without DS, but was very
rare  in  participants with DS.  This finding might have been a reflection of a younger,
and fairly small DS group. Baseline visual problems were identified more commonly in
participants with DS, which was probably due to the known increased rates of cataracts in
DS.  Hearing problems were also more frequently identified in participants with DS
compared to those without DS, and at rates similar to those described by direct
examination in the literature.  This was encouraging, as significant, unidentified hearing
problems may contribute towards apparent cognitive decline.   An increased rate of
thyroid problems in people with DS (compared to those without DS) was also found in
the study population, again suggesting that the study population was fairly representative
of the overall adult population with ID.  Dental problems were particularly common in
those with DS compared to those without DS. 
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In general, participants without DS were more likely than participants with DS to have
emotional, behavioural or psychiatric problems.  The rate of these problems did not
increase with the age of the cohort in participants  without DS, whereas those who did
have DS had an higher rate of both nervous and psychiatric problems with older cohort
age.  These findings are consistent with other research, which has found that people with
DS generally have the lowest rate of behavioural problems among the overall ID
population (Blacher & McIntyre, 2006), although behavioural problems tend to increase
in older adults with DS because of cognitive impairment (Prasher & Filer, 1995).  
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7.  FUNCTIONAL-COGNITIVE DECLINE: THE DMR
7.1  Introduction
As described in previous chapters, the DMR is a standardized, caregiver administered
instrument designed to evaluate cognitive and functional decline in people with ID. 
DMR data were obtained, scored and coded using methods described in previous
chapters.  This chapter analyses specific DMR subscales: short-term memory (STM),
long-term memory (LTM), spatial and temporal orientation (SPA), speech (SPE),
practical skills (PRA), mood (MOOD), activity and interest (ACT) and behavioural
disturbance (BEH). DMR subscale scores are analyzed in two ways: 
1. Cross-sectionally at the time of entry to the study 
2. Longitudinally as the individual participant progressed through the study.
7.2  Cross-sectional analysis of baseline DMR-subscale scores
Each set of DMR baseline subscale scores was initially explored by the use of scatter
diagrams, and mean observed scores were tabulated, including mean scores and standard
errors (Table 7-1).  Demographics of participants with available baseline DMR data were
tabulated in Table 4-3
Initial linear regression was performed with the core independent variables sex, age, and
diagnosis of DS, exploring all two-way and three-way interactions.  In every case, there
was a significant interaction between DS and age, and there was also an almost
significant (p=0.0633) three-way interaction in the DMR- BEH subscale, as shown in
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Table 7-2.  These positive interactions meant that in general, younger participants
without DS performed more poorly than older participants without DS, whereas, in
general, younger participants with DS performed better than older participants with DS.
Table 7-1. Mean (SE) observed baseline DMR-subscale scores
Subscale Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
STM Non-DS 5.48(0.74) 2.96(0.53) 2.42(0.51) 2.58(0.43) 3.13(0.28)
DS 1.20(0.37) 1.59(0.35) 2.92(0.66) 7.11(1.21) 2.84(0.37)
LTM Non-DS 8.65(0.77) 6.05(0.58) 6.43(0.58) 6.60(0.57) 6.73(0.31)
DS 3.20(0.71) 5.1(0.64) 6.53(0.79) 10.21(0.85) 6.05(0.43) 
SPA Non-DS 7.5(0.78) 4.38(0.57) 4.8( 0.56) 5.6( 0.55) 5.3( 0.31)
DS 3.4(0.78) 3.6(0.64) 6( 0.78) 9.3( 0.86) 5.2( 0.43)
SPE Non-DS 2.79(0.35) 1.6(0.26) 1.18(0.20) 1.28(0.20) 1.61(0.13)
DS 0.75(0.26 1.12(0.23) 1.47(0.32) 2.95(0.57) 1.47(0.18)
PRA Non-DS 4.38(0.81) 2.05(0.43) 1.67(0.43) 1.57(0.35) 2.2(0.24)
DS 0.3(0.15) 0.17(0.09) 1.31(0.49) 2.84(0.84) 0.98(0.22)
Mood Non-DS 4.53(0.34) 4.26(0.23) 3.08(0.23) 3.83(0.31) 3.87(0.14)
DS 2.75(0.48) 3.29(0.33) 3.78(0.39) 4.53(0.60) 3.55(0.22)
ACT Non-DS 3.75(0.45) 3.04(0.36) 2.57(0.37) 2.89(0.34) 2.99(0.19)
DS 1.3(0.36) 1.66(0.32) 3(0.50) 4.21(0.60) 2.43(0.24)
BEH Non-DS 4.63(0.36) 4.04(0.25) 3.31(0.28) 3.4(0.33) 3.77(0.15)
DS 2(0.34) 2.24(0.28) 3.56(0.43) 3.58(0.63) 2.83(0.21)
Table 7-2.  Interactions in linear regression analyses for baseline DMR subscales.
Subscale Interaction  (SE)â^ P value â^95% CI for 
STM DS*Age 0.2515(0.0422) <0.001 0.1686 - 0.3344
LTM DS*Age 0.2467(0.0483) <0.0001 0.1516 - 0.3417
SPA DS*Age 0.2199(0.0486) <0.0001 0.1243 - 0.3155
SPE DS*Age 0.1037(0.0198) <0.0001 0.0649 - 0.1426
PRA DS*Age 0.1385(0.0355) <0.0001 0.0687 - 0.2083
Mood DS*Age 0.0681(0.0232) <0.005 0.0226 - 0.1137
ACT DS*Age 0.1049(0.0296) <0.0001 0.0468 - 0.1631
BEH DS*Age 0.1233(0.0303) <0.0001 0.0638 - 0.1828
DS*Age*Sex -0.0231(0.0124) <0.1 -0.0475 - 0.0013
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Therefore, all subsequent regression analyses were performed separately for participants
with and without DS.  Curve estimation techniques from SPSS were then used to
estimate the best relationships between the DMR subscales and baseline age.  None of
these relationships for the DMR subscales with age were linear, and quadratic
relationships were found to be more appropriate.  All interactions with core independent
variables, which included sex, age, and the quadratic variable, age , were explored for2
significance.  Tables 7-3 and 7-4 (for participants without and with DS respectively)
summarize the final models chosen from these data to best predict DMR subscales at
baseline.  
Table 7-3.  Results of linear regression analyses for baseline DMR-subscales (Non-DS)
Subscale Parameter  (SE)â^              P value â^                    95% CI for 
STM Sex -0.8107 (0.5437) ns -1.8817   -  0.2603
Age -0.3986 (0.1135) <0.0001 -0.6222  -  -0.1751
Age 0.0037 (0.0012) <0.005 0.0014   -  0.00612
LTM Sex -1.2358 (0.6229) <0.05 -2.4628  - -0.0087
Age -0.2667 (0.1300) <0.05 -0.5228  - -0.0106
Age 0.0026 (0.0014) <0.1 -0.0001  -  0.00532
SPA Sex -0.6014 (0.6162) ns -1.8153  -  0.6125
Age -0.3694 (0.1286) <0.005 -0.6228  -- 0.1160
Age 0.0038 (0.0013) <0.005 0.0012  -  0.00652
SPE Sex -0.6527 (0.2485) <0.01 -1.1423  - -0.1631
Age -0.1723 (0.0519) <0.001 -0.2745  - -0.0701
Age 0.0015 (0.0005) <0.01 0.0005  -  0.00262
PRA Sex -0.479 (0.4791) ns -1.4228  -  0.4648
Age -0.4039 (0.1000) <0.0001 -0.6009 -  -0.2069
Age 0.0038 (0.0010) <0.0005 0.0017 -  0.00592
Mood Sex 0.7607 (0.2762) <0.01 0.2167  - 1.3047
Age -0.1616 (0.0576) <0.01 -0.2752 - -0.0481
Age 0.0015 (0.0006) <0.05 0.0003 -  0.00272
DMR-ACT Sex -0.2333 (0.3811) ns -0.9841  - 0.5174
Age -0.1942 (0.0796) <0.05 -0.3509 - -0.0375
Age 0.0019 (0.0008) <0.05 0.0003 -  0.00362
BEH Sex 0.3567 (0.3006) ns -0.2355 -  0.9490
Age -0.1611 (0.0628) <0.05 -0.2848 - -0.0375
Age 0.0014 (0.0007) <0.05 0.0001 -  0.00272
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Table 7-4.  Results of linear regression analyses for baseline DMR-subscales (DS)
Subscale Parameter  (SE)â^ P value â^         95% CI for 
STM Sex -0.8257 (0.6125) ns -2.0394  -  0.3879 
Age -0.4289 (0.2093) <0.05 -0.8435 - -0.0142 
Age 0.0077 (0.0025) <0.005 0.0027 -   0.0126 2
LTM Sex -1.0607 (0.7581) ns -2.5627 -  0.4412 
Age 0.2232 (0.0382 <0.001 0.1475 -  0.2988 
SPA Sex -0.5793 (0.7651) ns -0.9364 - -0.3694 
Age 0.0026 (0.0005) <0.0001 0.0017 -   0.0038 2
SPE Sex -0.6134 (0.3223) <0.1 -1.2519 -  0.0252 
Age 0.0009 (0.0002) <0.0001 0.0006  -  0.0013 2
PRA Sex -0.0977 (0.4167) ns -0.9233 -  0.7278 
Age 0.0012 (0.0003) <0.0001 0.0007  -  0.0017 2
Mood Sex 0.0789 (0.4272) ns -0.7675 -  0.9254 
Age 0.0492 (0.0215) <0.05 0.0066  -  0.0919 
ACT Sex 0.2416(0.4555) ns -0.6607 -  1.1440 
Age 0.0011(0.0003) <0.0001 0.0006 -  0.0017 2
BEH Sex 1.0611(0.9464) ns -0.8140 -  2.9362 
Age 0.0020(0.0008) <0.05 0.0005 -  0.0035 2
Age  *  Sex -0.0009(0.0005) <0.1 -0.0019 -  0.0001 2
Mean predicted (adjusted ) scores in this cross-sectional analysis showed that participants
without DS had the greatest impairments in the youngest age groups, and showed
progressively less impairment in older age groups, until a certain age (peak performance
age) was reached. (This age was obtained by differentiating the quadratic model equation
F[age], setting the derivative F´[age] to zero and solving for age.)  After this peak
performance age, which varied somewhat with the particular subscale, mean scores
started to decline again in older cohorts. The peak performance ages for people without
DS are shown below.
DMR-STM 54 DMR-SPE 56 DMR-PRA 53
DMR-LTM 51.5 DMR-BEH 57.8 DMR-Mood 53.5
DMR-SPA 48.4 DMR-ACT 50
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In contrast, mean predicted (adjusted ) scores in this cross-sectional analysis showed that
participants with DS were generally least impaired in the youngest age groups, and were
progressively more impaired in older age groups. Only in the DMR-STM subscale was
there a suggestion of a peak performance age (28 years), before which the impairments
were slightly greater, and after which the impairments were incrementally greater with
increased age of the cohorts.
There was no interaction between the age variables and sex in any analysis except for
behavioural problems in participants with DS, where this interaction was almost
significant (p= 0.0783) and negative.  This meant that younger women with DS had more
behavioural problems than younger males with DS, whereas older women with DS had
fewer behavioural problems than older males with DS.  In participants without DS,
female sex was associated with significantly better functioning (cross-sectional analysis)
in long-term memory and speech, but significantly worse functioning in mood.  In
participants with DS, female sex was associated with almost significantly (p=0.0596)
better functioning in the area of speech, but was not significant to any of the other
subscales.  Predicted model results are shown in Figures 7-1A and 7-1B. 
111
Figure 7-1A.  Mean predicted baseline DMR-subscale deficit scores (STM, LTM, SPA,
SPE)
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Figure 7-1B.  Mean predicted baseline DMR-subscale deficit scores (PRA, MOOD,
ACT, BEH)
7.3  Longitudinal analysis of DMR-subscale scores
All available data points were used to calculate individual pooled measures of DMR-
subscale score change per year (slope) for participants who had two or more tests
available. These individual slopes were calculated using the least squares method as
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described in chapter 3.  Most individual slopes were very small, suggesting little change
over the study period.  However, because a small number of participants had large
fluctuations, slopes had wide ranges.  Overall, participants with DS had greater average
yearly decline in DMR-subscales than those without DS.
Each set of DMR subscale slopes was explored similarly to the cross-sectional baseline
scores, and mean observed slopes were tabulated, including mean slopes and standard
errors (Table 7-5).  
Table 7-5.  Mean (SE) observed DMR-subscale slopes
Subscale Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
STM Non-DS -0.004 (0.098) 0.079 (0.118) 0.028 ( 0.071) 0.197(0.097) 0.082( 0.050) 
DS 0.072 (0.139) -0.060 (0.066) 0.480 ( 0.171) 0.524(0.321) 0.225( 0.084) 
LTM Non-DS -0.105 (0.906) 0.136 (0.086) 0.089 ( 0.080) 0.152(0.086) 0.087( 0.044) 
DS 0.359 (0.217) 0.014 (0.087) 0.453 ( 0.112) 0.594(0.182) 0.303( 0.069) 
SPA Non-DS 0.092 (0.080) 0.184 (0.092) 0.127 ( 0.087) 0.211(0.100) 0.16(0.047) 
DS -0.036 (0.113) -0.023 (0.065) 0.269 ( 0.118) 0.675(0.260 ) 0.181( 0.067) 
SPE Non-DS -0.020 (0.047) 0.036 (0.043) 0.069 ( 0.035) 0.088(0.040) 0.049( 0.021) 
DS 0.092 (0.060) 0.000 (0.041) 0.201 ( 0.064) 0.184(0.121)  0.108(0.034) 
PRA Non-DS 0.049 (0.079) 0.085 (0.049) 0.244 ( 0.083) 0.506(0.125) 0.231( 0.045) 
DS 0.027 (0.035) 0.026 (0.020) 0.220 ( 0.155) 1.252(0.363) 0.29(0.087) 
Mood Non-DS 0.060 (0.072) 0.078 (0.078) 0.186 ( 0.076) 0.193(0.066) 0.134( 0.038) 
DS 0.072 (0.123) 0.010( 0.083) 0.008 ( 0.136) 0.433(0.231) 0.090( 0.068) 
ACT Non-DS -0.046 (0.079) -0.016 (0.063) -0.020 (0.081) 0.138(0.089) 0.018( 0.039) 
DS 0.132 (0.086) 0.019 (0.057) 0.218 (0.150) 0.877(0.230) 0.242( 0.070) 
BEH Non-DS -0.033 (0.081) 0.027 (0.079) 0.073( 0.064) 0.183(0.057) 0.070(0.036) 
DS 0.210 (0.139)  0.148 (0.062) -0.131(0.114) 0.272(0.271) 0.093( 0.066) 
As in the cross-sectional analysis, there was either a significant or an almost significant
interaction between DS and age interaction in most subscales, and three-way interactions
in a few subscales.  These are shown in Table 7-6.
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Table 7-6.  Interactions in linear regression analyses for DMR-slope subscales.
Measure Interaction  (SE)â^ ) P value â^95% CI for 
STM-slope DS*Age 0.0818(0.0236) <0.001 0.0355 - 0.1282
DS*Sex 1.7406(0.6565) <0.01 0.4494 - 3.0318
DS*Age*Sex -0.0429(0.0156) <0.01 -0.0736 - -0.0122
LTM-slope DS*Age 0.0492(0.0203) <0.05 0.0092 - 0.0891
DS*Sex 1.0214(0.5653) <0.1 -0.0905 - 2.1334
DS*Age*Sex -0.026(0.0134) <0.1 -0.0525 - 0.0004
SPA-slope DS*Age 0.0266(0.0076) <0.0005 0.0117 - 0.0415
SPE-slope - - - -
PRA-slope DS*Age 0.1061(0.0207) <0.0001 0.0653 - 0.1469
DS*Sex 1.9077(0.5778) <0.005 0.7712 - 3.0442
DS*Age*Sex -0.0554(0.0137) <0.0001 -0.0824 - -0.0283
Mood-slope DS*Age50+ 0.3315(0.1824) <0.1 -0.0273 - 0.6903
ACT-slope DS*Age 0.0721(0.0186) <0.0001 0.0356 - 0.1086
DS*Sex 1.2115(0.517) <0.05 0.1946 - 2.2284
DS*Age*Sex -0.0343(0.0123) <0.01 -0.0585 - -0.0101
BEH-slope DS*Age -0.0925(0.0437) <0.05 -0.1785 - -0.0066
DS*Age 0.001(0.0005) <0.1 0.0000  -  0.0022
Because of the high number of significant interactions found above, regression analyses
were performed separately for participants with and without DS, using the same
procedure as for the cross-sectional analysis.  The best models to predict yearly changes
of DMR subscales in participants without DS were all linear, whereas in participants with
DS the best models were quadratic, except for those predicting behavioural problems. 
Tables 7-7 and 7-8 (for participants without DS and participants with DS respectively)
summarize the final models chosen from these data to best predict DMR subscales
slopes. 
Mean predicted (adjusted ) scores of participants without DS showed that, although in all
subscales there was a trend to increased yearly individual decline with increased baseline
age, baseline age was not statistically significant to this decline except in the analysis for
practical skills, where age significantly (p<0.0001) increased decline and behavioural
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problems, where age almost significantly (p=0.0532) increased decline. Sex was not
significant to yearly decline in any subscale, and there were no interactions between age
variables and sex.
Table 7-7.  Results of linear regression analyses for DMR-subscale slopes (Non-DS)
Measure Parameter  (SE)â^ P value â^95% CI for 
STM-slope Sex -0.0536 (0.1020) ns -0.2547 - 0.1475 
Age 0.0036 (0.0038) ns -0.0039 - 0.0111 
LTM-slope Sex 0.1273 (0.0896) ns -0.0492 - 0.3039 
Age 0.0049 (0.0034) ns -0.0017 - 0.0115 
SPA-slope Sex -0.0724 (0.0947) ns -0.2590 - 0.1143 
Age 0.0005 (0.0035) ns -0.0065 - 0.0075 
SPE-slope Sex 0.0041 (0.0420) ns -0.0786 - 0.0867 
Age 0.0021 (0.0016) ns -0.0010 - 0.0052 
PRA-slope Sex -0.091 (0.0886) ns -0.2657 - 0.0836 
Age 0.0146 (0.0033) <0.0001 0.0081 - 0.0212 
Mood-slope Sex -0.001 (0.0763) ns -0.1513 - 0.1493 
Age 0.0044 (0.0029) ns -0.0012 - 0.0101 
ACT-slope Sex -0.004 (0.0798) ns -0.1609 - 0.1526 
Age 0.0041 (0.0030) ns -0.0018 - 0.0100 
BEH-slope Sex -0.0548 (0.0724) ns -0.1975 - 0.0878 
Age 0.0053 (0.0027) <0.1 -0.0001 - 0.0106 
The reference category for sex is male
In contradistinction to this result, the mean predicted (adjusted ) slope scores of
participants with DS showed that in all subscales except for mood and behavioural
problems the baseline age variable (age or age ) was statistically significant to the yearly2
decline.  There were also significant or almost significant interactions between age  and2
sex in all subscales except for mood and behavioral problems, resulting in younger
women with DS having greater yearly decline than men of the same age, but older
women with DS having less decline than men of the same age.  
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Table 7-8.  Results of linear regression analyses for DMR-subscale slopes (DS)
Measure Parameter  (SE)â^ P value â^95% CI for 
STM-slope Sex 0.8621 (0.3733) <0.05 0.1224 - 1.6019
Age 0.0011 (0.0003) <0.0005 0.0005 - 0.00162
Age  * Sex -0.0005 (0.0002) <0.01 -0.0009 - -0.00012
LTM-slope Sex 0.6500 (0.3105) <0.05 -0.0009 - -0.0001
Age 0.0007 (0.0002) <0.01 0.0002  - 0.0012 2
Age  * Sex -0.0003 (0.0002) <0.1 -0.0006  - 0.0000 2
SPA-slope Sex 0.4204 (0.2914) ns -0.1570 -  0.9978
Age 0.0008 (0.0002) <0.005 0.0000  - 0.00122
Age  * Sex -0.0003 (0.0002) <0.1 -0.0006  - 0.0000 2
SPE-slope Sex 0.2035 (0.1557) ns -0.1051 - 0.5121
Age 0.0003 (0.0001) <0.05 0.0001 - 0.00062
Age  * Sex -0.0002 (0.0001) <0.1 -0.0003 - 0.00002
PRA-slope Sex 0.9576 (0.3102) <0.005 0.3427  - 1.5724 
Age -0.1748 (0.0470) <0.0005 -0.2679 - -0.0818 
Age  0.0037 (0.0006) <0.0001 0.0025  - 0.0050 2
Age  * Sex -0.0008 (0.0002) <0.0001 -0.0011 - -0.0005 2
Mood-slope Sex 0.1021 (0.1357) ns -0.1669  - 0.3710 
Age 0.0000 (0.0001) <0.1 0.0000  - 0.0003 2
ACT-slope Sex 0.6406 (0.2893) <0.05 0.0671  - 1.2141 
Age -0.1147 (0.0438) <0.05 -0.2015  - -0.0279 
Age 0.0024 (0.0006) <0.0001 0.0012  - 0.0035 2
Age  * Sex -0.0005 (0.0002) <0.005 -0.0008  - -0.00022
BEH-slope Sex 0.1416 (0.1338) ns -0.1235  - 0.4067 
Age -0.0026 (0.0068) ns -0.0161 - 0.0109 
The reference category for sex is male
Similar to the cross-sectional analysis, peak performance ages for DMR subscales slope
in people with DS were calculated and are shown below. 
STM slope 26(male) 43(female)  PRA slope     30(males) 40 (females)
LTM slope 29(males) 41(females) Mood slope -
SPA slope - ACT slope     30(males) 40 (females)
SPE  slope - BEH slope -
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Predicted model results are shown in Figures 7-2A and 7-2B. 
Figure 7-2A.  Mean predicted DMR-subscale deficit slopes (STM, LTM, SPA, SPE) 
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Figure 7-2B.  Mean predicted DMR-subscale deficit slopes (PRA, Mood, ACT, BEH)
7.4  Discussion
Cross-sectional analysis using DMR subscale scores showed that in participants without
DS, DMR subscales tended to have a quadratic relationship to baseline age, with high
impairments in the youngest ages, improved performances in older age cohorts until a
certain age was reached, and then gradually worse performance in older age cohorts.
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The pattern of greater impairment in young, community dwelling cohorts without DS is
likely a result of increased recent survival of infants with severe disabilities, coupled with
increased community care of these severely intellectually disabled people.  The
population with DS is more homogeneous, and thus the range of disabilities is narrower,
with fewer people with DS having very severe disabilities, and therefore changes in care
patterns can be expected to have less impact on cross-sectional cohort functioning in the
youngest cohorts.  
Also affecting performance is ongoing learning.  Because people with ID now have
greater opportunities, it is possible that ongoing learning improves performance during
the early adult years, resulting in better performance of older than younger cohorts.  As
new learning may be decreased in those with DS, even in young adulthood, this factor
may not result in the same apparent cohort improvement. 
Counteracting the factors described above (which result in better performance in older
cohorts) is the normal aging process.  This would be anticipated to worsen functioning in
most areas with age, although one would not necessarily expect all areas of functioning to
decline equally.  However, this aging effect might also result in increased
institutionalization and mortality, so that the individuals declining the most rapidly would
either not have been recruited at all by a community study, or be rapidly lost to followup,
resulting in the appearance of reduced yearly declines in direct testing.  Because of
known early aging and increased mortality in people with DS, we would expect that the 
measurement of age related decline would most underestimate the decline in this group. 
This underestimate would be less serious, of course, than the underestimate in direct
testing, described later, which would be limited much earlier than the caregiver
assessments in the DMR.
The overlay of cohort factors with aging factors likely resulted in the non-linear pattern
of cohort functioning seen in participants without DS.  In this group, peak performance
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ages (the turning point when aging effects have become stronger than the impact of
continued learning and cross-sectional changes in the pattern of care) were calculated,
which varied from 48.4 years (spatial orientation) to 57.8 years (behavioural changes). 
Differences in peak times among specific functions are probably due to differences in the
ability of learning to improve the function.  For example, while spatial and temporal
orientation may be largely determined by pre-existing biological deficits, with
superimposed, age determined biological deterioration, behaviour is probably more
affected by learning and environment, and is therefore more amenable to improvements
over time.  
Unlike the situation in participants without DS, cross-sectional analysis of DMR
subscales in participants with DS disclosed almost universally progressive decreased
functioning in older compared to younger cohorts.  This suggests that aging effects in
people with DS are more pronounced than cohort effects related to changes in care
provision, and start earlier in life than in the general population, probably by early
adulthood.  Furthermore, if one assumes that differential institutionalization of older
people with DS caused an underestimation of aging decline in this group, the actual
decline might be even greater.  
Dementia in the general population is known to have a very long premorbid phase, as
early biological changes (with no measurable clinical changes), are followed by very
subtle clinical changes which do not meet criteria for dementia, and only much later by a
clinical diagnosis of dementia.  It is therefore not surprising that adults with DS, who are
known to have an earlier onset of dementia,  already show declines in various functions
by early adulthood.
It was expected that longitudinal measurement of individual decline would be a better
gauge of true aging.  In general, longitudinal changes over time in individual DMR
subscales were greater in those with DS compared to those without DS, although sex-age
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interactions in participants with DS made these differences difficult to evaluate.  Older
males with DS generally had more yearly decline than older females with DS, and this
was statistically significant in many of the subscales.  This finding was consistent with
research by Schupf et al (1998), whose data suggested an earlier onset of dementia in
males than females with DS.  Schupf (2002) discussed these gender differences further in
her review of genetic and host factors for dementia in DS, noting the protective effects of
estrogen, and the finding that males with DS have greater gonadal dysfunction than
females. She speculated that this might decrease their relative advantage compared to
females which is seen in the general population.  However, in view of the earlier onset of
menopause in women with DS (Schupf et al., 1997) and the fairly strong association
between age of  menopause and onset of dementia (Schupf et al., 2003; Cosgrave,
Tyrrell, McCarron, Gill & Lawlor, 1999), this finding is still puzzling.
The finding of greater and earlier decline in males with DS was not replicated in
participants without DS, in whom sex was not significant to yearly decline in any of the
subscale analyses.  This finding more closely followed the underlying, general population
pattern, in which females, rather than males are thought to have a greater rate of
dementia, especially after menopause (Baum, 2005), although this may no longer hold
once increased female life expectancy is taken into account (Gatz, 2006). 
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8.  NEUROPSYCHOLOGICAL FUNCTIONING: DYSPRAXIA AND MEMORY
8.1  Dyspraxia
Demographic description of participants with available dyspraxia data is shown in Table 8-1.
Table 8-1. Demographics of participants with dyspraxia data
Non-DS males Non-DS females DS males DS females
Number in
each group
Age <30 9 6 9 7
Age 30-39 23 24 19 17
Age 40-49 40 18 16 16
Age 50+ 30 31 4 7
Mean age (SE) 46.43(1.31) 46.38(1.40) 38.58(1.32) 40.52(1.44)
Age range 24-86 22-75 23-62 20-63
Scores were coded in the database as percentage correct of the total i.e. a score of 80
correct on Part 1 would be coded as 100.  Each subscale was then analysed in two ways: 
Cross-sectionally at the time of entry to the study (participants tested over the
years 1997-2001)
Longitudinally as the individual participant progressed through the study.
8.1.1  Dyspraxia general data results
Basic cross-sectional descriptive statistics ( including the number of participants in each
group, mean percentage scores and standard error) for Dyspraxia Part 1, 2, 3 and Overall
data at baseline, time 1, time 2 and time 3 are displayed in Tables 8-2, 8-3, 8-4 and 8-5. 
Participants with DS had a more pronounced pattern of decreased scores with increased
cohort age at all test times. 
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Table 8-2.  Mean (SE) observed Dyspraxia Part 1 percentage scores.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 82 (6.82) 94.79 (1.53) 86.98 (2.39) 87.42 ( 2.1) 88.74(1.27)
DS 92.11 (2.86) 90.9 (2.04) 90.7 (1.71) 74.66 (4.62) 89.16(1.3)
Time 2 Non-DS 96.00(2.71) 94.13 (1.95) 92.70 (2.27) 93.22 (1.49) 93.43(1.03)
DS 98.86(0.62) 94.58 (1.66) 94.26 (1.06) 79.13 (8.90) 93.20(1.33)
Time 3 Non-DS 95.63 (1.88) 93.8 (2.43) 91.84 (2.22) 90.35 (1.73) 91.63(1.17) 
DS 97.50 (0.88) 94.17 (1.91) 90.90 (1.94) 70.13 (10.26) 89.34( 2.06)
Table 8-3.  Mean (SE) observed Dyspraxia Part 2 percentage scores.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 84.75 (5.46) 94.6 ( 1.33) 92.59 (1.4) 89.9 ( 1.64) 91.55 (0.92)
DS 90.47 (4.27) 93.51 (1.77) 90.47 (2.49) 73.18 (6 .49) 89.62 (1.60)
Time 2 Non-DS 98.63 (0.63) 94.6 9(1.56) 92.55 (2.26) 92.56 (1.24) 93.40 (0.94)
DS 97.73 (1.10) 95.23 (1.19) 93.65 (1.04) 74.63 (10.33) 92.47 (1.47)
Time 3 Non-DS 98.13 (0.63) 96.73 (1.42 ) 93.06 (2.00) 90.46 (1.90) 92.71 (1.13)
DS 97.00 (1.29) 94.05 (2.12) 91.29 (2.24) 71.88 (10.11) 89.71 (2.10)
Table 8-4.  Mean (SE) observed Dyspraxia Part 3 percentage scores.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 74.24 (7.04) 73.5 ( 3.45) 65.56 (3.36) 66.63 (3.26) 68.79 (1.88)
DS 65.34 (7.15) 66.41 ( 4.14) 61.51 (3.75) 46.28 (8.73) 62.25 (2.59)
Time 2 Non-DS 76.14 (5.92) 72.35 ( 4.19) 67.65 (3.75) 67.01 (3.00) 68.95 (1.96)
DS 78.51 (4.87) 64.98 (4.52) 63.17 (3.50) 45.45 (9.22) 63.64 (2.55)
Time 3 Non-DS 47.73 (20.45) 77.1 ( 3.41) 63.88 (3.67) 65.19 (3.04) 67.02 (2.01)
DS 72.73 (11.32) 60.17 (5.23) 59.80 (3.24) 37.73 (7.90) 57.62 (2.79)
Table 8-5.  Mean (SE) observed Dyspraxia Overall percentage scores.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 80.13(5.75) 87.17( 1.86) 81.07(2.09)  80.74( 2.16) 82.47(1.21) 
DS 82.11(3.90) 83.18( 2.43) 80.39(2.34) 64.08(5.77) 79.85(1.62) 
Time 2   Non-DS 89.80(2.28) 86.69( 2.39) 83.55(2.52) 83.71(1.74) 84.69(1.19) 
DS 91.28(2.04) 84.44( 2.31) 83.03(1.75) 65.73(8.81) 82.52(1.62) 
Time 3 Non-DS 79.44(8.06) 88.82, 2.02) 82.31(2.34) 81.47(1.98) 83.25(1.27) 
DS 86.94(4.29) 82.07( 2.92) 79.99(2.28) 59.19(9.13) 78.08(2.15) 
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Because of increased comfort with the testing situation, and therefore better cooperation
with test protocols on the second testing, it was decided to use data from the second
assessments to develop models for cross-sectional scores across diagnostic and age
groups.  Similarly, test changes from the second to the third test were felt to be a more
accurate assessment of aging than test changes from the first to the second test, so these
were used to develop a models for a longitudinal changes in the Dyspraxia subscales
across diagnostic and age groups (shown later).
8.1.2  Dyspraxia cross-sectional analyses
Linear regression analysis with all Dyspraxia subscale scores at time 2 as the dependent
variable and DS diagnosis, age and sex as independent variables showed that there were
significant second order interactions between DS diagnosis and age in all subscales, and
various other second and third order interactions in specific subscales.  These are shown
below in Table 8-6.
Table 8-6.  Interactions in linear regression analyses of Dyspraxia percentages 
Dyspraxia Subscale Interaction  (SE)â^ P value â^95% CI for 
Dyspraxia Part 1 DS * Age -0.384(0.175) <0.05 -0.730 - -0 .039
Dyspraxia Part 2 DS * Age -1.4984(0.4705) <0.005 -2.4251 -- 0.5717
DS * Sex -24.7576(12.549) <0.05 -49.4763 - - 0.0389
DS * Age *Sex 0.6838( 0.2964) <0.05 0.0999 - 1.2677
Dyspraxia Part 3 DS * Age -0.7098(0.3327) <0.05 -1.3651 - -0.0545
Dyspraxia Overall Score DS*Age -0.5313(0.2035) <0.01 -0.9321 - -0.1305
The reference category for DS is Non-DS, and the reference category for sex is male
Because of these interactions, data from participants with and without DS were analyzed
separately.  Curve estimation techniques from SPSS were used separately for those with
and without DS to estimate the best relationships between scores and age.  The
relationship between scores and age in participants without DS was found to be linear in
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Dyspraxia Part 1 and Part 2, but quadratic in Part 3, whereas in participants with DS the
relationship was quadratic in all subscales.  Model building was performed separately for
the two diagnostic groups, exploring effects of the independent variables, sex, age, and
age  (age squared) as well as all possible interactions.  Table 8-7 summarizes the best2
final models chosen for participants with and without DS.
Table 8-7.  Results of linear regression analysis for Dyspraxia percentages at time 2 
Dyspraxia Subscale Diagnosis Parameter  (SE)â^ P value â^95% CI for 
Dyspraxia Part 1 Non-DS Sex 0.6354(2.094) ns -3.4991 - 4.7700
Age -0.0560(0.0842) ns -0.2222 - 0.1101
DS Sex 67.9197(41.2755) ns -14.2056 - 150.0450
Age 6.5614(3.1523) <0.05 0.2893 - 12.8334
Age -0.0918(0.0367) <0.05 -0.1648 - -0.01872
Age * Sex -3.6542(1.9586) <0.1 -7.5512 - 0.2428
Age  * Sex 0.0491(0.0227) <0.05 0.0040 - 0.09432
Dyspraxia Part 2 Non-DS Sex -0.9948(1.8850 ns -4.7175 - 2.728
Age -0.1171(0.0758) ns -0.2667 - 0.0326
DS Sex 82.9131( 43.3011) <0.1 -3.2424 - 169.0686
Age 8.7753(3.3070) <0.01 2.1955 - 15.3551
Age -0.1226(0.0385) <0.005 -0.1993 - - 0.04592
Age * Sex -4.6845(2.0547) <0.05 -8.7727 - -0.5963
Age  *  Sex 0.0633(0.0238) <0.01 0.0160 - 0.11062
Dyspraxia Part 3 Non-DS Sex 4.7163( 3.9279) ns -3.0412 - 12.4739
Age -1.8756(1.0154) <0.1 -3.8811 - 0.1299
Age 0.0169(0.0098) <0.1 -0.003 - 0.03642
DS Sex 4.2541( 4.8798) ns -5.45 -  13.9582
Age -0.0102(0.0032) <0.005 -0.0166 -  -0.00382
Dyspraxia Overall
Score
Non-DS Sex 1.6025(2.4002) ns -3.1376 - 6.3426
Age -0.1090(0.0965) ns -0.2995 - 0.0816
DS Sex 104.6798(49.8366) <0.05 5.5205 - 203.8391
Age 9.274(3.8261) <0.05 1.7011 - 16.8470
Age -0.1229(0.0443) <0.01 -0.2112 - -0.03472
Age*Sex -5.3300(2.3648) <0.05 -10.0352 -  -0.6247
Age * Sex 0.0668(0.0274) <0.05 0.0123 - 0.12122
The reference category for sex is male
In participants without DS there were no interactions in any subscale analysis, sex was
not significant to the outcome by itself or in interaction in any subscale, and age was only
almost significant (p=0.0666 for age, p=0.0869 for age ) in Dyspraxia Part 3.  However,2
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DS cohort data disclosed significant interactions between age variables and sex in
Dyspraxia Parts 1 and 2, resulting in noticeably more impaired functioning in males than
females in the oldest cohorts, but less difference between males and females in the
youngest cohort.  In participants with DS age variables were also independently
significant to the outcome in all subscales, tending to decrease performance in older
cohorts. 
Figure 8-1.  Mean predicted Dyspraxia percentages (Time 2)
Figure 8-1 illustrates the predicted (adjusted) percentage scores in the subscales.   All
groups of participants experienced more difficulty in performing Dyspraxia Part 3
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(particularly the left-right discrimination tasks), and total scores are thus lower overall.  It
can also be seen from these graphs that, while all participants tend to have lower scores
in older cohorts, the most pronounced age effect is seen in the males with DS.
8.1.3  Dyspraxia longitudinal analysis
Basic descriptive statistics are shown in Tables 8-8 to 8-11 for the change per year in
Dyspraxia percentage scores from time 1 to 2, and from time 2 to 3.  Dyspraxia
percentage score yearly changes from time 2 to 3 were chosen to develop models for
aging effects, again because participant comfort and cooperation was greater for the
second and third testing compared to the first  testing. 
Table 8-8.  Mean (SE) observed Dyspraxia Part 1 percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year 1-2
Non-DS 4.14 (3.67) 0.22 (0.43) 2.27 (0.79) 2.62 (0.72) 1.97( 0.46)
DS 1.67 (0.79) 2.48 (0.72) 0.56 (0.91) 5.63 (2.44) 1.97( 0.51)
Change per
year 2-3
Non-DS -0.78 (0.89) -1.59 (0.53) -1.02 (0.58) -1.89 (0.49) -1.49(0.30)
DS -0.25 (0.51) -1.10  (0.55) -3.60 (1.64) -9.49 (4.21) -2.88(0.87)
Table 8-9.  Mean (SE) observed Dyspraxia Part 2 percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year 1-2
Non-DS 3.00 (1.53) 0.24 (0.36) -0.61 (0.88) 0.74 ( 0.67) 0.32 (0.40)
DS 3.09( 2.55) 0.92 (0.52) 0.81 (1.29) 2.55 ( 4.27) 1.41 (0.75)
Change per
year 2-3
Non-DS -0.25 (0.69) -0.63 (0.37) -0.22 (0.60) -1.42 (0.66) -0.82 (0.35)
DS -0.47 (0.33) -0.63 (0.56) -2.54 (1.83) -5.31 (4.60) -1.87 (0.91)
Table 8-10.  Mean (SE) observed Dyspraxia Part 3 percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year 1-2 
Non-DS -3.34 (2.06) -1.07 (1.52) -0.06 (1.48) 0.05 (1.35) -0.54 (0.79)
DS 3.48 (1.76) -0.79 (1.36) 1.14 (1.18) -5.63 (3.55) 0.17 (0.83)
Change per
year 2-3 
Non-DS -2.19 (2.73) -0.06 (1.28) -3.31 (1.06) -1.56 (0.99) -1.82 (0.62)
DS -1.38 (2.13) -2.33 (1.96) -3.48 (1.64) -5.29 (3.24) -2.98 (1.05)
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Table 8-11.  Mean (SE) observed Dyspraxia Overall percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year time  1-2 
Non-DS 1.12( 1.69) -0.18(0.64) 0.41( 0.75) 1.18(0.71) 0.55( 0.40) 
DS 2.77( 1.28) 0.86( 0.58) 0.76(0.80) 0.66( 2.57) 1.14(0.48)
Change per
year 2-3  
Non-DS -1.11(0.93) -0.81( 0.46) -1.44(0.59) -1.62(0.49) -1.36(0.30) 
DS -1.23(1.02) -1.38( 0.78) -3.21(1.54) -6.65(3.56) -2.66(0.80) 
Linear regression analysis was performed with Dyspraxia percentage changes from time
2 to time 3 as the dependent variables and DS, age and sex as independent variables. This
analysis showed significant interactions between DS and age in all Dyspraxia subscales,
as well as other interactions in specific subscales, as is shown in Table 8-12. 
Table 8-12.  Interactions in linear regression analyses of Dyspraxia percentage yearly
change 
Dyspraxia Subscale Interaction â^ P value â^95% CI for 
Dyspraxia Part 1 DS*Age -0.83 (0.22) <0.001 -1.27 - -0.40)
DS*Sex -11(5.45) <0.05 -21.7 -  -0.25)
DS*Sex*Age 0.32(0.13) <0.05 0.055 -   0.580
Dyspraxia Part 2 DS*Age -0.7452( 0.2488) <0.005 -1.2360 -  -0.2544
DS*Sex -11.4135(6.1331) <0.1 -23.5138 - 0.6868 
DS* Age * Sex 0.3528(0.1482) <0.05 0.0604 - 0.6452
Dyspraxia Part 3 DS * Age -0.4235(0.1508) <0.01 -0.7211 - -0.1259
DS * Sex* Age 0.1638( 0.0547) <0.005 0.0559 - 0.2717
Dyspraxia Overall Score DS*Age -0.3885(0.0919) <0.0001 -0.5698 -  -0.2072
DS*Sex*Age 0.1083(0.0333) <0.005 0.0426 - 0.1740
The reference category for DS is Non-DS, and the reference category for sex is male
Using similar methods as used in the cross-sectional analysis, model building was
therefore again performed separately for the two diagnostic groups, exploring effects of
the independent variables, sex, age, and age  as well as all possible interactions.  Table 8-2
13 summarizes the two best final models chosen for participants with and without DS.
In participants without DS, neither sex nor age were significant to any yearly Dyspraxia
percentage changes from time 2 to time 3, and there were no significant interactions. 
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However, in participants with DS, except for data from Dyspraxia Part 3, DS cohort data
disclosed significant interactions between age variables and sex.  In participants with DS
male sex conferred an additional and independent disadvantage to scores, which was
significant for Dyspraxia Parts 2 and 3, and almost significant to Dyspraxia Part 1
(p=0.0508).  Age (in participants with DS) was independently significant to the outcome
in all subscales except Dyspraxia Part 3, tending to decrease scores in older age cohorts.
Table 8-13.  Results of linear regression analysis for yearly Dyspraxia percentage changes
Dyspraxia Subscale Diagnosis Parameter
^
â P value â^95% CI for 
Dyspraxia Part 1 Non-DS Sex 0.117(0.6050) ns -1.080 - 1.3149
Age -0.0250(0.0233) ns -0.0712 - 0.0212
DS Sex 49.6779( 2 4.9357) <0.1 -0.1678 - 99.5237
Age 5.6976(2.0571) <0.01 1.5856 - 9.8796
Age -0.0804(0.0247) <0.005 -0.1298 - - 0.03092
Age * Sex -2.8006(1.2083) <0.05 -5.2160 - -0.3852
Age  * Sex 0.0383(0.0143) <0.01 0.0097 - 0.06692
Dyspraxia Part 2 Non-DS Sex 0.0265(0.7001) ns -1.3595 - 1.4126
Age -0.0419(0.0270) ns -0.0953 - 0.0115
DS Sex 65.5892(2 7.4541) <0.05 10.7092 - 120.4692
Age 7.1439(2.2648) <0.005 2.6166 - 11.6712
Age -0.0970( 0.0272) <0.001 -0.1514 - - 0.04262
Age * Sex -3.5850(1.3304  <0.01 -6.2443 - -0.9256
Age  * Sex 0.0482(0.0157) <0.005 0.0167 - 0.07972
Dyspraxia Part 3 Non-DS Sex -1.3152( 1.252) ns -3.7965 - 1.1662
Age -0.0027(0.0483) ns -0.0983 - 0.0929
DS Sex 5.893(2.0109) <0.005 1.877 - 9.9091
Age -0.0022(0.0013) 0.11 -0.005 - 0.00052
Dyspraxia Overall
Score
Non-DS Sex -0.5237(0.5988) ns -1.7092 - 0.6618
Age -0.0223(70231) ns -0.0680 - 0.0234
DS Sex 54.3210( 24.1870) <0.05 5.9718 - 102.6701
Age 5.6486(1.9953) <0.01 1.6601 - 9.6372
Age -0.0755( 0.0240) <0.005 -0.1234 -  -0.02752
Age*Sex -2.7856(, 1.1721) <0.05 -5.1285 - -0.4427
Age  Sex 0.0363(0.0139 <0.05 0.0086 - 0.06412
The reference category for sex is male
These models were used to calculate predicted scores for yearly change in each subscale, 
with the diagnostic categories calculated separately.  Results are shown graphically in
Figure 8-2. 
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Figure 8-2.  Mean predicted Dyspraxia yearly change
8.1.4  Discussion of Dyspraxia results
The three parts of the Dyspraxia Scale measure slightly different skills, and study
participants had more difficulty answering questions on Dyspraxia Part Three, body
parts/coin task, and also showed more deterioration in this subscale from younger to
older cohorts, starting with the youngest cohort.  Deficits in Part 3 occurred largely
because of difficulties in differentiating between left and right and greater difficulties
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identifying different coins.  These skills may be more sensitive to deficits in sophisticated
executive functioning, which are generally thought to be a hallmark of ID.  As reviewed
earlier, changes in executive functioning are also now thought to be one of the earliest
markers of Alzheimer’s Disease, which may explain why declines in Part 3 appeared to
start in the youngest cohort already, whereas declines in the other subscales occurred
mostly in the oldest cohorts.
In general, adjusted, mean  time 2 scores in all three subscales were worse in the older
age cohorts, with more pronounced drops in participants with DS, especially males. 
Yearly decline was also greater in participants with DS, (especially males), which is
consistent with the association between early dementia and early apraxic changes, as
published by Yesavage, Brooks, Taylor and Tinklenberg (1993).   Greater decline of
praxis is also consistent with work with adults who have DS published by Oliver,
Crayton, Holland, Hall and  Bradbury (1998), and Soininen et al. (1993).
Gender differences between age-related yearly decline in praxis depended on the
diagnosis of DS. Whereas in participants without DS, males and females generally had
similar adjusted yearly decline, in participants with DS, males generally declined
significantly more per year than females, especially in the oldest age cohorts.  Reasons
for this are unclear, and not previously reported in the literature, yet consistent with
results from caregiver reports of practical and other functional abilities on the DMR.
8.2.  Visual memory: the Dalton/McMurray Visual Memory Test (DMTS)
The Dalton/McMurray Visual Memory Test (Delayed Matching to Sample Cognitive
Test, DMTS)  was added to the protocol in 1997, and administered in the 1997, 1999 and
2001 waves of data-collection.  This chapter describes and analyses data from the two
subtests separately:  DMTS Shapes (16 items) and DMTS Colours (16 items).  Results
from each subscale were then analysed cross-sectionally (at both the time of entry to the
132
study and at the second testing) and longitudinally as the individual participant
progressed through the study.
8.2.1  DMTS general data results
The demographic description of participants with available DMTS data is shown in
Tables 8-14 and 8-15, and basic cross-sectional descriptive statistics ( including mean
percentage scores and standard error) for DMTS data at baseline, time 2 and time 3 are
displayed in tables 8-16 and 8-17.  Participant diagnostic cohorts tended to have  a
pattern of decreased scores at older ages in the three tests, although observed data
patterns varied somewhat between tests. 
Table 8-14. Demographics of participants with DMTS data (Shapes)
Non-DS males Non-DS females DS males DS females
Number in each
group
Age <30 7 6 9 7
Age 30-39 21 23 18 16
Age 40-49 34 17 17 17
Age 50+ 33 30 3 6
Mean age (SE) 47.04(1.34) 46.12(1.40) 38.1(1.25) 40.29(1.4)
Age range 24-86 22-71 23-60 20-62
Table 8-15. Demographics of participants with DMTS data (Colours)
Non-DS males Non-DS females DS males DS females
Number in each
group
Age <30 8 6 9 7
Age 30-39 21 24 18 16
Age 40-49 35 16 17 17
Age 50+ 32 31 3 6
Mean age (SE) 46.79(1.34) 46.14(1.38) 38.1(1.25) 40.29(1.4)
Age range 24-86 22-71 23-60 20-62
Table 8-16.  Mean (SE) observed DMTS-Shapes percentages.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 79.81(4.96) 78.41(3.12) 74.88(2.73) 68.55(2.43) 73.83(1.52)
DS 80.86(3.63) 73.9(3.97) 73.53(3.04) 54.17(3.9) 73.05(2.07)
Time 2 Non-DS 81.25(8.14) 80.03(3.19) 68.62(2.92) 68.55(1.96) 71.98(1.53)
DS 80.11(4.44) 79.33(3.23) 69.26(2.91) 65.18(5.26) 73.61(1.92)
Time 3 Non-DS 71.88(9.38) 78.91(3.48) 71.88(2.85) 66.62(2.25) 71.13(1.61)
DS 70.31(7.38) 72.5(3.34) 68.13(3.2) 48.21(10.27) 67.42(2.42)
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Table 8-17.  Mean (SE) observed DMTS-Colours percentages.
Time Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Baseline Non-DS 88.84(4.82) 91.11(2.20) 89.22(2.18) 88.00(1.73) 89.23(1.13)
DS 98.05(0.75) 91.18(2.74) 89.34(2.7) 82.64(6.23) 90.86(1.57)
Time 2 Non-DS 97.50(1.91) 94.29(1.65) 89.75(1.68) 88.96(1.94) 90.92(1.03)
DS 94.89(3.66) 93.52(2.07) 83.49(3.50) 91.96(3.53) 88.91(1.91)
Time 3 Non-DS 81.25(18.75) 92.55(2.02) 85.85(2.64) 80.67(3.29) 84.86(1.83)
DS 98.44(1.56) 91.37(3.30) 88.33(2.35) 64.06(10.81) 86.90(2.33)
Basic descriptive statistics are also shown in Tables 8-18 and 8-19 for the change per
year in DMTS percentage scores from time 1 to 2, and from time 2 to 3. 
Table 8-18.  Mean (SE) observed DMTS-Shapes percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year time 1-2
Non-DS -2.47(2.07) 0.42(1.33) -4.52(1.98) 0.74(1.57) -1.26(0.92)
DS -1.47(1.95) 1.46(1.34) -0.5(2.19) 4.27(4.41) 0.42(1.05)
Change per
year time 2-3
Non-DS 0.97(3.45) -3.64(1.2) 1.12(1.67) -2.21(1.25) -1.34(0.81)
DS -3.19(2.74) -2.3(1.66) -2.02(1.89) -14.67(4.1) -3.32(1.17)
Table 8-19.  Mean (SE) observed DMTS-Colours percentage yearly changes.
Measure Diagnosis Age <30 Age 30-39 Age 40-49  Age 50+ All ages
Change per
year time 1-2
Non-DS 1.06(1.37) 1.52(0.85) -0.03(1.08) 0.44(1.24) 0.63(0.59)
DS -3.17(1.9) 0.03(1.15) -2.69(1.80) -1.03(3.93) -1.62(0.90)
Change per
year time 2-3
Non-DS -3.11(1.36) -2.31(1.01) -4.16(1.52) -3.94(1.24) -3.61(0.73)
DS 1.08(2.57) -0.73(1.16) 0.2(1.97) -16.65(4.75) -1.65(1.2)
8.2.2  DMTS- cross-sectional analysis
For the same reasons as in the Dyspraxia analyses, it was decided to use data from the
second assessment to develop models for cross-sectional percentage scores across
diagnostic and age groups, and test change data from the second to the third test to
develop models for longitudinal (or aging) changes in the DMTS Test scores.
Curve estimation techniques from SPSS were used to estimate the best relationships
between DMTS percentage scores at time 2 and age, and these were found to be quadratic
in both the shapes and the colours test.   Linear regression analysis with DMTS Test
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scores at time 2 therefore used age, age  (age squared) and sex as independent variables2
for both analyses.  There were no significant second or third order interactions.  DS
diagnosis decreased the performance on both the shapes (not significantly) and the
colours analyses (almost significantly, with p=0.074).  Sex was not significant in either
the shapes or the colours analysis.  Age and age   were both independently significant (or2
almost significant) to the outcome.  Results are shown in Table 8-20. 
Table 8-20.  Results of linear regression analysis for DMTS percentages at time 2
Measure Parameter  (SE)â^ P value â^95% CI for 
DMTS Shapes
percentage
DS -0.9118(2.5738) ns -5.9828 - 4.1593
Sex 3.0287(2.3446) ns -1.5908 - 7.6482
Age -1.9565(0.6133) <0.005 -3.1649 - -0.748
Age 0.0165(0.0061) <0.01 0.0044 - 0.02862
DMTS Colours
percentage
DS -3.6933(2.0537) <0.1 -7.739 - 0.3525
Sex 1.7262(1.8693) ns -1.9562 - 5.4086
Age -1.157(0.4922) <0.05 -2.1267 - -0.1874
Age 0.0095(0.0049) <0.12 -0.0002 - 0.0192
Figure 8-3.  Mean predicted DMTS percentage scores at time 2.
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Figure 8-3 illustrates the predicted (adjusted) shapes and colours percentage scores in
DMTS Test data, based on the models shown in Table 8-17.  All groups of participants
experienced more difficulty in performing the shapes tests, and total scores are thus lower
overall.  It can also be seen from these graphs that participants tended to have lower
scores in older cohorts, with the lowest scores seen in the shapes data from females with
DS.
8.2.3  DMTS- longitudinal analysis, time 2 to time 3 
Curve estimation techniques from SPSS were used to estimate the best relationships
between DMTS Test yearly change scores and age from time 2 to time 3 and age, and
these were found to be quadratic in both the shapes and the colours test.  Linear
regression analyses with both shapes and colours data showed that there were a variety of
second and third order interactions between the three variable (DS, age and sex),
resulting in complicated differences between aging changes in participants with and
without DS.  Table 8-21 summarizes significant and almost significant interaction terms
found in the combined analysis.  Because of the interactions shown there,  model
building was performed separately for the participants with and without DS.  The best
models are shown in Table 8-22.
Table 8-21.  Interactions in linear regression analyses of DMTS yearly percentage change
Measure Interaction  (SE)â^ P value â^95% CI for 
DMTS Shapes percentage
yearly change 
DS * Age 1.7223(0.9436) 0.0699 -0.1415  - 3.5861
DS * Age -0.0284(0.0110) 0.0108 -0.0502 - -0.00672
DS*Age *Sex 0.0034(0.0014) 0.0190 0.0006  - 0.00632
DMTS Colours percentage
yearly change
DS * Age 2.0588(0.8988) 0.0232 0.2847    - 3.833
DS * Age -0.0293(0.0101) 0.0043 -0.0492 - -0.00932
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Table 8-22.  Results of linear regression analyses of DMTS yearly percentage change




Non-DS Sex -2.3493(1.6076) ns -5.5380   - 0.8393
Age -0.001(0.0006) <0.1 -0.0021   - 0.00022
DS Sex 3.5247(2.2127) ns -0.9061  - 7.9555
Age 2.0019(0.8804) <0.05 0.2389  - 3.7648




Non-DS Sex -36.386(21.2178) <0.1 -78.4347 - 5.6627
Age -2.2181(1.1656) <0.1 -4.528 - 0.0918
Age 0.0235(0.0111) <0.05 0.0015 - 0.04542
Sex*Age 1.7752(0.8683) <0.05 0.0544 - 3.4959
Sex*Age -0.0191(0.0085) <0.05 -0.036 - -0.00232
DS Sex 2.8882(2.0758) ns -1.2655 - 7.0419
Age 1.875(0.8319) <0.05 0.2104 - 3.5395
Age -0.028(0.0096) <0.01 -0.0473 - -0.00872
Analysis of the shapes yearly change data for participants without DS disclosed no
significant interactions, and sex was not significant to the outcome.  The age variable,
age , was almost significant (p=0.094), and increased the goodness of fit, so was left in2
the model. Analysis of the shapes yearly change data for participants with DS also
disclosed no significant interactions, and sex was again not significant to the outcome. 
However, both age and age  were independently significant to the outcome.  2
Analysis of the colours yearly change data for participants without DS disclosed
significant interactions between sex and age (p<0.05) as well as between sex and age2
(p<0.05).  Age  was also independently significant (p<0.05), and age was almost 2
independently significant (p=0.06) to the outcome.  Sex was almost  significant to the
outcome (p=0.09).  Analysis of the colours yearly change data for participants with DS
disclosed no significant interactions, and sex was not significant to the outcome.  Age
(p<0.05) and age  (p<0.01) were both independently  significant to the outcome. 2
Predicted, adjusted results based on the separate diagnostic models are illustrated in
Figure 8-4.  Figure 8-4 illustrates that yearly deterioration scores are greatest in the oldest
participants with DS, and fairly low in all of the participants without DS.
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Figure 8-4.  Mean predicted DMTS yearly percentage change.
8.2.4  Discussion of DMTS results
Longitudinal data suggested that visual memory tended to decline over the entire
lifespan, but that this process of decline became significantly more rapid in participants
with DS over the age of 50, unlike in the underlying, non-DS population.  It is possible
that the non-DS population also had an accelerated decline in older ages, but the study
population was too young to pick this up.  Unlike the results found in the dyspraxia data,
males with DS did not show more yearly deterioration than females, and the reasons for
this are unclear.  
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9.    CARE ISSUES: SERVICE PROVISION AND PSYCHOTROPIC MEDICATION
9.1  Service provision
Results of the caregiver survey (demographics of participants were shown in Table 4-3)
regarding service issues are tabulated in detail in the Appendix C, and graphically in
Figures 9-1 to 9-5.  Demographics of participants with available baseline health service
data were tabulated in Table 4-3.
9.1.1  Physical health issues
Figure 9-1. Percentage with perceived service deficits for physical problems
The greatest perceived deficits in service provision for physical problems were found to
be in the youngest participants without DS and the oldest participants with DS.  The
percentage of participants whose caregivers perceived deficits in service provision for
physical problems tended to decrease over four waves, except in the youngest non-DS
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group, where an increase was apparent. 
9.1.2 Emotional, behavioural and psychiatric health issues.
Participants with DS had a different pattern of psychiatric care across the age cohorts
than did participants without DS.  As can be seen in Figure 9-2, participants without DS
had the highest rate of psychiatric visits (within five years of study entry) in the youngest
cohort, lower rates in the second cohort, and lowest rates in the third cohort.  The oldest
cohort appears to have had a slight increase compared to the third cohort, but this was
still not as high as rates in the first two cohorts. The pattern for participants with DS was
quite different, with the lowest rates in the youngest cohort, and higher rates in each
subsequent cohort. 
Figure 9-2. Percentage with a psychiatric visit within five years of baseline 
Participants without DS were more likely overall to have perceived deficits in service
provision for emotional, behavioural and psychiatric problems, and this did not change
much over different age cohorts.  In participants with DS, older cohorts had greater
perceived deficits in service provision for emotional, behavioural and psychiatric
problems than younger cohorts.  The percentage of participants whose caregivers
perceived deficits in service provision for emotional, behavioural and psychiatric
problems tended to decrease over four waves. 
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Figure 9-3. Percentage with perceived service deficits for emotional, behavioural or
psychiatric problems
9.1.3  Aging issues and services
Caregivers rated those with DS and older participants as posing more baseline age related
care difficulties than other groups.  Although the percentage of participants felt to have
increased aging related care difficulties varied a bit over four waves, there was no clear
pattern of change over time obvious from these data.
Figure 9-4.  Percentage with increased aging related care difficulty
Aging related services were mostly used by the older participants, yet there were six
people under the age of fifty (four without and two with DS) who also participated in
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these.  Overall, a smaller proportion of participants with DS used these aging services,
which was probably a reflection of a younger DS population in the study sample. 
Although the percentage of participants using an age related service varied slightly over
four waves, there was no clear pattern of change over time obvious from these data.
Older participants tended to have higher use in all waves. 
Participants without DS were more likely to use aging services specialized for ID,
whereas participants with DS are about equally likely to access specialized as generic
aging services.  The percentage of participants using a specific age related service varies
over four waves, but there was no clear pattern of change over time obvious from these
data.  Older participants tended to have higher use in all waves. 
Figure 9-5.  Percentage using a particular aging service at baseline 
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9.1.4 Transinstitutionalization
Eight participants transferred from a residential situation to a nursing home (long-term
care facility) during the study.  Younger participants who transferred to a nursing home
tended  to have only perceived service deficits for emotional, behavioural or psychiatric
problems, whereas older participants were likely to have physical service deficits as well. 
No participants with DS under 45 years of age transferred to a nursing home, whereas
three participants without DS under 45 were transferred.  Numbers were too small to
perform any statistical analysis.
Table 9-1. Participants transferring into a nursing home (long-term care)
Diagnosis Sex Age (at last assessment Physical care Emotional, behavioural or
Non-DS Male 40.45 0 1
Non-DS Male 40.81 0 1
Non-DS Female 33.03 0 1
Non-DS Female 48.53 0 1
Non-DS Female 73.82 1 1
DS Male 46.18 1 1
DS Male 56.5 1 1
DS Male 57.84 0 1
9.2  The use of psychotropic medications  
9.2.1  Cross-sectional analysis
Baseline data for psychotropic medication use stratified for age and diagnosis are
presented in Table 9-2.  Observation of this raw data  suggests that the use of
psychotropic medications was generally more frequent overall in those without DS than
in those with DS.  There was a particularly high use of antipsychotics in the study
population, but a lower use of antidepressant and anxiolytic medications, and a very low
use of sedative-hypnotic medications.  Participants with DS tended to have a higher use
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of psychotropic medications in older cohorts, but participants without DS tended to have
higher use in the younger age cohorts, except for antidepressant medication use, which
was particularly high in the age group 40 to 49 years. 
Table 9-2.  Number (percentage) on a medication at baseline.
Medication Diagnosis Age# 30 Age 30-39 Age 40-49  Age 50+ All Ages
Antipsychotics Non-DS 13(33) 25(34) 18(28) 23(35) 79(32)
DS 0(0) 2(5) 6(17) 6(30) 14(12)
All 13(22) 27(24) 24(24) 29(34) 93(26)
Antidepressants Non-DS 5(12.5) 7(9.6) 14(21.5) 9(13.6) 35(14.3)
DS 0(0) 3(7.1) 4(11.4) 5(25) 12(10.3)
All 5(8.5) 10(8.7) 18(18) 14(16.3) 47(13.1)
Sedative-hypnotics Non-DS 2(5) 1(1.4) 2(3.1) 2(3) 7(2.9)
DS 0(0) 0(0) 0(0) 4(20) 4(3.4)
All 2(3.4) 1(0.9) 2(2) 6(7) 11(3.1)
Anxiolytics Non-DS 8(20) 9(12.3) 5(7.7) 11(16.7) 33(13.5)
DS 0(0) 1(2.4) 1(2.9) 1(5) 3(2.6)
All 8(13.6) 10(8.7) 6(6) 12(14) 36(10)
These data were explored further with the use of logistic regression analysis, using the
core independent variables DS diagnosis, sex, and age at baseline.  There were no third
order interactions, and the only significant second order interactions were between DS
and age.  Table 9-3 demonstrates these interactions, which were significant for the use of
antipsychotics, antidepressants and sedative-hypnotics, but not for anxiolytics.  The effect
of these positive interactions was a greater increase with age in the probability of
medication use among participants with DS, but not in participants without DS.
Table 9-3.  Logistic regression analysis for the baseline use of a medication (Interactions)
Medication Interaction term  (SE)â^          P value             OR(95% CI)
Antipsychotics DS*Age 0.0783(0.0319) <0.05 1.0814(1.016-1.1511)
Antidepressants DS*Age 0.0698(0.035) <0.05 1.0723(1.0012-1.1485)
Sedative-hypnotics DS*Age 0.2832(0.1076) <0.001 1.3273(1.0751-1.6388)
Anxiolytics DS*Age 0.0326(0.0603) ns 1.0331(0.9179-1.1627)
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Further data exploration disclosed that the pattern of antidepressant use with age in
participants without DS was not linear, but showed a peak in the years 40-49, whereas the
pattern with age in participants with DS was linear.  Age was therefore recoded into three
categories: age <40, age 40-49 and age 50+ , and data for antidepressant use in
participants without DS was analyzed separately, using these new age categories.   
The final models that were chosen to predict medication use in participants at baseline
are shown in Table 9-4.  Unexpectedly, sex was not found to be a significant predictor of
psychotropic medication use, except for the anxiolytics, where women had an almost
significantly increased probability for use (p<0.1). The predicted probability of
antidepressant use in participants without DS was significantly higher in the 40 to 49
year-old age group than in the under 40 year-old age group.  Mean predicted probabilities
based on these models for the use of psychotropic medications at baseline are illustrated
graphically in Figure 9-6.
Table 9-4.  Logistic regression analysis for the baseline use of a medication.
Medication Diagnosis Parameter  (SE)â^ P value             OR (95% CI)
Antipsychotics All DS -4.5515(1.4769) <0.005 0.0106(0.0006-0.1907)
Sex 0.1073(0.2489) ns 1.1133(0.6835-1.8134)
Age 0.0037(0.0102) ns 1.0037(0.9838-1.0239)
DS*Age 0.0783(0.0319) <0.05 1.0814(1.0160-1.1511)
Antidepressants Non-DS Sex -0.0743(0.3756) ns 0.9283(0.4446-1.9383)
Age (0):  <40
Age (1):  40-49 0.8459(0.4292) <0.05 2.3300(1.0046-5.4042)
Age (2):  50+ 0.3127(0.4713) ns 1.3671(0.5428-3.4435)
DS Sex 0.6058(0.6357) ns 1.8326(0.5271-6.3712)
Age 0.0744(0.0327) <0.05 1.0772(1.0104-1.1484)
Sedative-
hypnotics
All DS -13.7505(5.9796) <0.05 0.0000(0.0000-0.1313)
Sex -0.8106(0.7225) ns 0.4446(0.1079-1.8319)
Age -0.0215(0.0312) ns 0.9787(0.9207-1.0403)
DS*Age 0.2832(0.1076) <0.001 1.3273(1.0751-1.6388)
Anxiolytics All DS -1.7866(0.6171) <0.005 0.1675(0.0500-0.5615)
Sex 0.6264(0.3599) <0.1 1.8709(0.9241-3.7876)
Age 0.0057(0.0137) ns 1.0057(0.979-1.0332)
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Figure 9-6. Percentage using a medication at baseline
9.2.1.1  Types of antipsychotics used at baseline
Table 9-5 illustrates the types of antipsychotic used at entry to the study by the
participants, stratified into age groups.  Antipsychotics were coded as typicals (such as
haloperidol), atypicals (clozapine, risperidone, olanzapine and quetiapine for this study
period) or both atypicals and typicals used concurrently.  93% of participants who were
taking an antipsychotic at baseline were taking only a typical antipsychotic, whereas 5%
were taking only an atypical antipsychotic and 2% were taking both a typical and an
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atypical antipsychotic.  Mean cohort age did not seem to be associated with a noticeable
pattern of antipsychotic type used.
Table 9-5.  Type of antipsychotics used at baseline: Number (%).
Antipsychotic Type Age < 30 Age 30-39 Age 40-49 Age 50+     All ages
Typical AP 10(77) 25(93) 24(100) 27(93) 86(93)
Atypical AP 2(15) 1(4) 0(0) 2(6.9) 5(5)
Typical and atypical AP 1(8) 1(4) 0(0) 0(0) 2(2)
Total on any AP 13(100) 27(100) 24(100) 29(100) 93(100)
9.2.2  Changes in psychotropic medication use over four waves 
Cross-sectional data comparing types of psychotropic medications used in four waves
(1995, 1997, 1999 and 2001) of data collection are shown in Table 9-6, and although
percentages fluctuated because of the small numbers, there were no obvious time or age
associations.  
Table 9-6.  Psychotropic medication use (%) over four waves
Wave          AP      AD   SED         ANX Mean age (SD)
1995 65(26) 37(14.9) 8(3.2) 27(10.8) 43(13)
1997 85(26) 42(12.7) 22(6.6) 34(10.3) 43(13)
1999 103(31) 44(13.1) 17(5.1) 38(11.3) 45(12)
2001 98(30) 47(14.5) 14(4.3) 39(12) 46(12)
Data from study participants are presented graphically along with Saskatchewan service
data, illustrating percentages of eligible beneficiaries who have filled at least one
antipsychotic (Information Management Unit of Saskatchewan Health, personal
communication, July 19, 2005) or antidepressant (Information Management Unit of
Saskatchewan Health,  personal communication, March 29, 2006) prescription in a given
year (Figure 9-7).  
The comparison of these figures suggests that greater percentages of study participants
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used antipsychotics and antidepressants during these time periods than did the overall
Saskatchewan population. For example, although about 30% of all study participants
used antipsychotics, only about 3% of the overall Saskatchewan population had filled a
prescription for antipsychotics during similar time periods. The rate of antipsychotic and
antidepressant use in the youngest segment of the study population was particularly
different from that in the youngest segment of the Saskatchewan population, which had a
very low rate of use.  The trend to increased use of antipsychotics and antidepressants in
older ages, as is seen in the Saskatchewan population, is much less evident in the study
population.
1995 1997 1999 2001   
Figure 9-7.  Antipsychotic use in participants and Saskatchewan beneficiaries over four
years
The use of atypical antipsychotics has increased in the general population over this time
period, and Figure 9-8 illustrates the numbers and percentages of the study participants
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on an antipsychotic who were on only a typical (TYP), only an atypical (ATYP), or a
typical and an atypical concurrently (TYP-ATYP).  For comparison, similar data are
presented from Saskatchewan Health showing the percentages of eligible beneficiaries
aged 20 years and older that filled at least one prescription in each group of medications
in a given year.  (Note that these data from the Drug Plan do not necessarily mean the use
was concurrent). It can be seen that in both the study and the Drug Plan data the
percentage of participants who were only on a typical antipsychotic dropped rapidly, from
1995 to 2001.  The percentage of participants who took both a typical and an atypical
antipsychotic was low and changed little during the waves.  
1995 1997 1999 2001   
Figure 9-8.  Type of antipsychotic use in participants and Saskatchewan beneficiaries
over four years
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9.2.3  Longitudinal analysis of psychotropic medication use over the course of the study
Observed data suggested that the use of psychotropic medications was fairly stable in
individuals during the course of the study.  Predicted probabilities for the use of
psychotropic medications over the course of the study were obtained by fitting a logistic
regression model based on the Generalized Estimating Equations (GEE) approach, as
described in the methodology section earlier.  The following marginal models using the
GEE approach were fitted by using a SAS procedure PROC GENMOD to predict the
probability of psychotropic medication use. The variable, time lapse, represents the yearly
change in the probability of taking a particular medication.  Results of these analyses are
shown in Table 9-7.
Table 9-7.  Results of logistic regression for the prediction of the probability of use of a
particular medication based on GEE approach
Medication Parameter Robust estimate(SE) P value        OR  (95% CI)
AP DS -2.820(1.05) <0.01 0.059 (0.008-0.46)
Sex 0.095(0.22) ns 1.10 (0.71-1.69)
Age at baseline 0.004(0.0093) ns 1.00 (0.99-1.02)
Time lapse (years) 0.037(0.021 <0.1 1.04 (1.00-1.08)
DS*Age (baseline) 0.042(0.024) <0.1 1.04 (0.99-1.09)
AD DS  -2.010(1.086)  <0.1 0.13 (0.02-1.13)
Sex 0.067(0.25)  ns 1.07 (0.65-1.77)
Age at baseline  0.005(0.011) ns 1.01 (0.98-1.03)
Time lapse  0.031(0.033)  ns 1.03 (0.97-1.10)
DS* Age(baseline)  0.040(0.025) ns 1.04 (0.99-1.09)
SED DS  -11.360(2.97) < 0.0005 0.00 (0.00-0.00)
Sex -0.330(0.38)  ns 0.72 (0.34-1.51)
Age at baseline  0.013(0.014) ns 1.01 (0.99-1.04)
Time lapse (years)  0.084(0.050) <0.1 1.09 (0.99-1.20)
DS*Age (Baseline)  0.210(0.055) <0.0001 1.24 (1.11-1.38)
ANX DS  -3.70(1.400) < 0.01 0.02 (0.00-0.38)
Sex 0.34(0.250) ns 1.4 (0.85-2.30)0
Age (baseline)  0.012(0.011) ns 1.01(0.99-1.03)
Time lapse (years)  0.020(0.039) ns 1.02 (0.95-1.10)
Age(Baseline)*DS  0.048(0.028) <0.1 1.05 (0.99-1.11)
The reference category for DS is Non-DS, and the reference category for sex is male
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Although the likelihood for individuals to be on a psychotropic medication increased
with time from baseline, this was not statistically significant for any medication, although
almost significant (p<0.1) for antipsychotics and sedative-hypnotics. The interaction
between age at baseline with the diagnosis of DS was significant or almost significant in
all medications except for antidepressants.
9.3  Discussion
9.3.1  Care issues
Perceived deficits in  service delivery for physical problems were  more severe for young
people without DS and older people with DS.  This appears to be a reflection of
decreased institutionalization and increased survival of younger people with multiple
handicaps, as well as increasing age related problems particularly in those with DS. 
Perceived deficits in service delivery for  emotional, behavioural or psychiatric problems
was also rated as more problematic in general for those without DS.  There was no age
pattern in this group, although participants with DS had increasing perceived difficulties
in this area as they aged.
Very few people used specialized aging services, so detailed interpretation was difficult.
However, participants with DS appeared  more likely to use generic aging services than
those without DS.  This might have been because of the increased rate of dementia, with
characteristic behaviours that are well suited to generic dementia programs.
Very few participants (8/360) transferred from a community placement into a nursing
home during the study.  Although small numbers made inferences difficult, there was a
suggestion that unmet service needs for  emotional, behavioural or psychiatric problems
were a factor for nursing home placement in all age groups, whereas unmet service needs
for physical problems tended to be a precipitant for  nursing home placement mostly for
older participants. 
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9.3.2  Use of psychotropic medications
As expected,  participants without DS were more likely to use all four types of
psychotropic medications (antipsychotics, antidepressants, anxiolytics and sedative-
hypnotics) than participants with DS, with the exception of antidepressants and sedative-
hypnotics in the oldest (50+) cohort.  This is almost certainly a reflection of increased
emotional, behavioural and psychiatric morbidity in adults with ID who do not have DS,
and the possible reasons for this have been discussed earlier. 
As was expected, the use of antipsychotic medication in the study population was much
more common than it was in the general population at the time of the study.  Close to
30% of participants used an antipsychotic medication at baseline, whereas only about 3%
of the Saskatchewan population had filled at least one prescription for an antipsychotic
medication in 1995, with similar figures for 1997, 1999 and 2001. 
The pattern of use of antipsychotics also changed in tandem with the underlying
population trends. While the overwhelming majority of study participants who used an
antipsychotic used a typical antipsychotic exclusively in 1995, only half of study
participants exclusively used a typical antipsychotic by 2001. Meanwhile, the growing
use of atypical antipsychotics was similar to the underlying population, albeit a bit less
pronounced. 
About 13% of study participants used an antidepressant at baseline, which is a bit less
than the 15.5% prevalence found in the general Canadian population by Beck et al., 2005,
but greater than the approximately 7% of the Saskatchewan eligible beneficiaries over the
age of 20, who had at least one prescription of an antidepressant in 1995.  The age
distribution of antidepressant use in participants without DS was very similar to the
Canadian data presented by Beck and colleagues, which showed a pronounced increased
use in mid-life. There was no noticeable cross-sectional change of antidepressant usage
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throughout four waves of participant data-collection, and there was no individual trend to
greater use of an antidepressant in the years after the participant’s entry to the study. 
Very unlike general population findings, there was no increased use of antidepressants in
female study participants. The reason for this was not clear, although the study was not
specifically powered to measure this, so the numbers of antidepressant users were very
small in many of the age and diagnostic categories. 
Although the diagnosis of DS in general decreased the likelihood of using an
antidepressant at baseline, there was a significant and positive DS with age interaction. 
This meant, that, although younger people with DS rarely used an antidepressant, older
cohorts were progressively more likely to have been prescribed one.  This was an
interesting finding in light of the known increase in the prevalence of dementia in DS,
and the potential correlations between mood and cognitive disorders.     
Sedative-hypnotics were used only in about 3% of participants at baseline, which is
similar to general Canadian rates of 3.1 % described by Beck et al., 2005.  They were less
commonly used in participants with DS, although there was again a positive interaction
between DS diagnosis and age at baseline, with younger participants with DS having
lower rates of use than younger participants without DS, but older participants with DS
having higher rates of use than older participants without DS.  The longitudinal analysis
suggested is that there was a trend to the increased use of sedative-hypnotics over time,
although this was not quite statistically significant (p=0.093).
About 10% of study participants used an anxiolytic at baseline.  Participants with DS
were less likely to use an anxiolytic at baseline.  Female  participants had almost twice
the likelihood of being on an anxiolytic at baseline, but this was not statistically
significant (p= 0.082).  In the longitudinal analysis, only the diagnosis of DS was
significant to the probability of being on an anxiolytic over time. The interaction between
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age and DS was almost significant at p= 0.082.  Individual participants did not become
more likely over time to use an anxiolytic.    
Of interest is that the findings from the longitudinal analysis gave similar, but not
identical results to the findings from logistic regression analysis using only the baseline
data.  The longitudinal analysis included all data points throughout the study, which may
have led to some healthy survivor bias.  On the other hand, because more data points
were available for analysis, more subtle trends may have become apparent using this
methodology.  For example, as there were a few very old participants, changes related to
old age may have occurred in individual participants, but may not have been statistically
significant in the baseline analysis.
To explore the potential non-randomness of dropouts, and new variable called “dropout”
was created.  This variable was scored zero if the last available tests were completed, and
one if the last available tests were not completed for any reason.  This new variable was
entered into the logistic regression analysis for the use of all the medications of interest
individually, which included antipsychotics, antidepressants, sedative-hypnotics and
anxiolytics.  None of the logistic regression analyses showed that the new variable
“dropout” was significant to the outcome. In other words, completers and non-completers
of the study were equally likely to be taking any of these medications at entry to the
study. The healthy survivor effect  was therefore not likely to have adversely impacted
the longitudinal analysis of the probability of taking psychotropic medications at any time
after entry to the study.
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10.  GENERAL SUMMARY OF FINDINGS AND CONCLUSIONS
The initial goals of the study were to explore biological, psychological, and functional
aspects of the health of adults with ID, exploring cross-sectional predictive factors
relating to birth cohort (age and diagnostic category), as well as predictive factors for
individual longitudinal changes. The study also sought to study issues related to care
provision and the use of  psychotropic medications. 
Hypotheses were made in the introduction, which were based on clinical experience and
literature review.  These hypotheses will now be reviewed, synthesizing results of data
presented in the body of this thesis.  Fuller discussion of specific results will not be
reproduced, as this has been presented in earlier chapters.       
10.1 Review of hypotheses
10.1.1 Epidemiology/Mortality
Male gender, older age, more severe baseline impairments in physical and mental
functioning, and a diagnosis of DS will be associated with increased mortality.  
As expected, data presented in chapter 5 showed that participants with DS, males, older
participants, and those with more severe baseline impairments in their physical and
mental functioning were found to have increased mortality.  Also found (rather
unexpectedly) was that higher baseline depressive symptoms predicted increased
mortality.   Discussion of this finding appears in the discussion at the end of chapter on
mortality.   
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10.1.2 Physical morbidity
Cross-sectional data on the general health of adults with ID will reveal more typical,
aging related medical problems in older compared to younger cohorts with ID, but fewer
severe health conditions related to genetic, chromosomal or birth conditions. 
Caregiver data on general health and care issues presented in chapter six confirmed the
expected pattern of increased medical problems with increased cohort age, except in body
systems that are known to be affected by congenital problems, such as cardiac problems
in people with DS.  Unfortunately, the data were not precise enough to make detailed
comments about specific health problems within the general body system categories. 
10.1.3 Emotional, behavioural or psychiatric morbidity
Emotional, behavioural and psychiatric problems will be more common in those without
DS, particularly in the youngest cohorts.   
Overall, current emotional, behavioural, and psychiatric problems (no information on
specific diagnoses were available) were more common in participants without DS
compared to those with DS.  However, baseline caregiver data from participants without
DS did not show the expected association of lower age with increased nervous and
psychiatric problems, although visits to a psychiatrist were more common in the younger
cohorts.  In contradistinction to this finding, participants with DS had higher baseline
nervous or psychiatric problems in older cohorts, and also had a pattern of increased
psychiatric visits in the older cohorts.
Behavioral problems (from the BEH subscale of the standardized caregiver instrument,
the DMR) were more common overall in participants without DS, particularly in the
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youngest cohorts.      
10.1.4 Functional-cognitive decline
Cross-sectional data from adults with ID without DS on behavioural and functional
measures will reveal better functioning in mid-age compared to younger cohorts (related
to continued learning and differential community placement), but poorer scores in the
functions typically affected by aging in the oldest cohorts.  
Cross-sectional DMR data from participants without DS presented in chapter 7
confirmed the expected pattern of initially improved functioning in all subscales with
increasing age of the cohort, followed by worsening functioning across the oldest cohorts. 
Peak performances in specific functions were generally reached after the age of fifty, with
peak performances in spatial abilities being reached the earliest (age 48.4) and peak
performances in behaviours being reached the latest (57.8 years).  Possible reasons for
this were discussed in chapter 7. 
Cross-sectional data from adults with ID and DS on behavioural and functional
measures will reveal a pattern of poorer scores with older age starting with the youngest
age cohorts. 
     
Cross-sectional DMR data from participants with DS confirmed expected poorer
performances with increased age of the cohorts in participants with DS, starting at the
youngest cohorts.  This is likely a result of increasing cognitive impairment with age,
starting in early adulthood, although a formal diagnosis of dementia is unlikely to be
made until middle age or later.
Longitudinal data from adults with ID on behavioural and functional measures (using a
standardized caregiver instrument) will reveal yearly decline in most functions, most
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noticeably in the oldest cohorts, and more in those with DS compared to those without
DS.  Specific functions will exhibit different rates of decline.       
Results presented in chapter 7 were more complex than was originally hypothesized. 
Participants with DS exhibited unexpected gender differences, with older males declining
more per year than older female in all areas of functioning except for mood and behavior. 
These gender differences were not seen in participants without DS.  Probably because of
the relatively young age of the participants, there was no significant yearly worsening of
functioning in those without DS, but yearly worsening was apparent in those with DS,
and increased with increased age of the cohort.  
Cross-sectional data from adults with ID on specific neuropsychological measures (using
standardized instruments to measure dyspraxia and visual memory) will not reflect
continued learning (as in the case of functional data), but will reveal slightly lower
functioning in older age cohorts, except in the oldest cohorts with DS, where scores will
be more noticeably decreased. 
Although cross-sectional data from both diagnostic groups showed a very small trend to
decreased performance on the three dyspraxia tests in older age groups, this was only
statistically significant in participants with DS (where the only the oldest males had a
particularly poor performance), although it was almost (p<0.1) significant in participants
without DS in Part 3 (which is thought to more sensitive to executive dysfunction). 
However, visual memory scores in participants with DS showed a more uniform pattern
of decline across the age cohorts, starting with the youngest age cohort.  These findings
are consistent with research previously cited, which suggests that memory starts declining
earlier in the course of dementia than does praxis, and deficits in executive functioning
may be one of the earliest precursors of later dementia.
Longitudinal data from adults with ID on specific neuropsychological measures (using
158
standardized instruments to measure dyspraxia and visual memory) will reveal a small
yearly decline in most functions, most noticeably in the oldest cohorts, and more in those
with DS compared to those without DS.  Specific functions will exhibit different rates of
decline.
Research data supported most of this hypothesis.  Although there was a trend to yearly
decline in dyspraxia scores in all age and diagnostic categories, this decline was only
statistically significant in participants with DS.  The oldest male participants with DS had
a particularly large yearly decline in this test (males significantly more than females). 
Yearly decline in visual memory was also only statistically significant in participants
with DS, and the pattern of decline started at younger ages in memory for shapes
compared to the dyspraxia decline.  Males with DS again declined more than females
with DS, although this was not statistically significant.  However, females without DS
had more decline than males, and this almost reached significance (p<0.1).
10.1.5 Service provision
Perceived deficits in service provision for emotional, behavioural or psychiatric
problems will be greater than perceived deficits in service provision for physical
problems.  Younger participants without DS will have greater perceived deficits in
service provision for physical, emotional, behavioural and psychiatric problems than
older participants without DS, but older participants with DS will have  perceived
deficits in service provision for physical, emotional, behavioural and psychiatric
problems than younger participants with DS.
Fewer participants (11% of those without DS and 9% of those with DS) were considered 
to have service deficits for physical problems compared to those considered to have
service deficits for emotional, behavioral or psychiatric problems (28% of those without
DS and 16% of those with DS), so this hypothesis was correct.  However, although
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younger participants without DS did have greater deficits in service provision for
physical problems than older ones without DS, service deficits for emotional, behavioral
or psychiatric problems did not show a clear age cohort difference, as had been
hypothesized.  Participants with DS did tend to have greater perceived service deficits for
physical, emotional, behavioral or psychiatric problems in older compared to younger age
cohorts, and this is likely related to the increase in cognitive impairment.  
Perceived deficits in service provision for physical, emotional, behavioural or
psychiatric needs will increase the likelihood of institutionalization (for example, to a
nursing home), and this will be more pronounced for younger people with emotional,
behavioural or psychiatric unmet service needs and older people with unmet physical
service needs.
Because of the small numbers of people who transferred into a nursing home, it was not
possible to draw firm conclusions about the association between service deficits and
institutionalization.  However, all participants who transferred into a nursing home had
perceived deficits in service provision for emotional, behavioral or psychiatric problems,
whereas only older participants who transferred into a nursing home had additional
perceived deficits in service provision for their physical problems.  This suggests that
emotional, behavioral or psychiatric problems (especially aggression) pose a bigger
challenge to care provision in small, community settings, and are more likely to result in
institutionalization.  
Participants will be less likely than the underlying population to have seen a psychiatrist
recently, but psychiatric contact will be more likely  for younger people without DS and
older people with DS compared to the total study group.
It was not possible to make firm conclusions about differences in psychiatric access
between the general Saskatchewan population and the study participants, as the
equivalent Saskatchewan service data was not available.  However, as previously noted,
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in Saskatchewan only  about 2.5% of the general population receives some formal mental
health care each year (defined as a visit with a psychiatrist or psychologist), whereas 28%
of study participants without DS and 21% of participants with DS had received a
psychiatric visit within five years of baseline.  This suggests that people with ID are
probably more likely than the general population to receive formal mental health services
overall, although it is possible that they may receive less frequent services. 
 
Older participants will be more likely than younger participants to use aging programs. 
Older participants with DS will be more likely than older participants without DS to
participate in a generic (rather than a specialized ID) aging program (because their
behaviours will be more typical of a generic Alzheimer service population).  
The data were consistent with the hypothesis that older participants were more likely than
younger ones to use aging services.  Whereas participants without DS were more likely to
use aging services specialized for ID (probably because of challenging behaviors),
participants with DS were about equally likely to access specialized as generic aging
services.  
The overall use of aging programs will increase over the time of the study. 
Although participants with DS showed a trend to increased use of aging programs over
the course of the study, this was not the case for the overall population.
10.1.6 Psychotropic medications
Overall, people without DS will be more likely to use psychotropic medications than
those with DS.  
Research data supported the hypothesis that psychotropic medications were more
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commonly used in people without DS than with DS.  This is consistent with the increased
rate of emotional, behavioural and psychiatric problems in those without DS compared to
those with DS, discussed earlier.
Older people without DS will be more likely than young ones without DS  to use sedative-
hypnotic medication, but less likely than young participants without DS to use
medications such as antipsychotics to treat behavior disorders.  
The expected relationship between age and psychotropic medications in people without
DS was not found, in spite of the known increase of sleep disorders with age in the
general population, and the decrease in behavioural problems with age.  There was very
little change across the age cohorts in the use of any of the medications that were
explored, except for antidepressant medications, which were most commonly used in
middle-aged people without DS.  
The main reason for the loss of the ususal association between age and sedative-
hypnotics was probably the high use of these medications in earlier years related to
ongoing behavioural problems. 
Older people with DS  will be more likely than younger ones with DS to use
antipsychotic, sedative hypnotic, and anxiolytic medications because of the increased
prevalence of dementia.  
Older people with DS were more likely than younger people with DS to use antipsychotic
medications, antidepressant medications and sedative hypnotic medications, but the use
of anxiolytic medications was not different in any of the age cohorts.
Antidepressant use will be most common in middle-aged females. 
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Unlike patterns of use in the underlying population, females were not significantly more
likely to use antidepressants than males, although there appeared to be a trend for DS
females to have a greater use of antidepressants than DS males. It is possible that the use
of antidepressants for reasons other than depression (for example trazadone for
aggression or sleep) is more common in people with ID, obscuring the usual pattern of
midlife increase because of higher depression rates at that time of life.
There will not be much change in the individual, longitudinal use of particular
psychotropic medications.   
As expected, there was not much individual level change in the use of any of the
psychotropic medications.  This is probably not surprising, as, in spite of  some
fluctuations, most mental-health disorders tend to be lifelong problems, and the study
follow-up time was relatively short.    
There will be a systemic increase in the use of all psychotropic medications throughout
the time of the study, consistent with underlying population trends. There will be an
increase in the use of the newer, atypical antipsychotics throughout the time of this study,
but this will be less noticeable than that seen in the underlying population.  People with
ID will be more likely to use antipsychotic medications, but less likely to use
antidepressant medications than adults  in the underlying population.     
There was no systemic increase in the use of psychotropic medications among study
participants throughout the time of the study, unlike that apparent from the information
provided by the Saskatchewan Drug plan.  This discrepancy is probably related to
ongoing efforts by service providers to decrease the excessive use of psychotropic
medication in people with ID.  Patterns of antipsychotic use across the four waves of data
collection in the study population were consistent with underlying population trends
towards the use of atypical rather than typical agents. People with ID were more likely to
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use antipsychotic medications than those in the underlying population, but  the data did
not support the reduced use of antidepressants in adults with ID.    
10.2 Discussion of research findings
Research findings are largely consistent with data presented in the literature survey, as
discussed in each individual chapter, although differences in methodology make direct
comparisons difficult.   In addition, this research explored a broader range of functions
than  available in most published data, including individually linked information on
service provision, which is less commonly published.
Results reflected a variety of biological, psychological and social etiological factors,
consistent with the biopsychosocial model.  For example, the biological factor, trisomy
21, was found to be a strong factor predicting increased decline with age, which was
evident  in direct as well as indirect measures, as well as in cross-sectional and
longitudinal analyses.  The importance of psychological factors was suggested by
apparent improvements of many functions in middle aged compared to the youngest
cohorts (attributed to ongoing learning), and the association between depressive
symptoms at baseline and increased mortality, although causality could not be established
for either of these. Social factors resulting in deinstitutionalization and increased
community placement of very disabled people, were thought to be important factors
contributing to greater morbidity in younger than older cohorts in those without DS .   
10.3.  Clinical impact of findings 
Although this study set out to explore aging changes in people with ID, it became
apparent from research results that difficulties related to an increasingly more disabled
young population may have even greater clinical impact on services required in the
community. Difficulties with service provision for physical as well as emotional,
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behavioral or psychiatric problems in this young population can be anticipated to increase
with time, as infants with severe disabilities increasingly reach adulthood, and
institutions for people with ID continue to shrink.  
Challenging behaviors (particularly severe aggression) in these multihandicapped
individuals will continue to pose a greater service provision challenge than physical
problems.  Acute, inpatient psychiatric facilities are not well designed to teach new, more
adaptive behaviors, because of their short length of stay, rapid turnover, and focus on
major mental disorders that respond to medications.  They also do not generally have
staff trained in intellectual disabilities.  Therefore, it may be necessary to develop
intermediate level care facilities in the community which can manage severe behaviors,
and can also institute consistent, well designed behavioral management programs
designed to increase more productive behaviors.  These facilities will need to plan for
longer admissions than acute inpatient facilities, as the learning of new behaviors is not
as fast as the response to medications. 
Reliance on nursing homes to provide care will probably increase over time, even for
young people with ID, and this development is probably not in the spirit of normalization
and increased quality of life for people with ID.  However, unless alternative community
services are available for severely challenging behaviors, it is not likely that this trend
will change.  
Continued deinstitutionalization over time of people with ID will require  improved
training  of community care providers, such as physicians and nurses, in issues related to
ID.  More mandatory content on ID must be integrated into formal training programs,
such as programs to train residents in psychiatry and family medicine.  Increased informal
learning will also be necessary.   For example, staff of nursing homes will see more aging
adults with ID, and may benefit from gaining increased knowledge from staff
experienced in ID, who might come to give practical workshops.  Conversely, staff
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experienced in the behaviors related to dementia may be able to provide some teaching
about this to staff in core ID services who will increasingly provide services to enable
their clients to age in place. 
In spite of the increased rate of aging related cognitive disabilities in adults with DS,
most  clinically significant deterioration in this group will not take place until after
middle age, and not all individuals will necessarily receive a diagnosis of dementia. 
However, accommodations must be made for subtle declines in functioning, even in
younger adulthood, of these individuals, as the failure to do so can cause increased
frustration and declines in the quality of life. 
In view of the association of depressive symptoms with increased mortality, these
symptoms  should be energetically evaluated, including a search for underlying pathology
as well as aggressive treatment of depressive disorder, if appropriate.        
10.4 Limitations
A major limitation of this study was  the small number of participants (360), which
resulted in insufficient power to enable conclusions to be drawn in many areas, even ones
in which clinical experience suggested that research findings would be likely. Another
limitation was the selection of participants from an established, community dwelling
service population, rather than by random sampling, using a stratified process that
sampled from community as well as institutional settings.  Fortunately, most adults with
ID do now live in the community, so the lack of data from institutions is less problematic.
Still problematic, however, is the fact that many people with ID do not receive any
services, so were automatically excluded from this research study, and there was no way




Already under way is a phone follow-up component to the current study,  which will
establish mortality, cause of death and changes in residential placement on a yearly basis,
exploring baseline determinants for these outcomes.   The current study was not able to
ascertain causes of death and had a relatively short follow-up, which decreased the
potential for designing interventions that might improve the health of people with ID.   
   
10.5.2  Physical morbidity
This study was not able to perform individual physical examinations with all participants,
and therefore did not have access to accurate data about physical morbidity, and was thus 
unable to establish accurate diagnoses.  Future research will need to build  this
component into the research design, including standard physical assessments, and making
diagnoses using standard protocols.  
10.5.3 Emotional, behavioral and psychiatric morbidity
This study was also not able to perform mental health interviews with all participants,
and therefore did not have access to accurate data about emotional, behavioral and
psychiatric  morbidity, and thus was also unable to establish accurate psychiatric
diagnoses.  Future research will need to build a skilled psychiatric interview into the
research design, using a standardized process, and making diagnoses using standard
protocols.  
10.5.4 Functional-cognitive decline
This study was not able to directly assess the neuropsychological functioning of
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participants who had extremely low baseline IQ because of limitations in the instruments.
Follow-up research might need to include an instrument such as the Severe Impairment
Battery, which would increase the proportion of direct assessments available for analysis. 
10.5.5 Service provision    
Although this research project obtained some information on the adequacy of resources
to manage physical and mental health challenges, the questions to establish this were not
standardized, and did not include enough detail to allow for clinical planning.  Future
research might include a standardized instrument addressing satisfaction with services.  
10.5.6   Psychotropic medications 
The use of psychotropic medications to manage behaviors is still common among people
with ID, in spite of the known, and high prevalence of medication adverse effects.  Little
information is known about potential methods to reduce this, and future research should
ideally address this challenging topic. 
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APPENDIX B.  ADDITIONAL INFORMATION ABOUT INSTRUMENTS
B.1  Items from the three parts of the Dyspraxia Scale for Adults with Down Syndrome 
Part 1: Psychomotor skills Part 2: Apraxia Part 3: Body Parts/Coin Task 
walking make a fist point to your ear
standing salute point to your nose
look up wave goodbye point to your eye
bend your head scratch your head point to your chest
bow from the waist snap your fingers point to your neck
clap hands close your eyes point to your chain
lift one arm sniff a flower point to your thumb
lift other arm use a comb point your ring finger
turn head to one side use a toothbrush point to your index finger
turn head to the other side use a spoon point to your little finger
lift one leg use a hammer point to your middle finger
lift the other leg use the key point to your right ear
sitting open a jar point to your right shoulder
draw a circle close a jar point to your left knee
draw a straight line put on right glove point to your left ankle
clip two sheets put on left glove point to your right wrist
cut paper sheet unlock padlock point to your left elbow
three coins (one hand) lock padlock point to your right knee
coins (other hand) fold a sheet of paper give me a penny
put on cap/take off fold sheet again give me a nickel
  give me a quarter
  give me a dime
Adapted from: Dalton AJ,  Fedor BL. DYSPRAXIA Scale for Adults with Down Syndrome.
Available from NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest
Hill Road, Staten Island, NY 10314, USA 1997.; http:/ / daltonaj@aol.com
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B.2 Permission to reproduce items from the three parts of the Dyspraxia Scale for Adults
with Down Syndrome
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APPENDIX C.  SUPPLEMENTARY DATA
Table C-1 Profile definition of Community Living Division Clients
Profile Description Profile Description
0 -Individuals who would not likely be
assigned a level of care.  
-May have borderline intellectual
disability or developmental delay with
no other characteristics identified.





-Major personal assistance required
-Uncontrolled seizures
-Moderate intellectual disability with
one or more of the following: profound
hearing loss, total vision loss, chronic
health problems, limited
communication.
1 Individual has one or more of the
following characteristics:
-Mild intellectual disability
-Limited personal assistance required
-Independent with adapted environment
-Interpretation required
-Borderline intellectual disability with
one or more of mild hearing loss, slight
vision loss,  speech and language delay
or impairments, restricted mobility.










-Severe intellectual disability with one
or more of the following: profound
hearing loss, total vision loss, chronic
health problems, limited
communication.
2 Individual has one or more of the
following characteristics:
-Moderate intellectual disability
-Moderate personal assistance required
-Mild intellectual disability with one or
more of the following: profound




Table C-2.  Caregiver ratings (%) of seizure frequency at baseline.
Diagnosis Baseline seizure frequency Age <30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS No history of seizures 24(60) 52(70.27) 42(64.62) 43(66.15) 161(65.98)
Seizures, but none in past year 6(15) 14(18.92) 10(15.38) 15(23.08) 45(18.44)
Seizures, less than one per month 5(12.5) 2(2.7) 4(6.15) 5(7.69) 16(6.56)
Seizures, 1-4 per month 3(7.5) 4(5.41) 6(9.23) 2(3.08) 15(6.15)
Seizures, 2-6 per week 2(5) 2(2.7) 3(4.62) 0(0) 7(2.87)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS No history of seizures 19(95) 38(92.68) 29(80.56) 16(84.21) 102(87.93)
Seizures, but none in past year 1(5) 2(4.88) 4(11.11) 1(5.26) 8(6.9)
Seizures, less than one per month 0(0) 1(2.44) 3(8.33) 1(5.26) 5(4.31)
Seizures, 1-4 per month 0(0) 0(0) 0(0) 1(5.26) 1(0.86)
Seizures, 2-6 per week 0(0) 0(0) 0(0) 0(0) 0(0)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-3.  Caregiver ratings (%) of epilepsy at baseline.
Diagnosis Sex Age <30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Males 11(45.83) 11(26.19) 11(28.21) 9(24.32) 42(29.58)
Females 4(25.00) 8(25.00) 10(38.46) 9(32.14) 31(30.39)
DS Males 1(7.69) 1(4.55) 1(5.26) 1(10.00) 4(6.25)
Females 0(0.00) 1(5.26) 3(17.65) 0(0.00) 4(7.69)
Table C-4.  Caregiver ratings (%) of heart or blood pressure problems at baseline.
Diagnosis Blood/-blood pressure problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 39 (97.5) 70 (94.6) 59 (90.8) 51 (78.5) 219 (89.8)
Previously 0 (0) 0 (0) 0 (0) 4 (6.2) 4 (1.6)
Well controlled 1 (2.5) 2 (2.7) 3 (4.6) 6 (9.2) 12 (4.9)
Intermittently significant 0 (0) 1 (1.4) 3 (4.6) 3 (4.6) 7 (2.9)
Currently significant 0 (0) 1 (1.4) 0 (0) 1 (1) 2 (0.8)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 13 (65) 29 (70.8) 24 (66.8) 12 (63.2) 78 (67.2)
Previously 1 (5) 4 (9.8) 3 (8.3) 0 (0) 8 (6.9)
Well controlled 4 (20) 7 (17.1) 7 (19.4) 4 (21.1) 22 (19)
Intermittently significant 0 (0) 0 (0) 1 (2.8) 3 (15.8) 4 (3.5)
Currently significant 2 (10) 1 (2.4) 1 (2.8) 0 (0) 4 (3.5)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
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Table C-5.  Caregiver ratings (%) of breathing problems at baseline. 
Diagnosis Breathing problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 38 (95.0) 69 (93.2) 63 (96.9) 58 (89.2) 228 (93.4)
Previously 0 (0.0) 2 (2.7) 0 (.00) 0 (0.0) 2 (0.8)
Well controlled 2 (5.0) 0 (0.0) 1 (1.5) 3 (4.6) 6 (2.5)
Intermittently significant 0 (0.0) 2 (2.7) 1 (1.5) 1 (1.5) 4 (1.6)
Currently significant 0 (0.0) 1 (1.4) 0 (0.0) 3 (4.6) 4 (1.6)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 16 (80.0) 35 (85.4) 26 (72.2) 14 (73.7) 91 (78.4)
Previously 0 (0.0) 1 (2.4) 1 (2.8) 3 (15.8) 5 (4.3)
Well controlled 1 (5.0) 5 (12.2) 6 (16.7) 2 (10.5) 14 (12.1)
Intermittently significant 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.7)
Currently significant 1 (5.0) 0 (0.0) 3 (8.3) 0 (0.0) 4 (3.4)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-6.  Caregiver ratings (%) of stomach, bowel or liver  problems at baseline.
Diagnosis Gastrointestinal problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 30 (75.0) 54 (73.0) 50 (76.9) 44 (67.7) 178 (73.0)
Previously 1 (2.5) 4 (5.4) 0 (0.0) 6 (9.2) 11 (4.5)
Well controlled 4 (10.0) 11 (14.9) 10 (15.4) 11 (16.9) 36 (14.8)
Intermittently significant 3 (7.5) 2 (2.7) 3 (4.6) 1 (1.5) 9 (3.7)
Currently significant 2 (5.0) 3 (4.1) 2 (3.1) 3 (4.6) 10 (4.1)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 14 (70.0) 29 (70.7) 24 (66.7) 11 (57.9) 78 (67.2)
Previously 2 (10.0) 5 (12.2) 3 (8.3) 1 (5.3) 11 (9.5)
Well controlled 2 (10.0) 5 (12.2) 4 (11.1) 3 (15.8) 14 (12.1)
Intermittently significant 2 (10.0) 2 (4.9) 3 (8.3) 4 (21.1) 11 (9.5)
Currently significant 0 (0.0) 0 (0.0) 2 (5.6) 0 (0.0) 2 (1.7)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-7.  Caregiver ratings (%) of dental problems at baseline
Diagnosis Dental problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 33 (82.5) 61 (82.4) 53 (81.5) 41 (63.1) 188 (77)
Previously 0 (0.0) 2 (2.7) 4 (6.2) 13 (20.0) 19 (7.8)
Well controlled 4 (10.0) 8 (10.8) 5 (7.7) 6 (9.2) 23 (9.4)
Intermittently significant 1 (2.5) 2 (2.7) 2 (3.1) 4 (6.2) 9 (3.7)
Currently significant 2 (5.0) 1 (1.4) 1 (1.5) 1 (1.5) 5 (2)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 18 (90.0) 35 (85.4) 19 (52.8) 13 (68) 85 (73.3)
Previously 1 (5.0) 1 (2.4) 4 (11.1) 1 (5.3) 7 (6)
Well controlled 0 (0.0) 4 (9.8) 4 (11.1) 2 (10.5) 10 (8.6)
Intermittently significant 1 (5.0) 0 (0.0) 1 (2.8) 1 (5.3) 3 (2.6)
Currently significant 0 (0.0) 1 (2.4) 8 (22.2) 2 (10.5) 11 (9.5)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
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Table C-8.  Caregiver ratings (%) of diabetes at baseline.
Diagnosis Diabetes Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 39 (97.5) 71 (95.9) 63 (96.9) 60 (92.3) 233 (95.5)
Previously 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 1 (0.4)
Well controlled 0 (0.0) 1 (1.4) 0 (0.0) 2 (3.1) 3 (1.2)
Intermittently significant 0 (0.0) 1 (1.4) 1 (1.5) 1 (1.5) 3 (1.2)
Currently significant 1 (2.5) 0 (0.0) 1 (1.5) 2 (3.1) 4 (1.6)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 20 (100) 41 (100) 35 (97.2) 19 (100.0) 115 (99.1)
Previously 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Well controlled 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 1 (0.9)
Intermittently significant 0 (0.0) 0 (0.0) 0 (0) 0 (0.0) 0 (0.0)
Currently significant 0 (0.0) 0 (0.0) 0 (0.0) 0 (0) 0 (0)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-9.  Caregiver ratings (%) of thyroid problems at baseline
Diagnosis Thyroid problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 39 (97.5) 74 (100.0) 57 (87.7) 63 (96.9) 233 (95.5)
Previously 1 (2.5) 0 (0.0) 2 (3.1) 0 (0.0) 3 (1.2)
Well controlled 0 (0.0) 0 (0.0) 4 (6.2) 1 (1.5) 5 (2.0)
Intermittently significant 0 (0.0) 0 (0.0) 1 (1.5) 1 (1.5) 2 (0.8)
Currently significant 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.4)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 17 (85.0) 32 (78.0) 25 (69.4) 11 (57.9) 85 (73.3)
Previously 0 (0.0) 1 (2.4) 1 (2.8) 0 (0.0) 2 (1.7)
Well controlled 1 (5.0) 6 (14.6) 9 (25.0) 7 (36.8) 23 (19.8)
Intermittently significant 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.3) 1 (0.9)
Currently significant 2 (10.0) 2 (4.9) 1 (2.8) 0 (0.0) 5 (4.3)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-10.  Caregiver ratings (%) of visual problems at baseline.
Diagnosis Visual problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 29 (72.5) 45 (60.8) 41 (63.1) 32 (49.2) 147 (60.2)
Previously 1 (2.5) 2 (2.7) 2 (3.1) 6 (9.2) 11 (4.5)
Well controlled 6 (15) 21 (28.4) 17 (26.2) 21 (32.3) 65 (26.6)
Intermittently significant 0 (0) 1 (1.4) 2 (3.1) 1 (1.5) 4 (1.6)
Currently significant 4 (10) 5 (6.8) 3 (4.6) 5 (7.7) 17 (7)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 10 (50) 18 (43.9) 16 (44.4) 5 (26.3) 49 (42.2)
Previously 1 (5) 7 (17.1) 4 (11.1) 2 (10.5) 14 (12.1)
Well controlled 8 (40) 12 (29.3) 11 (30.6) 5 (26.3) 36 (31)
Intermittently significant 0 (0) 2 (4.9) 0 (0.0) 4 (21.1) 6 (5.2)
Currently significant 1 (5) 2 (4.9) 5 (13.9) 3 (15.8) 11 (9.5)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
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Table C-11.  Caregiver ratings (%) of hearing problems at baseline.
Diagnosis Hearing problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 40 (100.0) 68 (91.9) 60 (92.3) 53 (81.5) 221 (90.6)
Previously 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Well controlled 0 (0.0) 2 (2.7) 2 (3.1) 8 (12.3) 12 (4.9)
Intermittently significant 0 (0) 0 (0.0) 2 (3.1) 0 (0.0) 2 (0.8)
Currently significant 0 (0.0) 4 (5.4) 1 (1.5) 4 (6.2) 9 (3.7)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 15(75.0) 36 (87.8) 27 (75) 10 (52.6) 88 (75.9)
Previously 1 (5.0) 0 (0.0) 1 (2.8) 0 (0.0) 2 (1.7)
Well controlled 4 (20.0) 3 (7.3) 4 (11.1) 3 (16) 14 (12.1)
Intermittently significant 0 (0.0) 1 (2.4) 2 (5.6) 1 (5.3) 4 (3.4)
Currently significant 0 (0.0) 1 (2.4) 2 (5.6) 5 (26.3) 8 (6.9)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-12.  Caregiver ratings (%) of  “other” problems at baseline
Diagnosis Other problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 28 (70) 51 (68.9) 44 (67.7) 39 (60.0) 162 (66.4)
Previously 0 (0.0) 3 (4.1) 0 (0.0) 0 (0.0) 3 (1.2)
Well controlled 6 (15.4) 5 (6.8) 5 (7.8) 7 (10.8) 23 (9.5)
Intermittently significant 0 (0.0) 3 (4.1) 6 (9.4) 5 (7.7) 14 (5.8)
Currently significant 6 (15.4) 12 (16.2) 10 (15.6) 14 (21.5) 42 (17.4)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 12 (60.0) 27 (65.9) 18 (50.0) 9 (47.4) 66 (56.9)
Previously 1 (5.0) 2 (4.9) 1 (2.8) 0 (0.0) 4 (3.4)
Well controlled 4 (20.0) 8 (19.5) 8 (22.2) 2 (10.5) 22 (19.0)
Intermittently significant 1 (5.0) 1 (2.4) 1 (2.8) 3 (15.8) 6 (5.2)
Currently significant 2 (10.0) 3 (7.3) 8 (22.2) 5 (26) 18 (15.5)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
Table C-13.  Caregiver ratings (%) of nervous or psychiatric problems at baseline.
Diagnosis Nervous/psychiatric problems Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Never 26 (65.0) 39 (52.7) 38 (58.5) 32 (49.2) 135 (55.3)
Previously 1 (2.5) 4 (5.4) 4 (6.2) 4 (6.2) 13 (5.3)
Well controlled 4 (10.0) 12 (16.2) 6 (9.2) 7 (10.8) 29 (11.9)
Intermittently significant 1 (2.5) 4 (5.4) 8 (12.3) 11 (16.9) 24 (9.8)
Currently significant 8 (20.0) 15 (20.3) 9 (13.8) 11 (16.9) 43 (17.6)
Total 40(100) 74(100) 65(100) 65(100) 244(100)
DS Never 18 (90.0) 32 (78.0) 21 (58.3) 12 (63.2) 83 (71.6)
Previously 1 (5.0) 3 (7.3) 2 (5.6) 1 (5.3) 7 (6.0)
Well controlled 0 (0) 3 (7.3) 2 (5.6) 0 (0.0) 5 (4.3)
Intermittently significant 0 (0.0) 2 (4.9) 6 (16.7) 0 (0.0) 8 (6.9)
Currently significant 1 (5.0) 1 (2.4) 5 (13.9) 6 (32) 13 (11.2)
Total 20(100) 41(100) 36(100) 19(100) 116(100)
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Table C-14.  Participants (%) who saw a psychiatrist within five years of the baseline visit
Diagnosis Psychiatric visit Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS Yes 15 (37.5) 23 (31.1) 14 (21.5) 16 (24.6) 68 (27.9)
DS Yes 2 (10.0) 6 (14.6) 8 (22.2) 8 (42.1) 24 (20.7)
Table C-15.  Participants (%) with physical problems at baseline that were difficult to deal
with.
Diagnosis Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 8 (20) 8 (10.8) 4 (6.2) 6 (9.2) 26 (10.7)
DS 1 (5) 2 (4.9) 4 (11.1) 4 (21.1) 11 (9.5)
All 9 (15) 10 (8.7) 8 (7.9) 10 (11.9) 37 (10.3)
Table C-16.  Participants (%) with physical problems that were difficult to deal with (Waves
1-4)
Diagnosis Wave Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 1995 4 (14.8) 6 (11.5) 4 (7.5) 6 (11.8) 20 (10.9)
1997 6 (19.4) 9 (14.8) 4 (6.1) 6 (9.4) 25 (11.3)
1999 4 (18.2) 4 (6.8) 5 (7.5) 8 (10.3) 21 (9.3)
2001 4 (26.7) 2 (3.7) 3 (4.4) 8 (9.5) 17 (7.7)
DS 1995 1 (8.3) 2 (7.7) 3 (15.8) 3 (33.3) 9 (13.6)
1997 0 (0) 0 (0) 2 (5.6) 2 (11.1) 4 (3.7)
1999 1 (7.7) 0 (0) 3 (6.7) 2 (8.7) 6 (5.5)
2001 0 (0) 0 (0) 1 (2.1) 1 (4) 2 (1.9)
Table C-17.  Participants (%) with mental/emotional problems at baseline that were difficult
to deal with.
Diagnosis Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 11 (27.5) 23 (31.1) 17 (26.2) 17 (26.2) 68 (27.9)
DS 2 (10) 1 (2.4) 9 (25) 7 (36.8) 19 (16.4)
All 13 (21.8) 24 (20.9) 26 (25.7) 24 (28.6) 87 (24.2)
Table C-18.  Participants (%) with mental/emotional problems that were difficult to deal
with(Waves 1-4)
Diagnosis Wave Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 1995 9 (33.3) 18 (34.6) 15 (28.3) 15 (29.4) 57 (31.1)
1997 8 (25.8) 17 (27.9) 11 (16.7) 11 (17.2) 47 (21.2)
1999 2 (9.1) 14 (23.7) 9 (13.4) 14 (18) 39 (17.3)
2001 2 (13.3) 8 (14.8) 15 (22.1) 16 (19) 41 (18.6)
DS 1995 2 (16.7) 1 (3.8) 5 (26.3) 5 (55.6) 13 (19.7)
1997 0 (0) 3 (8.3) 6 (16.7) 2 (11.1) 11 (10.2)
1999 0 (0) 1 (3.4) 6 (13.3) 5 (21.7) 12 (10.9)
2001 2 (28.6) 1 (4.3) 4 (8.3) 3 (12) 10 (9.7)
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Table C-19.  Participants (%) at baseline with increased aging related care difficulty.
Diagnosis Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 0 (0) 5 (6.76) 8 (12.31) 20 (30.77) 33 (13.52)
DS 1 (5) 5 (12.2) 7 (19.44) 9 (47.37) 22 (18.97)
All 1 (1.67) 10 (8.7) 15 (14.85) 29 (34.52) 55 (15.28)
Table C-20.  Participants (%)  50+ with increased aging related care difficulty.
Diagnosis 1995 1997 1999 2001
Non-DS 16 (31.4) 15 (23.4) 30 (38.5) 24 (28.6)
DS 5 (55.6) 7 (38.9) 10 (43.5) 12 (48)
All 21 (35) 22 (26.8) 40 (39.6) 36 (33)
Table C-21. Participants (%) at baseline using an aging service.
Diagnosis Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 0 (0) 1 (1.4) 3 (4.6) 19 (29.2) 23 (9.4)
DS 0 (0) 1 (2.4) 1 (2.8) 5 (26.3) 7 (6)
All 0 (0) 2 (1.7) 4 (4) 24 (28.6) 30 (8.3)
Table C-22.  Participants (%)  50 + using an aging service.
Diagnosis 1995 1997 1999 2001
Non-DS 15 (29.4) 13 (20.3) 14 (17.9) 18 (21.4)
DS 3 (33.3) 4 (22.2) 4 (17.4) 5 (20)
All 18 (30) 17 (20.7) 18 (17.8) 23 (21.1)
Table C-23.  Participants (%) who used either specialized or generic aging services at
baseline.
Diagnosis Age<30 Age 30-39 Age 40-49 Age 50+ All ages
Non-DS 0 (0) 0 (0) 1 (1.5) 14 (21.5) 15 (6.1)
0 (0) 1 (1.3) 2 (3.1) 5 (7.7) 8 (3.3)
DS 0 (0) 1 (2.4) 0 (0) 2 (10.5) 3 (2.6)
0 (0) 0 (0) 1 (2.8) 3 (15.8) 4 (3.4)
All 0 (0) 1 (0.87) 1 (0.99) 16 (19) 18 (5)
0 (0) 1 (0.87) 3 (3) 8 (9.5) 12 (3.3)
Table C-24. Participants (%) 50+ using a specific aging service
Diagnosis Use of specific aging service 1995 1997 1999 2001
Non-DS Specialized 10 (19.6) 12 (18.8) 9 (11.5) 8 (9.5)
Generic 5 (9.8) 1 (1.6) 5 (6.4) 10 (11.9)
Any 15 (29.4) 13 (20.3) 14 (17.9) 18 (21.4)
DS Specialized 1 (11.1) 2 (11.1) 3 (13) 3 (12)
Generic 2 (22.2) 2 (11.1) 1 (4.3) 2 (8)
Any 3 (33.3) 4 (22.2) 4 (17.4) 5 (20)
All Specialized 11 (18.3) 14 (17.1) 12 (11.9) 11 (10.1)
Generic 7 (11.7) 3 (3.7) 6 (5.9) 12 (11)
Any 18 (30) 17 (20.7) 18 (17.8) 23 (21.1)
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Table C-25.  Unadjusted hazards ratio (HR), or odds of dying by the end of the study period.
Parameter P value HR 95% CI for HR
Down syndrome diagnosis 0.29 1.4 0.75-2.60
Age in units of ten years ( at baseline) 0 1.818 1.48-2.23
Sex (reference category female) 0.031 2.184 1.08-4.43
New Seizure during study 0.085 2.167 0.90-5.22
Epilepsy (baseline) 0.78 0.901 0.43-1.88
DMR-Short term memory deficits (baseline) 0.003 1.094 1.03-1.16
DMR-Long term memory deficits (baseline) 0.034 1.073 1.01-1.15
DMR-Spatial-temporal orientation deficits (baseline) 0.009 1.091 1.02-1.17
DMR- Speech deficits (baseline) 0.11 1.119 0.98-1.28
DMR- Mood problems (baseline) 0.001 1.24 1.09-1.40
DMR- Activity and interest deficits (baseline) 0.001 1.16 1.06-1.26
DMR- Behavioural disturbance (baseline) 0.001 1.22 1.08-1.37
DMR- Practical skills deficits(baseline) 0.001 1.11 1.04-1.17
Antipsychotic medication (baseline) 0.372 1.338 0.71-2.53
Antidepressant medication (baseline) 0.954 1.026 0.43-2.43
Anticonvulsant  medication (baseline) 0.53 1.23 0.65-2.32
Thyroid medication (baseline) 0.462 1.382 0.58-3.28
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